ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**

Xarelto 2.5 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 2.5 mg rivaroxaban.

*Excipient with known effect*

Each film-coated tablet contains 33.92 mg lactose (as monohydrate), see section 4.4.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Film-coated tablet (tablet)

Light yellow, round biconvex tablets (6 mm diameter, 9 mm radius of curvature) marked with the BAYER-cross on one side and "2.5" and a triangle on the other side.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).

Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.

4.2 **Posology and method of administration**

**Posology**

The recommended dose is 2.5 mg twice daily.

- **ACS**

Patients taking Xarelto 2.5 mg twice daily should also take a daily dose of 75 - 100 mg ASA or a daily dose of 75 - 100 mg ASA in addition to either a daily dose of 75 mg clopidogrel or a standard daily dose of ticlopidine.

Treatment should be regularly evaluated in the individual patient weighing the risk for ischaemic events against the bleeding risks. Extension of treatment beyond 12 months should be done on an individual patient basis as experience up to 24 months is limited (see section 5.1).
Treatment with Xarelto should be started as soon as possible after stabilisation of the ACS event (including revascularisation procedures); at the earliest 24 hours after admission to hospital and at the time when parenteral anticoagulation therapy would normally be discontinued.

- **CAD/PAD**
  Patients taking Xarelto 2.5 mg twice daily should also take a daily dose of 75 - 100 mg ASA.

Duration of treatment should be determined for each individual patient based on regular evaluations and should consider the risk for thrombotic events versus the bleeding risks.

In patients with an acute thrombotic event or vascular procedure and a need for dual antiplatelet therapy, the continuation of Xarelto 2.5 mg twice daily should be evaluated depending on the type of event or procedure and antiplatelet regimen. Safety and efficacy of Xarelto 2.5 mg twice daily in combination with ASA plus clopidogrel/ticlopidine has only been studied in patients with recent ACS (see section 4.1). Dual antiplatelet therapy has not been studied in combination with Xarelto 2.5 mg twice daily in patients with CAD/PAD (see sections 4.4 and 5.1).

If a dose is missed the patient should continue with the regular dose as recommended at the next scheduled time. The dose should not be doubled to make up for a missed dose.

**Converting from Vitamin K Antagonists (VKA) to Xarelto**

When converting patients from VKAs to Xarelto, International Normalised Ratio (INR) values could be falsely elevated after the intake of Xarelto. The INR is not valid to measure the anticoagulant activity of Xarelto, and therefore should not be used (see section 4.5).

**Converting from Xarelto to Vitamin K antagonists (VKA)**

There is a potential for inadequate anticoagulation during the transition from Xarelto to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Xarelto can contribute to an elevated INR.

In patients converting from Xarelto to VKA, VKA should be given concurrently until the INR is ≥ 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Xarelto and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Xarelto. Once Xarelto is discontinued INR testing may be done reliably at least 24 hours after the last dose (see sections 4.5 and 5.2).

**Converting from parenteral anticoagulants to Xarelto**

For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Xarelto 0 to 2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).

**Converting from Xarelto to parenteral anticoagulants**

Give the first dose of parenteral anticoagulant at the time the next Xarelto dose would be taken.

**Special populations**

**Renal impairment**

Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, Xarelto is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance < 15 ml/min (see sections 4.4 and 5.2).

No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) or moderate renal impairment (creatinine clearance 30 - 49 ml/min) (see section 5.2).
**Hepatic impairment**
Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).

**Elderly population**
No dose adjustment (see sections 4.4 and 5.2)
The risk of bleeding increases with increasing age (see section 4.4).

**Body weight**
No dose adjustment (see sections 4.4 and 5.2)

**Gender**
No dose adjustment (see section 5.2)

**Paediatric population**
The safety and efficacy of Xarelto in children aged 0 to 18 years have not been established. No data are available. Therefore, Xarelto is not recommended for use in children below 18 years of age.

**Method of administration**
Xarelto is for oral use.
The tablets can be taken with or without food (see sections 4.5 and 5.2).

For patients who are unable to swallow whole tablets, Xarelto tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally.
The crushed Xarelto tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water (see section 5.2).

**4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active clinically significant bleeding.

Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinol or intracerebral vascular abnormalities.

Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

Concomitant treatment of ACS with antiplatelet therapy in patients with a prior stroke or a transient ischaemic attack (TIA) (see section 4.4).

Concomitant treatment of CAD/PAD with ASA in patients with previous haemorrhagic or lacunar stroke, or any stroke within a month (see section 4.4).
4.4 Special warnings and precautions for use

In ACS patients, efficacy and safety of Xarelto 2.5 mg have been investigated in combination with the antiplatelet agents ASA alone or ASA plus clopidogrel/ticlopidine. Treatment in combination with other antiplatelet agents, e.g. prasugrel or ticagrelor, has not been studied and is not recommended. In patients at high risk of ischaemic events with CAD/PAD, efficacy and safety of Xarelto 2.5 mg have only been investigated in combination with ASA.

Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.

Haemorrhagic risk

As with other anticoagulants, patients taking Xarelto are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Xarelto administration should be discontinued if severe haemorrhage occurs.

In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment on top of single or dual anti-platelet therapy. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.

Several sub-groups of patients, as detailed below, are at increased risk of bleeding. Therefore, the use of Xarelto in combination with dual antiplatelet therapy in patients at known increased risk for bleeding should be balanced against the benefit in terms of prevention of atherothrombotic events. In addition these patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8). Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.

Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see sections 5.1 and 5.2).

Renal impairment

In patients with severe renal impairment (creatinine clearance < 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6 fold on average) which may lead to an increased bleeding risk. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance < 15 ml/min (see sections 4.2 and 5.2).

In patients with moderate renal impairment ( creatinine clearance 30 - 49 ml/min) concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations Xarelto is to be used with caution (see section 4.5).

Interaction with other medicinal products

The use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk (see section 4.5).
Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid (ASA) and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5). Patients on treatment with Xarelto and ASA or with Xarelto and ASA plus clopidogrel/ticlopidine should only receive concomitant treatment with NSAIDs if the benefit outweighs the bleeding risk.

Other haemorrhagic risk factors
As with other antithrombotics, rivaroxaban is not recommended in patients with an increased bleeding risk such as:
- congenital or acquired bleeding disorders
- uncontrolled severe arterial hypertension
- other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)
- vascular retinopathy
- bronchiectasis or history of pulmonary bleeding

It should be used with caution in ACS and CAD/PAD patients:
- ≥ 75 years of age if co-administered with ASA alone or with ASA plus clopidogrel or ticlopidine. The benefit-risk of the treatment should be individually assessed on a regular basis.
- with lower body weight (< 60 kg) if co-administered with ASA alone or with ASA plus clopidogrel or ticlopidine.

Patients with prosthetic valves
Safety and efficacy of Xarelto have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Xarelto provides adequate anticoagulation in this patient population. Treatment with Xarelto is not recommended for these patients.

Patients with prior stroke and/or TIA
Patients with ACS
Xarelto 2.5 mg is contraindicated for the treatment of ACS in patients with a prior stroke or TIA (see section 4.3). Few ACS patients with a prior stroke or TIA have been studied but the limited efficacy data available indicate that these patients do not benefit from treatment.

Patients with CAD/PAD
CAD/PAD patients with previous haemorrhagic or lacunar stroke, or an ischaemic, non-lacunar stroke with in the previous month were not studied (see section 4.3).

Spinal/epidural anaesthesia or puncture
When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. There is no clinical experience with the use of Xarelto 2.5 mg with ASA alone or with ASA plus clopidogrel or ticlopidine in these situations.

To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of
rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low (see section 5.2). However, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.
Platelet aggregation inhibitors should be discontinued as suggested by the manufacturer’s prescribing information.

Dosing recommendations before and after invasive procedures and surgical intervention
If an invasive procedure or surgical intervention is required, Xarelto 2.5 mg should be stopped at least 12 hours before the intervention, if possible and based on the clinical judgement of the physician. If a patient is to undergo elective surgery and anti-platelet effect is not desired, platelet aggregation inhibitors should be discontinued as directed by the manufacturer’s prescribing information.
If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.
Xarelto should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section 5.2).

Elderly population
Increasing age may increase haemorrhagic risk (see sections 5.1 and 5.2).

Dermatological reactions
Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.

Information about excipients
Xarelto contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

CYP3A4 and P-gp inhibitors
Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban C\textsubscript{max}, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp (see section 4.4).

Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5 fold increase in mean rivaroxaban AUC and a 1.4 fold increase in C\textsubscript{max}. The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).

Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3 fold increase in mean rivaroxaban AUC and C\textsubscript{max}. The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients.
In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8 fold increase in mean rivaroxaban AUC and 1.6 fold increase in C\textsubscript{max} when compared to subjects with
normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0 fold increase in mean rivaroxaban AUC and 1.6 fold increase in $C_{\text{max}}$ when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section 4.4).

Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold increase in mean rivaroxaban AUC and a 1.3 fold increase in mean $C_{\text{max}}$. The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).

Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.

**Anticoagulants**

After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban. Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections 4.3 and 4.4).

**NSAIDs/platelet aggregation inhibitors**

No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15 mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response. No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with 500 mg acetylsalicylic acid. Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.

Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).

**SSRIs/SNRIs**

As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical programme, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.

**Warfarin**

Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.

If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban.

If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the $C_{\text{trough}}$ of rivaroxaban (24 hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.

No pharmacokinetic interaction was observed between warfarin and rivaroxaban.
CYP3A4 inducers
Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John’s Wort (*Hypericum perforatum*)) may also lead to reduced rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.

Other concomitant therapies
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4. No clinically relevant interaction with food was observed (see section 4.2).

Laboratory parameters
Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of rivaroxaban (see section 5.1).

4.6 Fertility, pregnancy and lactation

Pregnancy
Safety and efficacy of Xarelto have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Xarelto is contraindicated during pregnancy (see section 4.3). Women of child-bearing potential should avoid becoming pregnant during treatment with rivaroxaban.

Breast-feeding
Safety and efficacy of Xarelto have not been established in breast-feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore Xarelto is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.

Fertility
No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).

4.7 Effects on ability to drive and use machines

Xarelto has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8). Patients experiencing these adverse reactions should not drive or use machines.

4.8 Undesirable effects

Summary of the safety profile
The safety of rivaroxaban has been evaluated in thirteen phase III studies including 53,103 patients exposed to rivaroxaban (see Table 1).
### Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of patients*</th>
<th>Total daily dose</th>
<th>Maximum treatment duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</td>
<td>6,097</td>
<td>10 mg</td>
<td>39 days</td>
</tr>
<tr>
<td>Prevention of VTE in medically ill patients</td>
<td>3,997</td>
<td>10 mg</td>
<td>39 days</td>
</tr>
<tr>
<td>Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recurrence</td>
<td>6,790</td>
<td>Day 1 - 21: 30 mg Day 22 and onwards: 20 mg After at least 6 months: 10 mg or 20 mg</td>
<td>21 months</td>
</tr>
<tr>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</td>
<td>7,750</td>
<td>20 mg</td>
<td>41 months</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients after an ACS</td>
<td>10,225</td>
<td>5 mg or 10 mg respectively, co-administered with either ASA or ASA plus clopidogrel or ticlopidine</td>
<td>31 months</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with CAD/PAD</td>
<td>18,244</td>
<td>5 mg co-administered with ASA or 10 mg alone</td>
<td>47 months</td>
</tr>
</tbody>
</table>

* Patients exposed to at least one dose of rivaroxaban

The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and ‘Description of selected adverse reactions’ below) (Table 2). The most commonly reported bleedings were epistaxis (4.5 %) and gastrointestinal tract haemorrhage (3.8 %).

### Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed phase III studies

<table>
<thead>
<tr>
<th>Indication</th>
<th>Any bleeding</th>
<th>Anaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</td>
<td>6.8% of patients</td>
<td>5.9% of patients</td>
</tr>
<tr>
<td>Prevention of venous thromboembolism in medically ill patients</td>
<td>12.6% of patients</td>
<td>2.1% of patients</td>
</tr>
<tr>
<td>Treatment of DVT, PE and prevention of recurrence</td>
<td>23% of patients</td>
<td>1.6% of patients</td>
</tr>
<tr>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</td>
<td>28 per 100 patient years</td>
<td>2.5 per 100 patient years</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients after an ACS</td>
<td>22 per 100 patient years</td>
<td>1.4 per 100 patient years</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with CAD/PAD</td>
<td>6.7 per 100 patient years</td>
<td>0.15 per 100 patient years**</td>
</tr>
</tbody>
</table>

* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.

** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied
Tabulated list of adverse reactions
The frequencies of adverse reactions reported with Xarelto are summarised in Table 3 below by system organ class (in MedDRA) and by frequency.

Frequencies are defined as:
very common (≥ 1/10)
common (≥ 1/100 to < 1/10)
uncommon (≥ 1/1,000 to < 1/100)
rare (≥ 1/10,000 to < 1/1,000)
very rare ( < 1/10,000)
not known (cannot be estimated from the available data)

Table 3: All adverse reactions reported in patients in phase III clinical trials or through post-marketing use*

<table>
<thead>
<tr>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Very rare</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaemia (incl. respective laboratory parameters)</td>
<td>Thrombocytosis (incl. platelet count increased)(^A), Thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allergic reaction, dermatitis allergic, Angioedema and allergic oedema</td>
<td></td>
<td>Anaphylactic reactions including anaphylactic shock</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness, headache</td>
<td>Cerebral and intracranial haemorrhage, syncope</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye haemorrhage (incl. conjunctival haemorrhage)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tachycardia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypotension, haematoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis, haemoptysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation(^A), diarrhoea, vomiting(^A)</td>
<td>Dry mouth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
<td>Very rare</td>
<td>Not known</td>
</tr>
<tr>
<td>--------</td>
<td>----------</td>
<td>------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase in transaminases</td>
<td>Hepatic impairment, Increased bilirubin, increased blood alkaline phosphatase(^A), increased GGT(^A)</td>
<td>Jaundice, Bilirubin conjugated increased (with or without concomitant increase of ALT), Cholestasis, Hepatitis (incl. hepatocellular injury)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus (incl. uncommon cases of generalised pruritus), rash, ecchymosis, cutaneous and subcutaneous haemorrhage</td>
<td>Urticaria</td>
<td>Stevens-Johnson syndrome/ Toxic Epidermal Necrolysis, DRESS syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain in extremity(^A)</td>
<td>Haemarthrosis</td>
<td>Muscle haemorrhage</td>
<td>Compartment syndrome secondary to a bleeding</td>
<td></td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urogenital tract haemorrhage (incl. haematuria and menorrhagia(^B)), renal impairment (incl. blood creatinine increased, blood urea increased)(^A)</td>
<td></td>
<td></td>
<td>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</td>
<td></td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever(^A), peripheral oedema, decreased general strength and energy (incl. fatigue and asthenia)</td>
<td>Feeling unwell (incl. malaise)</td>
<td>Localised oedema(^A)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased LDH(^A), increased lipase(^A), increased amylase(^A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Description of selected adverse reactions

Due to the pharmacological mode of action, the use of Xarelto may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 “Management of bleeding”). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section 4.4 “Haemorrhagic risk”). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed.

Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Xarelto. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

### 4.9 Overdose

Rare cases of overdose up to 600 mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50 mg rivaroxaban or above.

A specific antidote antagonising the pharmacodynamic effect of rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.
Management of bleeding
Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a half-life of approximately 5 to 13 hours (see section 5.2). Management should be individualised according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.

If bleeding cannot be controlled by the above measures, administration of a specific procoagulant reversal agent should be considered, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa). However, there is currently very limited clinical experience with the use of these medicinal products in individuals receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings (see section 5.1).

Protamine sulphate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic haemostatic desmopressin in individuals receiving rivaroxaban. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF01

Mechanism of action
Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.

Pharmacodynamic effects
Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant.

In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3-factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9). The activated partial thromboplastin time (aPTT) and HepTest are also prolonged dose-dependently; however, they are not recommended to assess the pharmacodynamic effect of rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated, rivaroxaban levels can be measured by calibrated quantitative anti-factor-Xa tests (see section 5.2).
Clinical efficacy and safety

ACS

The rivaroxaban clinical programme was designed to demonstrate the efficacy of Xarelto for the prevention of cardiovascular (CV) death, myocardial infarction (MI) or stroke in subjects with a recent ACS (ST-elevation myocardial infarction [STEMI], non-ST-elevation myocardial infarction [NSTEMI] or unstable angina [UA]). In the pivotal double-blind ATLAS ACS 2 TIMI 51 study, 15,526 patients were randomly assigned in a 1:1:1 fashion to one of three treatment groups: Xarelto 2.5 mg orally twice daily, 5 mg orally twice daily or to placebo twice daily co-administered with ASA alone or with ASA plus a thienopyridine (clopidogrel or ticlopidine). Patients with an ACS under the age of 55 had to have either diabetes mellitus or a previous MI. The median time on treatment was 13 months and overall treatment duration was up to almost 3 years. 93.2% of patients received ASA concomitantly plus thienopyridine treatment and 6.8% ASA only. Among patients receiving dual anti-platelets therapy 98.8% received clopidogrel, 0.9% received ticlopidine and 0.3% received prasugrel. Patients received the first dose of Xarelto at a minimum of 24 hours and up to 7 days (mean 4.7 days) after admission to the hospital, but as soon as possible after stabilisation of the ACS event, including revascularisation procedures and when parenteral anticoagulation therapy would normally be discontinued.

Both the 2.5 mg twice daily and the 5 mg twice daily regimens of rivaroxaban were effective in further reducing the incidence of CV events on a background of standard antiplatelet care. The 2.5 mg twice daily regimen reduced mortality, and there is evidence that the lower dose had lower bleeding risks, therefore rivaroxaban 2.5 mg twice daily co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine is recommended for the prevention of atherothrombotic events in adult patients after an ACS with elevated cardiac biomarkers.

Relative to placebo, Xarelto significantly reduced the primary composite endpoint of CV death, MI or stroke. The benefit was driven by a reduction in CV death and MI and appeared early with a constant treatment effect over the entire treatment period (see Table 4 and Figure 1). Also the first secondary endpoint (all-cause death, MI or stroke) was reduced significantly. An additional retrospective analysis showed a nominally significant reduction in the incidence rates of stent thrombosis compared with placebo (see Table 4). The incidence rates for the principal safety outcome (non-coronary artery bypass graft (CABG) TIMI major bleeding events) were higher in patients treated with Xarelto than in patients who received placebo (see Table 6). However the incidence rates were balanced between Xarelto and placebo for the components of fatal bleeding events, hypotension requiring treatment with intravenous inotropic agents and surgical intervention for ongoing bleeding.

In Table 5 the efficacy results of patients undergoing percutaneous coronary intervention (PCI) are presented. The safety results in this subgroup of patients undergoing PCI were comparable to the overall safety results.

Patients with elevated biomarkers (troponin or CK-MB) and without a prior stroke/TIA constituted 80% of the study population. The results of this patient population were also consistent with the overall efficacy and safety results.

<table>
<thead>
<tr>
<th>Study population</th>
<th>Patients with a recent acute coronary syndrome</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Xarelto 2.5 mg, twice daily, N=5,114</strong></td>
<td>Hazard Ratio (HR) (95% CI) p-value</td>
<td>N=5,113</td>
</tr>
<tr>
<td>Cardiovascular death, MI or stroke</td>
<td>313 (6.1%)</td>
<td>0.84 (0.72, 0.97) p = 0.020*</td>
</tr>
<tr>
<td>All-cause death, MI or stroke</td>
<td>320 (6.3%)</td>
<td>0.83 (0.72, 0.97) p = 0.016*</td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>94 (1.8%)</td>
<td>0.66 (0.51, 0.86) p = 0.002**</td>
</tr>
<tr>
<td>All-cause death</td>
<td>103 (2.0%)</td>
<td>0.68 (0.53, 0.87) p = 0.002**</td>
</tr>
<tr>
<td>MI</td>
<td>205 (4.0%)</td>
<td>229 (4.5%)</td>
</tr>
<tr>
<td>Study population</td>
<td>Patients with a recent acute coronary syndrome a)</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Treatment dose</td>
<td>Xarelto 2.5 mg, twice daily, N=5,114 n (%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hazard Ratio (HR) (95% CI) p-value b)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.90 (0.75, 1.09) p = 0.270</td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td>46 (0.9%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.13 (0.74, 1.73) p = 0.562</td>
<td></td>
</tr>
<tr>
<td>Stent thrombosis</td>
<td>61 (1.2%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.70 (0.51, 0.97) p = 0.033**</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>N=5,113 n (%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>41 (0.8%)</td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td>41 (0.8%)</td>
<td></td>
</tr>
<tr>
<td>Stent thrombosis</td>
<td>87 (1.7%)</td>
<td></td>
</tr>
</tbody>
</table>

a) modified intent to treat analysis set (intent to treat total analysis set for stent thrombosis)
b) vs. placebo; Log-Rank p-value
* statistically superior
** nominally significant

### Table 5: Efficacy results from phase III ATLAS ACS 2 TIMI 51 in patients undergoing PCI

<table>
<thead>
<tr>
<th>Study population</th>
<th>Patients with recent acute coronary syndrome undergoing PCI a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment dose</td>
<td>Xarelto 2.5 mg, twice daily, N=3114 n (%)</td>
</tr>
<tr>
<td></td>
<td>HR (95% CI) p-value b)</td>
</tr>
<tr>
<td>Cardiovascular death, MI or stroke</td>
<td>153 (4.9%)</td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>24 (0.8%)</td>
</tr>
<tr>
<td>All-cause death</td>
<td>31 (1.0%)</td>
</tr>
<tr>
<td>MI</td>
<td>115 (3.7%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>27 (0.9%)</td>
</tr>
<tr>
<td>Stent thrombosis</td>
<td>47 (1.5%)</td>
</tr>
<tr>
<td>Placebo</td>
<td>N=3096 n (%)</td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>165 (5.3%)</td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>45 (1.5%)</td>
</tr>
<tr>
<td>All-cause death</td>
<td>49 (1.6%)</td>
</tr>
<tr>
<td>MI</td>
<td>113 (3.6%)</td>
</tr>
<tr>
<td>Stroke</td>
<td>21 (0.7%)</td>
</tr>
<tr>
<td>Stent thrombosis</td>
<td>71 (2.3%)</td>
</tr>
</tbody>
</table>

a) modified intent to treat analysis set (intent to treat total analysis set for stent thrombosis)
b) vs. placebo; Log-Rank p-value
** nominally significant
Table 6: Safety results from phase III ATLAS ACS 2 TIMI 51

<table>
<thead>
<tr>
<th>Study population</th>
<th>Patients with recent acute coronary syndrome a)</th>
<th>Placebo N=5,125 n(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose</strong></td>
<td>Xarelto 2.5 mg, twice daily, N=5,115 n (%)</td>
<td>Placebo</td>
</tr>
<tr>
<td>Non-CABG TIMI major bleeding event</td>
<td>65 (1.3%) HR (95% CI) p-value b)</td>
<td>19 (0.4%)</td>
</tr>
<tr>
<td>Fatal bleeding event</td>
<td>6 (0.1%) HR (0.24, 1.89) p = 0.450</td>
<td>9 (0.2%)</td>
</tr>
<tr>
<td>Symptomatic intracranial haemorrhage</td>
<td>14 (0.3%) HR (1.02, 7.86) p = 0.037</td>
<td>5 (0.1%)</td>
</tr>
<tr>
<td>Hypotension requiring treatment with intravenous inotropic agents</td>
<td>3 (0.1%) HR (0.24, 1.89) p = 0.450</td>
<td>3 (0.1%)</td>
</tr>
<tr>
<td>Surgical intervention for ongoing bleeding</td>
<td>7 (0.1%) HR (0.24, 1.89) p = 0.450</td>
<td>9 (0.2%)</td>
</tr>
<tr>
<td>Transfusion of 4 or more units of blood over a 48 hour period</td>
<td>19 (0.4%) HR (0.24, 1.89) p = 0.450</td>
<td>6 (0.1%)</td>
</tr>
</tbody>
</table>

a) safety population, on treatment b) vs. placebo; Log-Rank p-value
* statistically significant

Figure 1: Time to first occurrence of primary efficacy endpoint (CV death, MI or stroke)

**CAD/PAD**
The phase III COMPASS study (27,395 patients, 78.0% male, 22.0% female) demonstrated the efficacy and safety of Xarelto for the prevention of a composite of CV death, MI, stroke in patients with CAD or symptomatic PAD at high risk of ischaemic events. Patients were followed for a median of 23 months and maximum of 3.9 years.

Subjects without a continuous need for treatment with a proton pump inhibitor were randomized to pantoprazole or placebo. All patients were then randomized 1:1:1 to rivaroxaban 2.5 mg twice
daily/ASA 100 mg once daily, to rivaroxaban 5 mg twice daily, or ASA 100 mg once daily alone, and their matching placebos.

CAD patients had multivessel CAD and/or prior MI. For patients < 65 years of age atherosclerosis involving at least two vascular beds or at least two additional cardiovascular risk factors were required.

PAD patients had previous interventions such as bypass surgery or percutaneous transluminal angioplasty or limb or foot amputation for arterial vascular disease or intermittent claudication with ankle/arm blood pressure ratio < 0.90 and/or significant peripheral artery stenosis or previous carotid revascularization or asymptomatic carotid artery stenosis ≥ 50%.

Exclusion criteria included the need for dual antiplatelet or other non-ASA antiplatelet or oral anticoagulant therapy and patients with high bleeding risk, or heart failure with ejection fraction < 30% or New York Heart Association class III or IV, or any ischaemic, non-lacunar stroke within 1 month or any history of haemorrhagic or lacunar stroke.

Xarelto 2.5 mg twice daily in combination with ASA 100 mg once daily was superior to ASA 100 mg, in the reduction of the primary composite outcome of CV death, MI, stroke (see Table 7 and Figure 2).

There was a significant increase of the primary safety outcome (modified ISTH major bleeding events) in patients treated with Xarelto 2.5 mg twice daily in combination with ASA 100 mg once daily compared to patients who received ASA 100 mg (see Table 8).

For the primary efficacy outcome, the observed benefit of Xarelto 2.5 mg twice daily plus ASA 100 mg once daily compared with ASA 100 mg once daily was HR=0.89 (95% CI 0.7-1.1) in patients ≥ 75 years (incidence: 6.3% vs 7.0%) and HR=0.70 (95% CI 0.6-0.8) in patients <75 years (3.6% vs 5.0%). For modified ISTH major bleeding, the observed risk increase was HR=2.12 (95% CI 1.5-3.0) in patients ≥ 75 years (5.2% vs 2.5%) and HR=1.53 (95% CI 1.2-1.9) in patients <75 years (2.6% vs 1.7%).
Table 7: Efficacy results from phase III COMPASS

<table>
<thead>
<tr>
<th>Study Population</th>
<th>Patients with CAD/PAD a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment Dosage</td>
<td></td>
</tr>
<tr>
<td>Xarelto 2.5 mg bid in combination with ASA 100 mg od N=9152</td>
<td>ASA 100 mg od N=9126</td>
</tr>
<tr>
<td>Patients with events</td>
<td>KM %</td>
</tr>
<tr>
<td>---------------------</td>
<td>-----</td>
</tr>
<tr>
<td>Stroke, MI or CV death</td>
<td>379 (4.1%)</td>
</tr>
<tr>
<td>- Stroke</td>
<td>83 (0.9%)</td>
</tr>
<tr>
<td>- MI</td>
<td>178 (1.9%)</td>
</tr>
<tr>
<td>- CV death</td>
<td>160 (1.7%)</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>313 (3.4%)</td>
</tr>
<tr>
<td>Acute limb ischaemia</td>
<td>22 (0.2%)</td>
</tr>
</tbody>
</table>

a) intention to treat analysis set, primary analyses
b) vs. ASA 100 mg; Log-Rank p-value

* The reduction in the primary efficacy outcome was statistically superior.

Table 8: Safety results from phase III COMPASS

<table>
<thead>
<tr>
<th>Study population</th>
<th>Patients with CAD/PAD a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment Dose</td>
<td></td>
</tr>
<tr>
<td>Xarelto 2.5 mg bid in combination with ASA 100 mg od, N=9152</td>
<td>ASA 100 mg od N=9126</td>
</tr>
<tr>
<td>Modified ISTH major bleeding n (Cum. risk %)</td>
<td>Hazard Ratio (95 % CI)</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>288 (3.9%)</td>
<td>170 (2.5%)</td>
</tr>
<tr>
<td>- Fatal bleeding event</td>
<td>15 (0.2%)</td>
</tr>
<tr>
<td>- Symptomatic bleeding in critical organ (non-fatal)</td>
<td>63 (0.9%)</td>
</tr>
<tr>
<td>- Bleeding into the surgical site requiring reoperation (non-fatal, not in critical organ)</td>
<td>10 (0.1%)</td>
</tr>
<tr>
<td>- Bleeding leading to hospitalisation (non-fatal, not in critical organ, not requiring reoperation)</td>
<td>208 (2.9%)</td>
</tr>
<tr>
<td>- With overnight stay</td>
<td>172 (2.3%)</td>
</tr>
<tr>
<td>- Without overnight stay</td>
<td>36 (0.5%)</td>
</tr>
</tbody>
</table>
Study population | Patients with CAD/PAD a)
--- | ---
Treatment Dose | Xarelto 2.5 mg bid in combination with ASA 100 mg od, N=9152 n (Cum. risk %) | ASA 100 mg od N=9126 n (Cum. risk %) | Hazard Ratio (95 % CI) p-value b)
Major gastrointestinal bleeding | 140 (2.0%) | 65 (1.1%) | 2.15 (1.60;2.89) p < 0.00001
Major intracranial bleeding | 28 (0.4%) | 24 (0.3%) | 1.16 (0.67;2.00) p = 0.59858

a) intention-to-treat analysis set, primary analyses  
b) vs. ASA 100 mg; Log-Rank p-value  
bid: twice daily; CI: confidence interval; Cum. Risk: Cumulative incidence risk (Kaplan-Meier estimates) at 30 months; ISTH: International Society on Thrombosis and Haemostasis; od: once daily

Figure 2: Time to first occurrence of primary efficacy outcome (stroke, myocardial infarction, cardiovascular death) in COMPASS

bid: twice daily; od: once daily; CI: confidence interval

Paediatric population
The European Medicines Agency has deferred the obligation to submit the results of studies with Xarelto in one or more subsets of the paediatric population in the treatment of thromboembolic events. The European Medicines Agency has waived the obligation to submit the results of studies with Xarelto in all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption
Rivaroxaban is rapidly absorbed with maximum concentrations ($C_{\text{max}}$) appearing 2 - 4 hours after tablet intake.
Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5 mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or C\text{max} at the 2.5 mg and 10 mg dose. Rivaroxaban 2.5 mg and 10 mg tablets can be taken with or without food.

Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose. This is more marked in fasting state than in fed state. Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV\%) ranging from 30% to 40%.

Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and C\text{max} compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure.

Bioavailability (AUC and C\text{max}) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.

**Distribution**

Plasma protein binding in humans is high at approximately 92% to 95%, with serum albumin being the main binding component. The volume of distribution is moderate with V\text{ss} being approximately 50 litres.

**Biotransformation and elimination**

Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.

Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on in vitro investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).

Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.

**Special populations**

**Gender**

There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients.

**Elderly population**

Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.

**Different weight categories**

Extremes in body weight (< 50 kg or > 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.
Inter-ethnic differences
No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.

Hepatic impairment
Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment. The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT. Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).

Renal impairment
There was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively. There are no data in patients with creatinine clearance < 15 ml/min.

Due to the high plasma protein binding rivaroxaban is not expected to be dialysable. Use is not recommended in patients with creatinine clearance < 15 ml/min. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).

Pharmacokinetic data in patients
In patients receiving rivaroxaban 2.5 mg twice daily for the prevention of atherothrombotic events in patients with ACS the geometric mean concentration (90% prediction interval) 2 - 4 h and about 12 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 47 (13 - 123) and 9.2 (4.4 - 18) mcg/l, respectively.

Pharmacokinetic/pharmacodynamic relationship
The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor-Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor-Xa activity was best described by an E_{max} model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 mcgl). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects.

Paediatric population
Safety and efficacy have not been established for children and adolescents up to 18 years.
5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.

Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.

In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. haemorrhagic complications). Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
- Microcrystalline cellulose
- Croscarmellose sodium
- Lactose monohydrate
- Hypromellose 2910
- Sodium laurilsulphate
- Magnesium stearate

Film-coat
- Macrogol 3350
- Hypromellose 2910
- Titanium dioxide (E 171)
- Iron oxide yellow (E 172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

PP/Aluminium foil blisters in cartons of 14, 20, 28, 30, 56, 60, 98, 168 or 196 film-coated tablets or perforated unit dose blisters in cartons of 10 x 1 or 100 x 1 or in multipacks containing 100 (10 packs of 10 x 1) film-coated tablets.

PVC/PVDC/Aluminium foil blisters in cartons of 14 film-coated tablets.

HDPE bottles with a PP screw cap containing 100 film-coated tablets.

Not all pack sizes may be marketed.
6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/472/025-035, EU/1/08/472/041, EU/1/08/472/046-047

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 30 September 2008
Date of latest renewal: 22 May 2018

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Xarelto 10 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 10 mg rivaroxaban.

Excipient with known effect
Each film-coated tablet contains 26.51 mg lactose (as monohydrate), see section 4.4. For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet)

Light red, round biconvex tablets (6 mm diameter, 9 mm radius of curvature) marked with the BAYER-cross on one side and "10" and a triangle on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)

4.2 Posology and method of administration

Posology

Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery
The recommended dose is 10 mg rivaroxaban taken orally once daily. The initial dose should be taken 6 to 10 hours after surgery, provided that haemostasis has been established.

The duration of treatment depends on the individual risk of the patient for venous thromboembolism which is determined by the type of orthopaedic surgery.

- For patients undergoing major hip surgery, a treatment duration of 5 weeks is recommended.
- For patients undergoing major knee surgery, a treatment duration of 2 weeks is recommended.

If a dose is missed the patient should take Xarelto immediately and then continue the following day with once daily intake as before.
Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE

The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE.

Short duration of therapy (at least 3 months) should be considered in patients with DVT or PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT or PE not related to major transient risk factors, unprovoked DVT or PE, or a history of recurrent DVT or PE.

When extended prevention of recurrent DVT and PE is indicated (following completion of at least 6 months therapy for DVT or PE), the recommended dose is 10 mg once daily. In patients in whom the risk of recurrent DVT or PE is considered high, such as those with complicated comorbidities, or who have developed recurrent DVT or PE on extended prevention with Xarelto 10 mg once daily, a dose of Xarelto 20 mg once daily should be considered.

The duration of therapy and dose selection should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).

<table>
<thead>
<tr>
<th>Time period</th>
<th>Dosing schedule</th>
<th>Total daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVT and PE</td>
<td>Day 1-21</td>
<td>15 mg twice daily</td>
</tr>
<tr>
<td></td>
<td>Day 22 onwards</td>
<td>20 mg once daily</td>
</tr>
<tr>
<td>Prevention</td>
<td>Following completion</td>
<td>10 mg once daily or 10 mg or 20 mg</td>
</tr>
<tr>
<td>of recurrent DVT and PE</td>
<td>of at least 6 months therapy for DVT or PE</td>
<td>20 mg once daily</td>
</tr>
</tbody>
</table>

To support the dose switch from 15 mg to 20 mg after Day 21 a first 4 weeks treatment initiation pack of Xarelto for treatment of DVT/PE is available.

If a dose is missed during the 15 mg twice daily treatment phase (day 1 - 21), the patient should take Xarelto immediately to ensure intake of 30 mg Xarelto per day. In this case two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.

If a dose is missed during the once daily treatment phase, the patient should take Xarelto immediately, and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.

Converting from Vitamin K Antagonists (VKA) to Xarelto
For patients treated for DVT, PE and prevention of recurrence, VKA treatment should be stopped and Xarelto therapy should be initiated once the INR is ≤ 2.5.

When converting patients from VKAs to Xarelto, International Normalised Ratio (INR) values will be falsely elevated after the intake of Xarelto. The INR is not valid to measure the anticoagulant activity of Xarelto, and therefore should not be used (see section 4.5).

Converting from Xarelto to Vitamin K antagonists (VKA)
There is a potential for inadequate anticoagulation during the transition from Xarelto to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Xarelto can contribute to an elevated INR. In patients converting from Xarelto to VKA, VKA should be given concurrently until the INR is ≥ 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Xarelto and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of
Xarelto. Once Xarelto is discontinued INR testing may be done reliably at least 24 hours after the last dose (see sections 4.5 and 5.2).

Converting from parenteral anticoagulants to Xarelto
For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Xarelto 0 to 2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).

Converting from Xarelto to parenteral anticoagulants
Give the first dose of parenteral anticoagulant at the time the next Xarelto dose would be taken.

Special populations
Renal impairment
Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, Xarelto is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance < 15 ml/min (see sections 4.4 and 5.2).

- For the prevention of VTE in adult patients undergoing elective hip or knee replacement surgery, no dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) or moderate renal impairment (creatinine clearance 30- 49 ml/min) (see section 5.2).

- For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE, no dose adjustment from the recommended dose is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).

In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment: patients should be treated with 15 mg twice daily for the first 3 weeks. Thereafter, when the recommended dose is 20 mg once daily, a reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient’s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2).

When the recommended dose is 10 mg once daily, no dose adjustment from the recommended dose is necessary.

Hepatic impairment
Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).

Elderly population
No dose adjustment (see section 5.2)

Body weight
No dose adjustment (see section 5.2)

Gender
No dose adjustment (see section 5.2)

Paediatric population
The safety and efficacy of Xarelto in children aged 0 to 18 years have not been established. No data are available. Therefore, Xarelto is not recommended for use in children below 18 years of age.
Method of administration
Xarelto is for oral use.
The tablets can be taken with or without food (see sections 4.5 and 5.2).

For patients who are unable to swallow whole tablets, Xarelto tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally.
The crushed Xarelto tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water (see section 5.2).

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active clinically significant bleeding.

Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives ( fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2).

Pregnancy and breast-feeding (see section 4.6).

4.4 Special warnings and precautions for use

Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.

Haemorrhagic risk
As with other anticoagulants, patients taking Xarelto are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Xarelto administration should be discontinued if severe haemorrhage occurs.

In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.

Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8). In patients receiving Xarelto for VTE prevention following elective hip or knee replacement surgery, this may be done by regular physical examination of the patients, close observation of the surgical wound drainage and periodic measurements of haemoglobin. Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.
Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see sections 5.1 and 5.2).

Renal impairment
In patients with severe renal impairment (creatinine clearance < 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6 fold on average) which may lead to an increased bleeding risk. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance < 15 ml/min (see sections 4.2 and 5.2).
In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations Xarelto is to be used with caution (see section 4.5).

Interaction with other medicinal products
The use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk (see section 4.5).

Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid (ASA) and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5).

Other haemorrhagic risk factors
As with other antithrombotics, rivaroxaban is not recommended in patients with an increased bleeding risk such as:

• congenital or acquired bleeding disorders
• uncontrolled severe arterial hypertension
• other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)
• vascular retinopathy
• bronchiectasis or history of pulmonary bleeding

Patients with prosthetic valves
Safety and efficacy of Xarelto have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Xarelto provides adequate anticoagulation in this patient population. Treatment with Xarelto is not recommended for these patients.

Hip fracture surgery
Rivaroxaban has not been studied in interventional clinical studies in patients undergoing hip fracture surgery to evaluate efficacy and safety.

Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy
Xarelto is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of Xarelto have not been established in these clinical situations.
Spinal/epidural anaesthesia or puncture
When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.

To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low (see section 5.2).

At least 18 hours should elapse after the last administration of rivaroxaban before removal of an epidural catheter. Following removal of the catheter, at least 6 hours should elapse before the next rivaroxaban dose is administered.
If traumatic puncture occurs the administration of rivaroxaban is to be delayed for 24 hours.

Dosing recommendations before and after invasive procedures and surgical intervention other than elective hip or knee replacement surgery
If an invasive procedure or surgical intervention is required, Xarelto 10 mg should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician. If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.
Xarelto should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section 5.2).

Elderly population
Increasing age may increase haemorrhagic risk (see section 5.2).

Dermatological reactions
Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.

Information about excipients
Xarelto contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction
CYP3A4 and P-gp inhibitors
Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban Cmax, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Xarelto is not recommended in patients receiving concomitant systemic treatment withazole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp (see section 4.4).
Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5 fold increase in mean rivaroxaban AUC and a 1.4 fold increase in $C_{max}$. The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).

Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3 fold increase in mean rivaroxaban AUC and $C_{max}$. The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8 fold increase in mean rivaroxaban AUC and 1.6 fold increase in $C_{max}$ when compared to subjects with normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0 fold increase in mean rivaroxaban AUC and 1.6 fold increase in $C_{max}$ when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section 4.4).

Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold increase in mean rivaroxaban AUC and a 1.3 fold increase in mean Cmax. The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).

Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.

Anticoagulants
After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban. Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections 4.3 and 4.4).

NSAIDs/platelet aggregation inhibitors
No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15 mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response. No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with 500 mg acetylsalicylic acid. Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels. Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).

SSRIs/SNRIs
As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical programme, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.

Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin)
more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.

If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban. If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the C\textsubscript{trough} of rivaroxaban (24 hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.

No pharmacokinetic interaction was observed between warfarin and rivaroxaban.

**CYP3A4 inducers**
Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John’s Wort (Hypericum perforatum)) may also lead to reduced rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.

**Other concomitant therapies**
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4.

No clinically relevant interaction with food was observed (see section 4.2).

**Laboratory parameters**
Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of rivaroxaban (see section 5.1).

### 4.6 Fertility, pregnancy and lactation

**Pregnancy**
Safety and efficacy of Xarelto have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Xarelto is contraindicated during pregnancy (see section 4.3).

Women of child bearing potential should avoid becoming pregnant during treatment with rivaroxaban.

**Breast-feeding**
Safety and efficacy of Xarelto have not been established in breast-feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore Xarelto is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.

**Fertility**
No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).

### 4.7 Effects on ability to drive and use machines

Xarelto has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8).

Patients experiencing these adverse reactions should not drive or use machines.
4.8 Undesirable effects

Summary of the safety profile

The safety of rivaroxaban has been evaluated in thirteen phase III studies including 53,103 patients exposed to rivaroxaban (see Table 1).

Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of patients*</th>
<th>Total daily dose</th>
<th>Maximum treatment duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</td>
<td>6,097</td>
<td>10 mg</td>
<td>39 days</td>
</tr>
<tr>
<td>Prevention of VTE in medically ill patients</td>
<td>3,997</td>
<td>10 mg</td>
<td>39 days</td>
</tr>
<tr>
<td>Treatment of DVT, PE and prevention of recurrence</td>
<td>6,790</td>
<td>Day 1 - 21: 30 mg Day 22 and onwards: 20 mg After at least 6 months: 10 mg or 20 mg</td>
<td>21 months</td>
</tr>
<tr>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</td>
<td>7,750</td>
<td>20 mg</td>
<td>41 months</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS)</td>
<td>10,225</td>
<td>5 mg or 10 mg respectively, co-administered with either ASA or ASA plus clopidogrel or ticlopidine</td>
<td>31 months</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with CAD/PAD</td>
<td>18,244</td>
<td>5 mg co-administered with ASA or 10 mg alone</td>
<td>47 months</td>
</tr>
</tbody>
</table>

* Patients exposed to at least one dose of rivaroxaban

The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and ‘Description of selected adverse reactions’ below) (Table 2). The most commonly reported bleedings were epistaxis (4.5 %) and gastrointestinal tract haemorrhage (3.8 %).
Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed phase III studies

<table>
<thead>
<tr>
<th>Indication</th>
<th>Any bleeding</th>
<th>Anaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</td>
<td>6.8% of patients</td>
<td>5.9% of patients</td>
</tr>
<tr>
<td>Prevention of venous thromboembolism in medically ill patients</td>
<td>12.6% of patients</td>
<td>2.1% of patients</td>
</tr>
<tr>
<td>Treatment of DVT, PE and prevention of recurrence</td>
<td>23% of patients</td>
<td>1.6% of patients</td>
</tr>
<tr>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</td>
<td>28 per 100 patient years</td>
<td>2.5 per 100 patient years</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients after an ACS</td>
<td>22 per 100 patient years</td>
<td>1.4 per 100 patient years</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with CAD/PAD</td>
<td>6.7 per 100 patient years</td>
<td>0.15 per 100 patient years**</td>
</tr>
</tbody>
</table>

* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.

** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied

Tabulated list of adverse reactions
The frequencies of adverse reactions reported with Xarelto are summarised in Table 3 below by system organ class (in MedDRA) and by frequency.

Frequencies are defined as:
very common (≥ 1/10)
common (≥ 1/100 to < 1/10)
uncommon (≥ 1/1,000 to < 1/100)
rare (≥ 1/10,000 to < 1/1,000)
very rare (< 1/10,000)
not known (cannot be estimated from the available data)

Table 3: All adverse reactions reported in patients in phase III clinical trials or through post-marketing use*

<table>
<thead>
<tr>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Very rare</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaemia (incl. respective laboratory parameters)</td>
<td>Thrombocytosis (incl. platelet count increased)A, Thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td>Allergic reaction, dermatitis allergic, Angioedema and allergic oedema</td>
<td>Anaphylactic reactions including anaphylactic shock</td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td>Dizziness, headache</td>
<td>Cerebral and intracranial haemorrhage, syncope</td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
<td>Very rare</td>
<td>Not known</td>
</tr>
<tr>
<td>--------</td>
<td>----------</td>
<td>------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye haemorrhage (incl. conjunctival haemorrhage)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tachycardia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypotension, haematoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis, haemoptysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation, diarrhoea, vomiting</td>
<td>Dry mouth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase in transaminases</td>
<td>Hepatic impairment, Increased bilirubin, increased blood alkaline phosphatase, increased GGT</td>
<td>Jaundice, Bilirubin conjugated increased (with or without concomitant increase of ALT), Cholestasis, Hepatitis (incl. hepatocellular injury)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus (incl. uncommon cases of generalised pruritus), rash, ecchymosis, cutaneous and subcutaneous haemorrhage</td>
<td>Urticaria</td>
<td></td>
<td>Stevens-Johnson syndrome/ Toxic Epidermal Necrolysis, DRESS syndrome</td>
<td></td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>Haemarthrosis</td>
<td>Muscle haemorrhage</td>
<td>Compartent syndrome secondary to a bleeding</td>
<td></td>
</tr>
<tr>
<td>Common Uncommon Rare Very rare Not known</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>------------------</td>
<td>----------------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</td>
</tr>
<tr>
<td>Urogenital tract haemorrhage (incl. haematuria and menorrhagia&lt;sup&gt;B&lt;/sup&gt;), renal impairment (incl. blood creatinine increased, blood urea increased)&lt;sup&gt;A&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever&lt;sup&gt;A&lt;/sup&gt;, peripheral oedema, decreased general strength and energy (incl. fatigue and asthenia)</td>
<td>Feeling unwell (incl. malaise)</td>
<td>Localised oedema&lt;sup&gt;A&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased LDH&lt;sup&gt;A&lt;/sup&gt;, increased lipase&lt;sup&gt;A&lt;/sup&gt;, increased amylase&lt;sup&gt;A&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Injury, poisoning and procedural complications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postprocedural haemorrhage (incl. postoperative anaemia, and wound haemorrhage), contusion, wound secretion&lt;sup&gt;A&lt;/sup&gt;</td>
<td>Vascular pseudoaneurysm&lt;sup&gt;C&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery  
B: observed in treatment of DVT, PE and prevention of recurrence as very common in women < .55 years  
C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)  
* A pre-specified selective approach to adverse event collection was applied. As incidence of adverse reactions did not increase and no new adverse reaction was identified, COMPASS study data were not included for frequency calculation in this table.

**Description of selected adverse reactions**  
Due to the pharmacological mode of action, the use of Xarelto may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 “Management of bleeding”). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section 4.4 “Haemorrhagic risk”). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained...
swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed. Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Xarelto. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

### 4.9 Overdose

Rare cases of overdose up to 600 mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50 mg rivaroxaban or above. A specific antidote antagonising the pharmacodynamic effect of rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.

**Management of bleeding**

Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a half-life of approximately 5 to 13 hours (see section 5.2). Management should be individualised according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.

If bleeding cannot be controlled by the above measures, administration of a specific procoagulant reversal agent should be considered, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa). However, there is currently very limited clinical experience with the use of these medicinal products in individuals receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings (see section 5.1).

Protamine sulphate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic haemostatic desmopressin in individuals receiving rivaroxaban. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.

### 5. PHARMACOLOGICAL PROPERTIES

#### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF01

**Mechanism of action**

Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.
Pharmacodynamic effects
Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant. In patients undergoing major orthopaedic surgery, the 5/95 percentiles for PT (Neoplastin) 2 - 4 hours after tablet intake (i.e. at the time of maximum effect) ranged from 13 to 25 s (baseline values before surgery 12 to 15 s).
In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3-factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9).
The activated partial thomboplastin time (aPTT) and HepTest are also prolonged dose-dependently; however, they are not recommended to assess the pharmacodynamic effect of rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated rivaroxaban levels can be measured by calibrated quantitative anti-factor Xa tests (see section 5.2).

Clinical efficacy and safety
Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery
The rivaroxaban clinical programme was designed to demonstrate the efficacy of rivaroxaban for the prevention of VTE, i.e. proximal and distal deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing major orthopaedic surgery of the lower limbs. Over 9,500 patients (7,050 in total hip replacement surgery and 2,531 in total knee replacement surgery) were studied in controlled randomised double-blind phase III clinical studies, the RECORD-programme. Rivaroxaban 10 mg once daily (od) started no sooner than 6 hours post-operatively was compared with enoxaparin 40 mg once daily started 12 hours pre-operatively.
In all three phase III studies (see table 4), rivaroxaban significantly reduced the rate of total VTE (any venographically detected or symptomatic DVT, non-fatal PE and death) and major VTE (proximal DVT, non-fatal PE and VTE-related death), the pre-specified primary and major secondary efficacy endpoints. Furthermore, in all three studies the rate of symptomatic VTE (symptomatic DVT, non-fatal PE, VTE-related death) was lower in rivaroxaban treated patients compared to patients treated with enoxaparin.
The main safety endpoint, major bleeding, showed comparable rates for patients treated with rivaroxaban 10 mg compared to enoxaparin 40 mg.
Table 4: Efficacy and safety results from phase III clinical studies

<table>
<thead>
<tr>
<th>Study population</th>
<th>RECORD 1</th>
<th>RECORD 2</th>
<th>RECORD 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4,541 patients undergoing total hip replacement surgery</td>
<td>2,509 patients undergoing total hip replacement surgery</td>
<td>2,531 patients undergoing total knee replacement surgery</td>
</tr>
<tr>
<td>Treatment dose and duration after surgery</td>
<td>Rivaroxaban 10 mg od 35 ± 4 days</td>
<td>Rivaroxaban 10 mg od 35 ± 4 days</td>
<td>Rivaroxaban 10 mg od 12 ± 2 days</td>
</tr>
<tr>
<td></td>
<td>Enoxaparin 40 mg od 35 ± 4 days</td>
<td>Enoxaparin 40 mg od 12 ± 2 days</td>
<td>Enoxaparin 40 mg od 12 ± 2 days</td>
</tr>
<tr>
<td>Total VTE</td>
<td>18 (1.1%) 17 (2.0%) 79 (9.6%)</td>
<td>58 (3.7%) 81 (9.3%) 166 (18.9%)</td>
<td>&lt; 0.001 &lt; 0.001 &lt; 0.001</td>
</tr>
<tr>
<td>Major VTE</td>
<td>4 (0.2%) 6 (0.6%) 9 (1.0%)</td>
<td>33 (2.0%) 49 (5.1%) 24 (2.6%)</td>
<td>&lt; 0.001 &lt; 0.001 0.01</td>
</tr>
<tr>
<td>Symptomatic VTE</td>
<td>6 (0.4%) 3 (0.4%) 8 (1.0%)</td>
<td>11 (0.7%) 15 (1.7%) 24 (2.7%)</td>
<td>0.01</td>
</tr>
<tr>
<td>Major bleedings</td>
<td>6 (0.3%) 1 (0.1%) 7 (0.6%)</td>
<td>2 (0.1%) 1 (0.1%) 6 (0.5%)</td>
<td>0.01</td>
</tr>
</tbody>
</table>

The analysis of the pooled results of the phase III studies corroborated the data obtained in the individual studies regarding reduction of total VTE, major VTE and symptomatic VTE with rivaroxaban 10 mg once daily compared to enoxaparin 40 mg once daily.

In addition to the phase III RECORD programme, a post-authorization, non-interventional, open-label cohort study (XAMOS) has been conducted in 17,413 patients undergoing major orthopaedic surgery of the hip or knee, to compare rivaroxaban with other pharmacological thromboprophylaxis (standard-of-care) under real-life setting. Symptomatic VTE occurred in 57 (0.6%) patients in the rivaroxaban group (n=8,778) and 88 (1.0%) of patients in the standard-of-care group (n=8,635; HR 0.63; 95% CI 0.43-0.91); safety population). Major bleeding occurred in 35 (0.4%) and 29 (0.3%) of patients in the rivaroxaban and standard-of-care groups (HR 1.10; 95% CI 0.67-1.80). Thus, the results were consistent with the results of the pivotal randomised studies.

Treatment of DVT, PE and prevention of recurrent DVT and PE
The Xarelto clinical programme was designed to demonstrate the efficacy of Xarelto in the initial and continued treatment of acute DVT and PE and prevention of recurrence. Over 12,800 patients were studied in four randomised controlled phase III clinical studies (Einstein DVT, Einstein PE, Einstein Extension and Einstein Choice). and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted. The overall combined treatment duration in all studies was up to 21 months.

In Einstein DVT 3,449 patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study). The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator. For the initial 3 week treatment of acute DVT 15 mg rivaroxaban was administered twice daily. This was followed by 20 mg rivaroxaban once daily.

In Einstein PE, 4,832 patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE. The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator. For the initial treatment of acute PE 15 mg rivaroxaban was administered twice daily for three weeks. This was followed by 20 mg rivaroxaban once daily.

In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until
the PT/INR was in therapeutic range (≥ 2.0). Treatment was continued with a vitamin K antagonist dose-adjusted to maintain the PT/INR values within the therapeutic range of 2.0 to 3.0.

In Einstein Extension 1,197 patients with DVT or PE were studied for the prevention of recurrent DVT and PE. The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator. Xarelto 20 mg once daily was compared with placebo.

Einstein DVT, PE and Extension used the same pre-defined primary and secondary efficacy outcomes. The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE. The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all-cause mortality.

In Einstein Choice, 3,396 patients with confirmed symptomatic DVT and/or PE who completed 6-12 months of anticoagulant treatment were studied for the prevention of fatal PE or non-fatal symptomatic recurrent DVT or PE. Patients with an indication for continued therapeutic-dosed anticoagulation were excluded from the study. The treatment duration was up to 12 months depending on the individual randomisation date (median: 351 days). Xarelto 20 mg once daily and Xarelto 10 mg once daily were compared with 100 mg acetylsalicylic acid once daily.

The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE.

In the Einstein DVT study (see Table 5) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p < 0.0001 (test for non-inferiority); Hazard Ratio (HR): 0.680 (0.443 - 1.042), p=0.076 (test for superiority)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.67 ((95% CI: 0.47 - 0.95), nominal p value p=0.027) in favour of rivaroxaban. INR values were within the therapeutic range a mean of 60.3% of the time for the mean treatment duration of 189 days, and 55.4%, 60.1%, and 62.8% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 – 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).

The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.
<table>
<thead>
<tr>
<th>Study population</th>
<th>3,449 patients with symptomatic acute deep vein thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose and duration</strong></td>
<td>Xarelto(^a) 3, 6 or 12 months N=1,731</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>36 (2.1%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>20 (1.2%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>14 (0.8%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>1 (0.1%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>4 (0.2%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>139 (8.1%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>14 (0.8%)</td>
</tr>
</tbody>
</table>

\(^a\) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily

\(^b\) Enoxaparin for at least 5 days, overlapped with and followed by VKA

\(^*\) p < 0.0001 (non-inferiority to a prespecified HR of 2.0); HR: 0.680 (0.443 - 1.042), p=0.076 (superiority)

In the Einstein PE study (see Table 6) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); HR: 1.123 (0.749 – 1.684)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.849 ((95% CI: 0.633 - 1.139), nominal p value p= 0.275). INR values were within the therapeutic range a mean of 63% of the time for the mean treatment duration of 215 days, and 57%, 62%, and 65% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 – 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.642 (95% CI: 0.277 - 1.484).

The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4% (274/2405)). The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a HR 0.493 (95% CI: 0.308 - 0.789).
Table 6: Efficacy and safety results from phase III Einstein PE Study population

<table>
<thead>
<tr>
<th>Treatment dose and duration</th>
<th>Xarelto(^{a)}) 3, 6 or 12 months N=2,419</th>
<th>Enoxaparin/VKA(^{b)}) 3, 6 or 12 months N=2,413</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>50 (2.1%)</td>
<td>44 (1.8%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>23 (1.0%)</td>
<td>20 (0.8%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>18 (0.7%)</td>
<td>17 (0.7%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>0</td>
<td>2 (&lt;0.1%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>11 (0.5%)</td>
<td>7 (0.3%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>249 (10.3%)</td>
<td>274 (11.4%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>26 (1.1%)</td>
<td>52 (2.2%)</td>
</tr>
</tbody>
</table>

\(^{a)}\) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily

\(^{b)}\) Enoxaparin for at least 5 days, overlapped with and followed by VKA

\(*\) \(p < 0.0026\) (non-inferiority to a prespecified HR of 2.0); HR: 1.123 (0.749 – 1.684)

A prespecified pooled analysis of the outcome of the Einstein DVT and PE studies was conducted (see Table 7).

Table 7: Efficacy and safety results from pooled analysis of phase III Einstein DVT and Einstein PE Study population

<table>
<thead>
<tr>
<th>Treatment dose and duration</th>
<th>Xarelto(^{a)}) 3, 6 or 12 months N=4,150</th>
<th>Enoxaparin/VKA(^{b)}) 3, 6 or 12 months N=4,131</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>86 (2.1%)</td>
<td>95 (2.3%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>43 (1.0%)</td>
<td>38 (0.9%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>32 (0.8%)</td>
<td>45 (1.1%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>1 (&lt;0.1%)</td>
<td>2 (&lt;0.1%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>15 (0.4%)</td>
<td>13 (0.3%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>388 (9.4%)</td>
<td>412 (10.0%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>40 (1.0%)</td>
<td>72 (1.7%)</td>
</tr>
</tbody>
</table>

\(^{a)}\) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily

\(^{b)}\) Enoxaparin for at least 5 days, overlapped with and followed by VKA

\(*\) \(p < 0.0001\) (non-inferiority to a prespecified HR of 1.75); HR: 0.886 (0.661 – 1.186)

The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a HR of 0.771 ((95% CI: 0.614 – 0.967), nominal p value \(p = 0.0244\)).
In the Einstein Extension study (see Table 8) rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes. For the primary safety outcome (major bleeding events) there was a non-significant numerically higher incidence rate for patients treated with rivaroxaban 20 mg once daily compared to placebo. The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with rivaroxaban 20 mg once daily compared to placebo.

Table 8: Efficacy and safety results from phase III Einstein Extension

<table>
<thead>
<tr>
<th>Study population</th>
<th>1,197 patients continued treatment and prevention of recurrent venous thromboembolism</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose and duration</strong></td>
<td><strong>Xarelto&lt;sup&gt;a)&lt;/sup&gt; 6 or 12 months N=602</strong></td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>8 (1.3%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>2 (0.3%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>5 (0.8%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>4 (0.7%)</td>
</tr>
<tr>
<td>Clinically relevant non-major bleeding</td>
<td>32 (5.4%)</td>
</tr>
</tbody>
</table>

<sup>a)</sup> Rivaroxaban 20 mg once daily
* p < 0.0001 (superiority), HR: 0.185 (0.087 - 0.393)

In the Einstein Choice study (Table 9) Xarelto 20 mg and 10 mg were both superior to 100 mg acetylsalicylic acid for the primary efficacy outcome. The principal safety outcome (major bleeding events) was similar for patients treated with Xarelto 20 mg and 10 mg once daily compared to 100 mg acetylsalicylic acid.
Table 9: Efficacy and safety results from phase III Einstein Choice

<table>
<thead>
<tr>
<th>Study population</th>
<th>3,396 patients continued prevention of recurrent venous thromboembolism</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose</strong></td>
<td>Xarelto 20 mg od N=1,107</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE</td>
<td>17 (1.5%)*</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>6 (0.5%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>9 (0.8%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>2 (0.2%)</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE, MI, stroke, or non-CNS systemic embolism</td>
<td>19 (1.7%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>6 (0.5%)</td>
</tr>
<tr>
<td>Clinically relevant non-major bleeding</td>
<td>30 (2.7)</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE or major bleeding (net clinical benefit)</td>
<td>23 (2.1%)*</td>
</tr>
</tbody>
</table>

* p<0.001 (superiority) Xarelto 20 mg od vs ASA 100 mg od; HR=0.34 (0.20–0.59)
** p<0.001 (superiority) Xarelto 10 mg od vs ASA 100 mg od; HR=0.26 (0.14–0.47)
+ Xarelto 20 mg od vs. ASA 100 mg od; HR=0.44 (0.27–0.71), p=0.0009 (nominal)
++ Xarelto 10 mg od vs. ASA 100 mg od; HR=0.32 (0.18–0.55), p<0.0001 (nominal)

In addition to the phase III EINSTEIN programme, a prospective, non-interventional, open-label cohort study (XALIA) with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted. 5,142 patients with acute DVT were enrolled to investigate the long-term safety of rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice. Rates of major bleeding, recurrent VTE and all-cause mortality for rivaroxaban were 0.7%, 1.4% and 0.5%, respectively. There were differences in patient baseline characteristics including age, cancer and renal impairment. A pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results. Adjusted HRs comparing rivaroxaban and standard-of-care for major bleeding, recurrent VTE and all-cause mortality were 0.77 (95% CI 0.40 - 1.50), 0.91 (95% CI 0.54 - 1.54) and 0.51 (95% CI 0.24 - 1.07), respectively. These results in clinical practice are consistent with the established safety profile in this indication.

Paediatric population
The European Medicines Agency has deferred the obligation to submit the results of studies with Xarelto in one or more subsets of the paediatric population in the treatment of thromboembolic events. The European Medicines Agency has waived the obligation to submit the results of studies with Xarelto in all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption
Rivaroxaban is rapidly absorbed with maximum concentrations ($C_{max}$) appearing 2 - 4 hours after tablet intake.
Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5 mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or C\text{max} at the 2.5 mg and 10 mg dose. Rivaroxaban 2.5 mg and 10 mg tablets can be taken with or without food. Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose. This is more marked in fasting state than in fed state. Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%, apart from on the day of surgery and the following day when variability in exposure is high (70%).

Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and C\text{max} compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure.

Bioavailability (AUC and C\text{max}) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.

**Distribution**

Plasma protein binding in humans is high at approximately 92% to 95%, with serum albumin being the main binding component. The volume of distribution is moderate with V\text{ss} being approximately 50 litres.

**Biotransformation and elimination**

Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.

Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on in vitro investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).

Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.

**Special populations**

**Gender**

There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients.

**Elderly population**

Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.

**Different weight categories**

Extremes in body weight (< 50 kg or > 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.
**Inter-ethnic differences**
No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.

**Hepatic impairment**
Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.

The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT.

Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).

**Renal impairment**
There was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively. There are no data in patients with creatinine clearance < 15 ml/min.

Due to the high plasma protein binding rivaroxaban is not expected to be dialysable. Use is not recommended in patients with creatinine clearance < 15 ml/min. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).

**Pharmacokinetic data in patients**
In patients receiving rivaroxaban for prevention of VTE 10 mg once daily the geometric mean concentration (90% prediction interval) 2 - 4 h and about 24 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 101 (7 - 273) and 14 (4 - 51) mcg/l, respectively.

**Pharmacokinetic/pharmacodynamic relationship**
The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor Xa activity was best described by an E\text{max} model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 mcg/l). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects. In patients, baseline factor Xa and PT were influenced by the surgery resulting in a difference in the concentration-PT slope between the day post-surgery and steady state.

**Paediatric population**
Safety and efficacy have not been established for children and adolescents up to 18 years.
5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.

Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.

In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. haemorrhagic complications). Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and postnatal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
- Microcrystalline cellulose
- Croscarmellose sodium
- Lactose monohydrate
- Hypromellose 2910
- Sodium laurilsulphate
- Magnesium stearate

Film-coat
- Macrogol 3350
- Hypromellose 2910
- Titanium dioxide (E 171)
- Iron oxide red (E 172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

PP/Aluminium foil blisters in cartons of 5, 10, 14, 28, 30 or 98 film-coated tablets or perforated unit dose blisters in cartons of 10 x 1, 100 x 1, or in multipacks containing 100 (10 packs of 10 x 1) film-coated tablets.

PVC/PVDC/Aluminium foil blisters in cartons of 5, 10 or 30 film-coated tablets or perforated unit dose blisters in cartons of 10 x 1 or 100 x 1 film-coated tablets.

HDPE bottles with a PP screw cap containing 100 film-coated tablets.

Not all pack sizes may be marketed.
6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/472/001-010, EU/1/08/472/022, EU/1/08/472/042-045.

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 30 September 2008
Date of latest renewal: 22 May 2018

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**

Xarelto 15 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 15 mg rivaroxaban.

**Excipient with known effect**
Each film-coated tablet contains 24.13 mg lactose (as monohydrate), see section 4.4.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Film-coated tablet (tablet)

Red, round biconvex tablets (6 mm diameter, 9 mm radius of curvature) marked with the BAYER-cross on one side and “15” and a triangle on the other side.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)

4.2 **Posology and method of administration**

**Posology**

*Prevention of stroke and systemic embolism*

The recommended dose is 20 mg once daily, which is also the recommended maximum dose.

Therapy with Xarelto should be continued long term provided the benefit of prevention of stroke and systemic embolism outweighs the risk of bleeding (see section 4.4).

If a dose is missed the patient should take Xarelto immediately and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.

*Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE*

The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE.
Short duration of therapy (at least 3 months) should be considered in patients with DVT or PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT or PE not related to major transient risk factors, unprovoked DVT or PE, or a history of recurrent DVT or PE.

When extended prevention of recurrent DVT and PE is indicated (following completion of at least 6 months therapy for DVT or PE), the recommended dose is 10 mg once daily. In patients in whom the risk of recurrent DVT or PE is considered high, such as those with complicated comorbidities, or who have developed recurrent DVT or PE on extended prevention with Xarelto 10 mg once daily, a dose of Xarelto 20 mg once daily should be considered.

The duration of therapy and dose selection should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).

<table>
<thead>
<tr>
<th>Time period</th>
<th>Dosing schedule</th>
<th>Total daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment and prevention of recurrent DVT and PE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1 - 21</td>
<td>15 mg twice daily</td>
<td>30 mg</td>
</tr>
<tr>
<td>Day 22 onwards</td>
<td>20 mg once daily</td>
<td>20 mg</td>
</tr>
<tr>
<td>Prevention of recurrent DVT and PE</td>
<td>Following completion of at least 6 months therapy for DVT or PE</td>
<td>10 mg once daily or 20 mg once daily</td>
</tr>
</tbody>
</table>

To support the dose switch from 15 mg to 20 mg after Day 21 a first 4 weeks treatment initiation pack of Xarelto for treatment of DVT/PE is available.

If a dose is missed during the 15 mg twice daily treatment phase (day 1 - 21), the patient should take Xarelto immediately to ensure intake of 30 mg Xarelto per day. In this case two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.

If a dose is missed during the once daily treatment phase, the patient should take Xarelto immediately, and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.

**Converting from Vitamin K Antagonists (VKA) to Xarelto**

For patients treated for prevention of stroke and systemic embolism, VKA treatment should be stopped and Xarelto therapy should be initiated when the International Normalised Ratio (INR) is ≤ 3.0.

For patients treated for DVT, PE and prevention of recurrence, VKA treatment should be stopped and Xarelto therapy should be initiated once the INR is ≤ 2.5.

When converting patients from VKAs to Xarelto, INR values will be falsely elevated after the intake of Xarelto. The INR is not valid to measure the anticoagulant activity of Xarelto, and therefore should not be used (see section 4.5).

**Converting from Xarelto to Vitamin K antagonists (VKA)**

There is a potential for inadequate anticoagulation during the transition from Xarelto to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Xarelto can contribute to an elevated INR.

In patients converting from Xarelto to VKA, VKA should be given concurrently until the INR is ≥ 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Xarelto and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Xarelto. Once Xarelto is discontinued INR testing may be done reliably at least 24 hours after the last dose (see sections 4.5 and 5.2).
Converting from parenteral anticoagulants to Xarelto
For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Xarelto 0 to 2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).

Converting from Xarelto to parenteral anticoagulants
Give the first dose of parenteral anticoagulant at the time the next Xarelto dose would be taken.

Special populations
Renal impairment
Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, Xarelto is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance < 15 ml/min (see sections 4.4 and 5.2).

In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15-29 ml/min) renal impairment the following dose recommendations apply:

- For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the recommended dose is 15 mg once daily (see section 5.2).

- For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE: patients should be treated with 15 mg twice daily for the first 3 weeks. Thereafter, when the recommended dose is 20 mg once daily, a reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient’s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2). When the recommended dose is 10 mg once daily, no dose adjustment from the recommended dose is necessary.

No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).

Hepatic impairment
Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).

Elderly population
No dose adjustment (see section 5.2)

Body weight
No dose adjustment (see section 5.2)

Gender
No dose adjustment (see section 5.2)

Paediatric population
The safety and efficacy of Xarelto in children aged 0 to 18 years have not been established. No data are available. Therefore, Xarelto is not recommended for use in children below 18 years of age.

Patients undergoing cardioversion
Xarelto can be initiated or continued in patients who may require cardioversion. For transesophageal echocardiogram (TEE) guided cardioversion in patients not previously treated with anticoagulants, Xarelto treatment should be started at least 4 hours before cardioversion to ensure
adequate anticoagulation (see sections 5.1 and 5.2). For all patients, confirmation should be sought prior to cardioversion that the patient has taken Xarelto as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.

Patients with non-valvular atrial fibrillation who undergo PCI (percutaneous coronary intervention) with stent placement
There is limited experience of a reduced dose of 15 mg Xarelto once daily (or 10 mg Xarelto once daily for patients with moderate renal impairment [creatinine clearance 30 - 49 ml/min]) in addition to a P2Y12 inhibitor for a maximum of 12 months in patients with non-valvular atrial fibrillation who require oral anticoagulation and undergo PCI with stent placement (see sections 4.4 and 5.1).

Method of administration
Xarelto is for oral use. The tablets are to be taken with food (see section 5.2).

For patients who are unable to swallow whole tablets, Xarelto tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally. After the administration of crushed Xarelto 15 mg or 20 mg film-coated tablets, the dose should be immediately followed by food.
The crushed Xarelto tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water. After the administration of crushed Xarelto 15 mg or 20 mg film-coated tablets, the dose should then be immediately followed by enteral feeding (see section 5.2).

4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active clinically significant bleeding.

Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2).

Pregnancy and breast-feeding (see section 4.6).

4.4 Special warnings and precautions for use
Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.
Haemorrhagic risk
As with other anticoagulants, patients taking Xarelto are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Xarelto administration should be discontinued if severe haemorrhage occurs.

In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.

Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8). Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.

Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see sections 5.1 and 5.2).

Renal impairment
In patients with severe renal impairment (creatinine clearance < 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6 fold on average) which may lead to an increased bleeding risk. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance < 15 ml/min (see sections 4.2 and 5.2). Xarelto should be used with caution in patients with renal impairment concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations (see section 4.5).

Interaction with other medicinal products
The use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk (see section 4.5).

Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5).

Other haemorrhagic risk factors
As with other antithrombotics, rivaroxaban is not recommended in patients with an increased bleeding risk such as:
- congenital or acquired bleeding disorders
- uncontrolled severe arterial hypertension
- other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)
- vascular retinopathy
- bronchiectasis or history of pulmonary bleeding
Patients with prosthetic valves
Safety and efficacy of Xarelto have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Xarelto provides adequate anticoagulation in this patient population. Treatment with Xarelto is not recommended for these patients.

Patients with non-valvular atrial fibrillation who undergo PCI with stent placement
Clinical data are available from an interventional study with the primary objective to assess safety in patients with non-valvular atrial fibrillation who undergo PCI with stent placement. Data on efficacy in this population are limited (see sections 4.2 and 5.1). No data are available for such patients with a history of stroke/ transient ischaemic attack (TIA).

Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy
Xarelto is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of Xarelto have not been established in these clinical situations.

Spinal/epidural anaesthesia or puncture
When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. There is no clinical experience with the use of 15 mg rivaroxaban in these situations.

To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low. However, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.

For the removal of an epidural catheter and based on the general PK characteristics at least 2x half-life, i.e. at least 18 hours in young patients and 26 hours in elderly patients should elapse after the last administration of rivaroxaban (see section 5.2). Following removal of the catheter, at least 6 hours should elapse before the next rivaroxaban dose is administered.

If traumatic puncture occurs the administration of rivaroxaban is to be delayed for 24 hours.

Dosing recommendations before and after invasive procedures and surgical intervention
If an invasive procedure or surgical intervention is required, Xarelto 15 mg should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician. If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.

Xarelto should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section 5.2).

Elderly population
Increasing age may increase haemorrhagic risk (see section 5.2).

Dermatological reactions
Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of
rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.

Information about excipients
Xarelto contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

CYP3A4 and P-gp inhibitors
Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban C\text{max}, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp (see section 4.4).

Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5 fold increase in mean rivaroxaban AUC and a 1.4 fold increase in C\text{max}. The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).

Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3 fold increase in mean rivaroxaban AUC and C\text{max}. The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8 fold increase in mean rivaroxaban AUC and 1.6 fold increase in C\text{max} when compared to subjects with normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0 fold increase in mean rivaroxaban AUC and 1.6 fold increase in C\text{max} when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section 4.4).

Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold increase in mean rivaroxaban AUC and a 1.3 fold increase in mean C\text{max}. The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).

Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.

Anticoagulants
After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban. Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections 4.3 and 4.4).
NSAIDs/platelet aggregation inhibitors
No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15 mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response.
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with 500 mg acetylsalicylic acid.
Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.
Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).

SSRIs/SNRIs
As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical programme, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.

Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.
If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban.
If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the C_{trough} of rivaroxaban (24 hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.
No pharmacokinetic interaction was observed between warfarin and rivaroxaban.

CYP3A4 inducers
Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John’s Wort (Hypericum perforatum)) may also lead to reduced rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.

Other concomitant therapies
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4.

Laboratory parameters
Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of rivaroxaban (see section 5.1).
4.6 Fertility, pregnancy and lactation

Pregnancy
Safety and efficacy of Xarelto have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Xarelto is contraindicated during pregnancy (see section 4.3). Women of child-bearing potential should avoid becoming pregnant during treatment with rivaroxaban.

Breast-feeding
Safety and efficacy of Xarelto have not been established in breast-feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore Xarelto is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.

Fertility
No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).

4.7 Effects on ability to drive and use machines
Xarelto has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8). Patients experiencing these adverse reactions should not drive or use machines.

4.8 Undesirable effects

Summary of the safety profile
The safety of rivaroxaban has been evaluated in thirteen phase III studies including 53,103 patients exposed to rivaroxaban (see Table 1).
Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of patients*</th>
<th>Total daily dose</th>
<th>Maximum treatment duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of venous thromboembolism (VTE) in adult patients undergoing</td>
<td>6,097</td>
<td>10 mg</td>
<td>39 days</td>
</tr>
<tr>
<td>elective hip or knee replacement surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevention of venous thromboembolism in medically ill patients</td>
<td>3,997</td>
<td>10 mg</td>
<td>39 days</td>
</tr>
<tr>
<td>Treatment of DVT, PE and prevention of recurrence</td>
<td>6,790</td>
<td>Day 1 - 21: 30 mg Day 22 and onwards: 20 mg After at least 6 months: 10 mg or 20 mg</td>
<td>21 months</td>
</tr>
<tr>
<td>Prevention of stroke and systemic embolism in patients with non-valvular</td>
<td>7,750</td>
<td>20 mg</td>
<td>41 months</td>
</tr>
<tr>
<td>atrial fibrillation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients after an ACS</td>
<td>10,225</td>
<td>5 mg or 10 mg respectively, co-administered with either ASA or ASA plus clopidogrel or ticlopidine</td>
<td>31 months</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with CAD/PAD</td>
<td>18,244</td>
<td>5 mg co-administered with ASA or 10 mg alone</td>
<td>47 months</td>
</tr>
</tbody>
</table>

* Patients exposed to at least one dose of rivaroxaban

The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and ‘Description of selected adverse reactions’ below) (Table 2). The most commonly reported bleedings were epistaxis (4.5 %) and gastrointestinal tract haemorrhage (3.8 %).
Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed phase III studies

<table>
<thead>
<tr>
<th>Indication</th>
<th>Any bleeding</th>
<th>Anaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</td>
<td>6.8% of patients</td>
<td>5.9% of patients</td>
</tr>
<tr>
<td>Prevention of venous thromboembolism in medically ill patients</td>
<td>12.6% of patients</td>
<td>2.1% of patients</td>
</tr>
<tr>
<td>Treatment of DVT, PE and prevention of recurrence</td>
<td>23% of patients</td>
<td>1.6% of patients</td>
</tr>
<tr>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</td>
<td>28 per 100 patient years</td>
<td>2.5 per 100 patient years</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients after an ACS</td>
<td>22 per 100 patient years</td>
<td>1.4 per 100 patient years</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with CAD/PAD</td>
<td>6.7 per 100 patient years</td>
<td>0.15 per 100 patient years**</td>
</tr>
</tbody>
</table>

* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.
** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied.

Tabulated list of adverse reactions

The frequencies of adverse reactions reported with Xarelto are summarised in Table 3 below by system organ class (in MedDRA) and by frequency.

Table 3: All adverse reactions reported in patients in phase III clinical trials or through post-marketing use*

<table>
<thead>
<tr>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Very rare</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaemia (incl. respective laboratory parameters)</td>
<td>Thrombocytosis (incl. platelet count increased)^A, Thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Allergic reaction, dermatitis allergic, Angioedema and allergic oedema</td>
<td></td>
<td>Anaphylactic reactions including anaphylactic shock</td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness, headache</td>
<td>Cerebral and intracranial haemorrhage, syncope</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Frequencies are defined as:
very common (≥ 1/10)
common (≥ 1/100 to < 1/10)
uncommon (≥ 1/1,000 to < 1/100)
rare (≥ 1/10,000 to < 1/1,000)
very rare (< 1/10,000)
not known (cannot be estimated from the available data)
<table>
<thead>
<tr>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Very rare</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye haemorrhage (incl. conjunctival</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>haemorrhage)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tachycardia</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypotension, haematoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis, haemoptysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gingival bleeding, gastrointestinal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tract haemorrhage (incl. rectal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>haemorrhage), gastrointestinal and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>abdominal pains, dyspepsia, nausea,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>constipation(^A), diarrhoea,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vomiting(^A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase in transaminases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic impairment, Increased</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bilirubin, increased blood alkaline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>phosphatase(^A), increased GGT(^A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jaundice, Bilirubin conjugated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>increased (with or without</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>concomitant increase of ALT),</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholestasis, Hepatitis (incl.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hepatocellular injury)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>**Skin and subcutaneous tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>disorders**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus (incl. uncommon cases of</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>generalised pruritus), rash,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ecchymosis, cutaneous and</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>subcutaneous haemorrhage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urticaria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stevens-Johnson syndrome/ Toxic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epidermal Necrolysis, DRESS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>**Musculoskeletal and connective</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tissue disorders**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain in extremity(^A)</td>
<td></td>
<td>Haemarthrosis</td>
<td>Muscle haemorrhage</td>
<td>Compartement syndrome secondary to a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>bleeding</td>
</tr>
<tr>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
<td>Very rare</td>
<td>Not known</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urogenital tract haemorrhage (incl. haematuria and menorrhagia(^B)), renal impairment (incl. blood creatinine increased, blood urea increased)(^A)</td>
<td></td>
<td></td>
<td></td>
<td>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever(^A), peripheral oedema, decreased general strength and energy (incl. fatigue and asthenia)</td>
<td>Feeling unwell (incl. malaise)</td>
<td>Localised oedema(^A)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased LDH(^A), increased lipase(^A), increased amylase(^A)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postprocedural haemorrhage (incl. postoperative anaemia, and wound haemorrhage), contusion, wound secretion(^A)</td>
<td>Vascular pseudoaneurysm(^C)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B: observed in treatment of DVT, PE and prevention of recurrence as very common in women &lt; 55 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* A pre-specified selective approach to adverse event collection was applied. As incidence of adverse reactions did not increase and no new adverse reaction was identified, COMPASS study data were not included for frequency calculation in this table.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Description of selected adverse reactions
Due to the pharmacological mode of action, the use of Xarelto may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 “Management of bleeding”). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section 4.4 “Haemorrhagic risk”). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained
swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed. Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Xarelto. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

Rare cases of overdose up to 600 mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50 mg rivaroxaban or above. A specific antidote antagonising the pharmacodynamic effect of rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.

Management of bleeding

Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a half-life of approximately 5 to 13 hours (see section 5.2). Management should be individualised according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.

If bleeding cannot be controlled by the above measures, administration of a specific procoagulant reversal agent should be considered, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa). However, there is currently very limited clinical experience with the use of these medicinal products in individuals receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings (see section 5.1).

Protamine sulphate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic haemostatic desmopressin in individuals receiving rivaroxaban. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF01

Mechanism of action

Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.
Pharmacodynamic effects
Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant.

In patients receiving rivaroxaban for treatment of DVT and PE and prevention of recurrence, the 5/95 percentiles for PT (Neoplastin) 2 - 4 hours after tablet intake (i.e. at the time of maximum effect) for 15 mg rivaroxaban twice daily ranged from 17 to 32 s and for 20 mg rivaroxaban once daily from 15 to 30 s. At trough (8 - 16 h after tablet intake) the 5/95 percentiles for 15 mg twice daily ranged from 14 to 24 s and for 20 mg once daily (18 - 30 h after tablet intake) from 13 to 20 s.

In patients with non-valvular atrial fibrillation receiving rivaroxaban for the prevention of stroke and systemic embolism, the 5/95 percentiles for PT (Neoplastin) 1 - 4 hours after tablet intake (i.e. at the time of maximum effect) in patients treated with 20 mg once daily ranged from 14 to 40 s and in patients with moderate renal impairment treated with 15 mg once daily from 10 to 50 s. At trough (16 - 36 h after tablet intake) the 5/95 percentiles in patients treated with 20 mg once daily ranged from 12 to 26 s and in patients with moderate renal impairment treated with 15 mg once daily from 12 to 26 s.

In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3-factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9). The activated partial thromboplastin time (aPTT) and HepTest are also prolonged dose-dependently; however, they are not recommended to assess the pharmacodynamic effect of rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated rivaroxaban levels can be measured by calibrated quantitative anti-factor Xa tests (see section 5.2).

Clinical efficacy and safety
Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
The Xarelto clinical programme was designed to demonstrate the efficacy of Xarelto for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. In the pivotal double-blind ROCKET AF study, 14,264 patients were assigned either to Xarelto 20 mg once daily (15 mg once daily in patients with creatinine clearance 30 - 49 ml/min) or to warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0). The median time on treatment was 19 months and overall treatment duration was up to 41 months. 34.9% of patients were treated with acetylsalicylic acid and 11.4% were treated with class III antiarrhythmic including amiodarone.

Xarelto was non-inferior to warfarin for the primary composite endpoint of stroke and non-CNS systemic embolism. In the per-protocol population on treatment, stroke or systemic embolism occurred in 188 patients on rivaroxaban (1.71% per year) and 241 on warfarin (2.16% per year) (HR 0.79; 95% CI, 0.66 - 0.96; P<0.001 for non-inferiority). Among all randomised patients analysed according to ITT, primary events occurred in 269 on rivaroxaban (2.12% per year) and 306 on warfarin (2.42% per year) (HR 0.88; 95% CI, 0.74 - 1.03; P<0.001 for non-inferiority; P=0.117 for superiority). Results for secondary endpoints as tested in hierarchical order in the ITT analysis are displayed in Table 4. Among patients in the warfarin group, INR values were within the therapeutic range (2.0 to 3.0) a mean of 55% of the time (median, 58%; interquartile range, 43 to 71). The effect of rivaroxaban did not differ across the level of centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized quartiles (P=0.74 for interaction). Within the highest quartile according to centre, the Hazrad Ration (HR) with rivaroxaban versus warfarin was 0.74 (95% CI, 0.49 - 1.12).
The incidence rates for the principal safety outcome (major and non-major clinically relevant bleeding events) were similar for both treatment groups (see Table 5).

Table 4: Efficacy results from phase III ROCKET AF

<table>
<thead>
<tr>
<th>Study population</th>
<th>Xarelto 20 mg od (15 mg od in patients with moderate renal impairment) Event rate (100 pt-yr)</th>
<th>Warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0) Event rate (100 pt-yr)</th>
<th>HR (95% CI) p-value, test for superiority</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke and non-CNS systemic embolism</td>
<td>269 (2.12)</td>
<td>306 (2.42)</td>
<td>0.88 (0.74 - 1.03) 0.117</td>
</tr>
<tr>
<td>Stroke, non-CNS systemic embolism and vascular death</td>
<td>572 (4.51)</td>
<td>609 (4.81)</td>
<td>0.94 (0.84 - 1.05) 0.265</td>
</tr>
<tr>
<td>Stroke, non-CNS systemic embolism, vascular death and myocardial infarction</td>
<td>659 (5.24)</td>
<td>709 (5.65)</td>
<td>0.93 (0.83 - 1.03) 0.158</td>
</tr>
<tr>
<td><strong>Stroke</strong></td>
<td>253 (1.99)</td>
<td>281 (2.22)</td>
<td>0.90 (0.76 - 1.07) 0.221</td>
</tr>
<tr>
<td><strong>Non-CNS systemic embolism</strong></td>
<td>20 (0.16)</td>
<td>27 (0.21)</td>
<td>0.74 (0.42 - 1.32) 0.308</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>130 (1.02)</td>
<td>142 (1.11)</td>
<td>0.91 (0.72 - 1.16) 0.464</td>
</tr>
</tbody>
</table>
Table 5: Safety results from phase III ROCKET AF

<table>
<thead>
<tr>
<th>Study population</th>
<th>Patients with non-valvular atrial fibrillation</th>
<th>Warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0)</th>
<th>HR (95% CI) p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment dose</td>
<td>Xarelto 20 mg once a day (15 mg once a day in patients with moderate renal impairment)</td>
<td>Warfarin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Event rate (100 pt-yr)</td>
<td>Event rate (100 pt-yr)</td>
<td></td>
</tr>
<tr>
<td>Major and non-major clinically relevant bleeding events</td>
<td>1,475 (14.91)</td>
<td>1,449 (14.52)</td>
<td>1.03 (0.96 - 1.11) 0.442</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>395 (3.60)</td>
<td>386 (3.45)</td>
<td>1.04 (0.90 - 1.20) 0.576</td>
</tr>
<tr>
<td>Death due to bleeding*</td>
<td>27 (0.24)</td>
<td>55 (0.48)</td>
<td>0.50 (0.31 - 0.79) 0.003</td>
</tr>
<tr>
<td>Critical organ bleeding*</td>
<td>91 (0.82)</td>
<td>133 (1.18)</td>
<td>0.69 (0.53 - 0.91) 0.007</td>
</tr>
<tr>
<td>Intracranial haemorrhage*</td>
<td>55 (0.49)</td>
<td>84 (0.74)</td>
<td>0.67 (0.47 - 0.93) 0.019</td>
</tr>
<tr>
<td>Haemoglobin drop*</td>
<td>305 (2.77)</td>
<td>254 (2.26)</td>
<td>1.22 (1.03 - 1.44) 0.019</td>
</tr>
<tr>
<td>Transfusion of 2 or more units of packed red blood cells or whole blood*</td>
<td>183 (1.65)</td>
<td>149 (1.32)</td>
<td>1.25 (1.01 - 1.55) 0.044</td>
</tr>
<tr>
<td>Non-major clinically relevant bleeding events</td>
<td>1,185 (11.80)</td>
<td>1,151 (11.37)</td>
<td>1.04 (0.96 - 1.13) 0.345</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>208 (1.87)</td>
<td>250 (2.21)</td>
<td>0.85 (0.70 - 1.02) 0.073</td>
</tr>
</tbody>
</table>

a) Safety population, on treatment

* Nominally significant

In addition to the phase III ROCKET AF study, a prospective, single-arm, post-authorization, non-interventional, open-label cohort study (XANTUS) with central outcome adjudication including thromboembolic events and major bleeding has been conducted. 6,785 patients with non-valvular atrial fibrillation were enrolled for prevention of stroke and non-central nervous system (CNS) systemic embolism in clinical practice. The mean CHADS2 and HAS-BLED scores were both 2.0 in XANTUS, compared to a mean CHADS2 and HAS-BLED score of 3.5 and 2.8 in ROCKET AF, respectively. Major bleeding occurred in 2.1 per 100 patient years. Fatal haemorrhage was reported in 0.2 per 100 patient years and intracranial haemorrhage in 0.4 per 100 patient years. Stroke or non-CNS systemic embolism was recorded in 0.8 per 100 patient years. These observations in clinical practice are consistent with the established safety profile in this indication.

Patients undergoing cardioversion

A prospective, randomised, open-label, multicentre, exploratory study with blinded endpoint evaluation (X-VERT) was conducted in 1504 patients (oral anticoagulant naive and pre-treated) with non-valvular atrial fibrillation scheduled for cardioversion to compare rivaroxaban with dose-adjusted VKA (randomised 2:1), for the prevention of cardiovascular events. TEE-guided (1 - 5 days of pre-treatment) or conventional cardioversion (at least three weeks of pre-treatment) strategies were employed. The primary efficacy outcome (all stroke, transient ischaemic attack, non-CNS systemic embolism, myocardial infarction (MI) and cardiovascular death) occurred in 5 (0.5%) patients in the rivaroxaban group (n = 978) and 5 (1.0%) patients in the VKA group (n = 492; RR 0.50; 95% CI 0.15-
The principal safety outcome (major bleeding) occurred in 6 (0.6%) and 4 (0.8%) patients in the rivaroxaban (n = 988) and VKA (n = 499) groups, respectively (RR 0.76; 95% CI 0.21-2.67; safety population). This exploratory study showed comparable efficacy and safety between rivaroxaban and VKA treatment groups in the setting of cardioversion.

Patients with non-valvular atrial fibrillation who undergo PCI with stent placement
A randomised, open-label, multicentre study (PIONEER AF-PCI) was conducted in 2,124 patients with non-valvular atrial fibrillation who underwent PCI with stent placement for primary atherosclerotic disease to compare safety of two rivaroxaban regimens and one VKA regimen. Patients were randomly assigned in a 1:1:1 fashion for an overall 12-month-therapy. Patients with a history of stroke or TIA were excluded.

Group 1 received rivaroxaban 15 mg once daily (10 mg once daily in patients with creatinine clearance 30 - 49 ml/min) plus P2Y12 inhibitor. Group 2 received rivaroxaban 2.5 mg twice daily plus DAPT (dual antiplatelet therapy i.e. clopidogrel 75 mg [or alternate P2Y12 inhibitor] plus low-dose acetylsalicylic acid [ASA]) for 1, 6 or 12 months followed by rivaroxaban 15 mg (or 10 mg for subjects with creatinine clearance 30 - 49 ml/min) once daily plus low-dose ASA. Group 3 received dose-adjusted VKA plus DAPT for 1, 6 or 12 months followed by dose-adjusted VKA plus low-dose ASA.

The primary safety endpoint, clinically significant bleeding events, occurred in 109 (15.7%), 117 (16.6%), and 167 (24.0%) subjects in group 1, group 2 and group 3, respectively (HR 0.59; 95% CI 0.47-0.76; p<0.001, and HR 0.63; 95% CI 0.50-0.80; p<0.001, respectively). The secondary endpoint (composite of cardiovascular events CV death, MI, or stroke) occurred in 41 (5.9%), 36 (5.1%), and 36 (5.2%) subjects in the group 1, group 2 and group 3, respectively. Each of the rivaroxaban regimens showed a significant reduction in clinically significant bleeding events compared to the VKA regimen in patients with non-valvular atrial fibrillation who underwent a PCI with stent placement.

The primary objective of PIONEER AF-PCI was to assess safety. Data on efficacy (including thromboembolic events) in this population are limited.

Treatment of DVT, PE and prevention of recurrent DVT and PE
The Xarelto clinical programme was designed to demonstrate the efficacy of Xarelto in the initial and continued treatment of acute DVT and PE and prevention of recurrence.

Over 12,800 patients were studied in four randomised controlled phase III clinical studies (Einstein DVT, Einstein PE, Einstein Extension and Einstein Choice) and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted. The overall combined treatment duration in all studies was up to 21 months.

In Einstein DVT 3,449 patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study). The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.

For the initial 3 week treatment of acute DVT 15 mg rivaroxaban was administered twice daily. This was followed by 20 mg rivaroxaban once daily.

In Einstein PE, 4,832 patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE. The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.

For the initial treatment of acute PE 15 mg rivaroxaban was administered twice daily for three weeks. This was followed by 20 mg rivaroxaban once daily.

In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until the PT/INR was in therapeutic range (≥ 2.0). Treatment was continued with a vitamin K antagonist dose-adjusted to maintain the PT/INR values within the therapeutic range of 2.0 to 3.0.
In Einstein Extension 1,197 patients with DVT or PE were studied for the prevention of recurrent DVT and PE. The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator. Xarelto 20 mg once daily was compared with placebo.

Einstein DVT, PE and Extension used the same pre-defined primary and secondary efficacy outcomes. The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE. The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all-cause mortality.

In Einstein Choice, 3,396 patients with confirmed symptomatic DVT and/or PE who completed 6-12 months of anticoagulant treatment were studied for the prevention of fatal PE or non-fatal symptomatic recurrent DVT or PE. Patients with an indication for continued therapeutic-dosed anticoagulation were excluded from the study. The treatment duration was up to 12 months depending on the individual randomisation date (median: 351 days). Xarelto 20 mg once daily and Xarelto 10 mg once daily were compared with 100 mg acetylsalicylic acid once daily.

The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE.

In the Einstein DVT study (see Table 6) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p < 0.0001 (test for non-inferiority); HR: 0.680 (0.443 - 1.042), p=0.076 (test for superiority)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.67 ((95% CI: 0.47 - 0.95), nominal p value p=0.027) in favour of rivaroxaban. INR values were within the therapeutic range a mean of 60.3% of the time for the mean treatment duration of 189 days, and 55.4%, 60.1%, and 62.8% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).

The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.
### Table 6: Efficacy and safety results from phase III Einstein DVT

<table>
<thead>
<tr>
<th>Study population</th>
<th>3,449 patients with symptomatic acute deep vein thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment dose and duration</td>
<td>Xarelto&lt;sup&gt;a&lt;/sup&gt; 3, 6 or 12 months N=1,731</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>36 (2.1%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>20 (1.2%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>14 (0.8%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>1 (0.1%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>4 (0.2%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>139 (8.1%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>14 (0.8%)</td>
</tr>
</tbody>
</table>

a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily
b) Enoxaparin for at least 5 days, overlapped with and followed by VKA

* p < 0.0001 (non-inferiority to a prespecified HR of 2.0); HR: 0.680 (0.443 - 1.042), p=0.076 (superiority)

In the Einstein PE study (see Table 7) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); HR: 1.123 (0.749 - 1.684)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.849 ((95% CI: 0.633 - 1.139), nominal p value p= 0.275). INR values were within the therapeutic range a mean of 63% of the time for the mean treatment duration of 215 days, and 57%, 62%, and 65% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.642 (95% CI: 0.277 - 1.484).

The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4% (274/2405)). The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a HR 0.493 (95% CI: 0.308 - 0.789).
Table 7: Efficacy and safety results from phase III Einstein PE

<table>
<thead>
<tr>
<th>Study population</th>
<th>4,832 patients with an acute symptomatic PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment dose and duration</td>
<td>Xarelto&lt;sup&gt;a&lt;/sup&gt;) 3, 6 or 12 months N=2,419</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>50 (2.1%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>23 (1.0%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>18 (0.7%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>0</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>11 (0.5%)</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>50 (2.1%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>23 (1.0%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>18 (0.7%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>0</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>11 (0.5%)</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>50 (2.1%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>23 (1.0%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>18 (0.7%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>0</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>11 (0.5%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>249 (10.3%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>26 (1.1%)</td>
</tr>
</tbody>
</table>

<sup>a</sup>) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily
<sup>b</sup>) Enoxaparin for at least 5 days, overlapped with and followed by VKA

* p < 0.0026 (non-inferiority to a prespecified HR of 2.0); HR: 1.123 (0.749 - 1.684)

A prespecified pooled analysis of the outcome of the Einstein DVT and PE studies was conducted (see Table 8).

Table 8: Efficacy and safety results from pooled analysis of phase III Einstein DVT and Einstein PE

<table>
<thead>
<tr>
<th>Study population</th>
<th>8,281 patients with an acute symptomatic DVT or PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment dose and duration</td>
<td>Xarelto&lt;sup&gt;a&lt;/sup&gt;) 3, 6 or 12 months N=4,150</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>86 (2.1%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>43 (1.0%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>32 (0.8%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>1 (&lt;0.1%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>15 (0.4%)</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>86 (2.1%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>43 (1.0%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>32 (0.8%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>1 (&lt;0.1%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>15 (0.4%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>388 (9.4%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>40 (1.0%)</td>
</tr>
</tbody>
</table>

<sup>a</sup>) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily
<sup>b</sup>) Enoxaparin for at least 5 days, overlapped with and followed by VKA

* p < 0.0001 (non-inferiority to a prespecified HR of 1.75); HR: 0.886 (0.661 - 1.186)

The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a HR of 0.771 ((95% CI: 0.614 - 0.967), nominal p value p=0.0244).

In the Einstein Extension study (see Table 9) rivaroxaban was superior to placebo for the primary and
secondary efficacy outcomes. For the primary safety outcome (major bleeding events) there was a non-significant numerically higher incidence rate for patients treated with rivaroxaban 20 mg once daily compared to placebo. The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with rivaroxaban 20 mg once daily compared to placebo.

Table 9: Efficacy and safety results from phase III Einstein Extension

<table>
<thead>
<tr>
<th>Study population</th>
<th>1,197 patients continued treatment and prevention of recurrent venous thromboembolism</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose and duration</strong></td>
<td><strong>Xarelto®</strong></td>
</tr>
<tr>
<td>6 or 12 months</td>
<td>N=602</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>8 (1.3%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>2 (0.3%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>5 (0.8%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>4 (0.7%)</td>
</tr>
<tr>
<td>Clinically relevant non-major bleeding</td>
<td>32 (5.4%)</td>
</tr>
</tbody>
</table>

a) Rivaroxaban 20 mg once daily
* p < 0.0001 (superiority), HR: 0.185 (0.087 - 0.393)

In the Einstein Choice study (see Table 10) Xarelto 20 mg and 10 mg were both superior to 100 mg acetylsalicylic acid for the primary efficacy outcome. The principal safety outcome (major bleeding events) was similar for patients treated with Xarelto 20 mg and 10 mg once daily compared to 100 mg acetylsalicylic acid.

Table 10: Efficacy and safety results from phase III Einstein Choice

<table>
<thead>
<tr>
<th>Study population</th>
<th>3,396 patients continued prevention of recurrent venous thromboembolism</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose</strong></td>
<td><strong>Xarelto 20 mg od N=1,107</strong></td>
</tr>
<tr>
<td>Symptomatic recurrent VTE</td>
<td>17 (1.5%)*</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>6 (0.5%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>9 (0.8%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>2 (0.2%)</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE, MI, stroke, or non-CNS systemic embolism</td>
<td>19 (1.7%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>6 (0.5%)</td>
</tr>
<tr>
<td>Clinically relevant non-major bleeding</td>
<td>30 (2.7)</td>
</tr>
</tbody>
</table>
Study population
3,396 patients continued prevention of recurrent venous thromboembolism

<table>
<thead>
<tr>
<th>Treatment dose</th>
<th>Xarelto 20 mg od N=1,107</th>
<th>Xarelto 10 mg od N=1,127</th>
<th>ASA 100 mg od N=1,131</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic recurrent VTE or major bleeding (net clinical benefit)</td>
<td>23 (2.1%)⁺</td>
<td>17 (1.5%)++</td>
<td>53 (4.7%)</td>
</tr>
</tbody>
</table>

* p<0.001 (superiority) Xarelto 20 mg od vs ASA 100 mg od; HR=0.34 (0.20-0.59)
** p<0.001 (superiority) Xarelto 10 mg od vs ASA 100 mg od; HR=0.26 (0.14-0.47)
⁺ Xarelto 20 mg od vs. ASA 100 mg od; HR=0.44 (0.27-0.71), p=0.0009 (nominal)
++ Xarelto 10 mg od vs. ASA 100 mg od; HR=0.32 (0.18-0.55), p<0.0001 (nominal)

In addition to the phase III EINSTEIN programme, a prospective, non-interventional, open-label cohort study (XALIA) with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted. 5,142 patients with acute DVT were enrolled to investigate the long-term safety of rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice.
Rates of major bleeding, recurrent VTE and all-cause mortality for rivaroxaban were 0.7%, 1.4% and 0.5%, respectively. There were differences in patient baseline characteristics including age, cancer and renal impairment. A pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results. Adjusted HRs comparing rivaroxaban and standard-of-care for major bleeding, recurrent VTE and all-cause mortality were 0.77 (95% CI 0.40 - 1.50), 0.91 (95% CI 0.54 - 1.54) and 0.51 (95% CI 0.24 - 1.07), respectively. These results in clinical practice are consistent with the established safety profile in this indication.

Paediatric population
The European Medicines Agency has deferred the obligation to submit the results of studies with Xarelto in one or more subsets of the paediatric population in the treatment of thromboembolic events. The European Medicines Agency has waived the obligation to submit the results of studies with Xarelto in all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption
Rivaroxaban is rapidly absorbed with maximum concentrations (Cmax) appearing 2 - 4 hours after tablet intake.
Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5 mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or Cmax at the 2.5 mg and 10 mg dose.
Due to a reduced extent of absorption an oral bioavailability of 66% was determined for the 20 mg tablet under fasting conditions. When Xarelto 20 mg tablets are taken together with food increases in mean AUC by 39% were observed when compared to tablet intake under fasting conditions, indicating almost complete absorption and high oral bioavailability. Xarelto 15 mg and 20 mg are to be taken with food (see section 4.2).
Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily in fasting state. Under fed conditions Xarelto 10 mg, 15 mg and 20 mg tablets demonstrated dose-proportionality. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose.
Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%.
Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and Cmax compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure.
Bioavailability (AUC and Cmax) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.

Distribution
Plasma protein binding in humans is high at approximately 92% to 95%, with serum albumin being the main binding component. The volume of distribution is moderate with Vss being approximately 50 litres.

Biotransformation and elimination
Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.
Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on in vitro investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).
Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.

Special populations
Gender
There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients.

Elderly population
Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.

Different weight categories
Extremes in body weight (< 50 kg or > 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.

Inter-ethnic differences
No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.

Hepatic impairment
Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.
The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor
of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT. Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).

Renal impairment
There was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively. There are no data in patients with creatinine clearance < 15 ml/min. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable. Use is not recommended in patients with creatinine clearance < 15 ml/min. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).

Pharmacokinetic data in patients
In patients receiving rivaroxaban for treatment of acute DVT 20 mg once daily the geometric mean concentration (90% prediction interval) 2 - 4 h and about 24 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 215 (22 - 535) and 32 (6 - 239) mcg/l, respectively.

Pharmacokinetic/pharmacodynamic relationship
The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor Xa activity was best described by an E\textsubscript{max} model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 mcg/l). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects.

Paediatric population
Safety and efficacy have not been established for children and adolescents up to 18 years.

5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.
Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.
In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. haemorrhagic complications), Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.
6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Microcrystalline cellulose
Croscarmellose sodium
Lactose monohydrate
Hypermellose 2910
Sodium laurilsulphate
Magnesium stearate

Film-coat
Macrogol 3350
Hypermellose 2910
Titanium dioxide (E 171)
Iron oxide red (E 172)

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
3 years

6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container
PP/Aluminium foil blisters in cartons of 10, 14, 28, 42 or 98 film-coated tablets or perforated unit dose blisters in cartons of 10 x 1, or 100 x 1 or in multipacks containing 100 (10 packs of 10 x 1) film-coated tablets.
PVC/PVDC/Aluminium foil blisters in cartons of 14 film-coated tablets.
HDPE bottles with a PP screw cap containing 100 film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORITY

Bayer AG
51368 Leverkusen
Germany

8. MARKETING AUTHORISATION NUMBER(S)
EU/1/08/472/011-016, EU/1/08/472/023, EU/1/08/472/036, EU/1/08/472/038, EU/1/08/472/048.
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 30 September 2008
Date of latest renewal: 22 May 2018

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT
Xarelto 20 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 20 mg rivaroxaban.

Excipient with known effect
Each film-coated tablet contains 21.76 mg lactose (as monohydrate), see section 4.4.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Brown-red, round biconvex tablets (6 mm diameter, 9 mm radius of curvature) marked with the BAYER-cross on one side and “20” and a triangle on the other side.

4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)

4.2 Posology and method of administration

Posology
Prevention of stroke and systemic embolism
The recommended dose is 20 mg once daily, which is also the recommended maximum dose.

Therapy with Xarelto should be continued long term provided the benefit of prevention of stroke and systemic embolism outweighs the risk of bleeding (see section 4.4).

If a dose is missed the patient should take Xarelto immediately and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.

Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE
The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE.
Short duration of therapy (at least 3 months) should be considered in patients with DVT or PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT or PE not related to major transient risk factors, unprovoked DVT or PE, or a history of recurrent DVT or PE.

When extended prevention of recurrent DVT and PE is indicated (following completion of at least 6 months therapy for DVT or PE), the recommended dose is 10 mg once daily. In patients in whom the risk of recurrent DVT or PE is considered high, such as those with complicated comorbidities, or who have developed recurrent DVT or PE on extended prevention with Xarelto 10 mg once daily, a dose of Xarelto 20 mg once daily should be considered.

The duration of therapy and dose selection should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).

<table>
<thead>
<tr>
<th>Time period</th>
<th>Dosing schedule</th>
<th>Total daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment and prevention of recurrent DVT and PE</td>
<td>Day 1 - 21</td>
<td>15 mg twice daily</td>
</tr>
<tr>
<td></td>
<td>Day 22 onwards</td>
<td>20 mg once daily</td>
</tr>
<tr>
<td>Prevention of recurrent DVT and PE</td>
<td>Following completion of at least 6 months therapy for DVT or PE</td>
<td>10 mg once daily or 20 mg once daily</td>
</tr>
</tbody>
</table>

To support the dose switch from 15 mg to 20 mg after Day 21 a first 4 weeks treatment initiation pack of Xarelto for treatment of DVT/PE is available.

If a dose is missed during the 15 mg twice daily treatment phase (day 1 - 21), the patient should take Xarelto immediately to ensure intake of 30 mg Xarelto per day. In this case two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.

If a dose is missed during the once daily treatment phase, the patient should take Xarelto immediately, and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.

**Converting from Vitamin K Antagonists (VKA) to Xarelto**

For patients treated for prevention of stroke and systemic embolism, VKA treatment should be stopped and Xarelto therapy should be initiated when the International Normalised Ratio (INR) is ≤ 3.0.

For patients treated for DVT, PE and prevention of recurrence, VKA treatment should be stopped and Xarelto therapy should be initiated once the INR is ≤ 2.5.

When converting patients from VKAs to Xarelto, INR values will be falsely elevated after the intake of Xarelto. The INR is not valid to measure the anticoagulant activity of Xarelto, and therefore should not be used (see section 4.5).

**Converting from Xarelto to Vitamin K antagonists (VKA)**

There is a potential for inadequate anticoagulation during the transition from Xarelto to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Xarelto can contribute to an elevated INR.

In patients converting from Xarelto to VKA, VKA should be given concurrently until the INR is ≥ 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Xarelto and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Xarelto. Once Xarelto is discontinued INR testing may be done reliably at least 24 hours after the last dose (see sections 4.5 and 5.2).
Converting from parenteral anticoagulants to Xarelto
For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Xarelto 0 to 2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).

Converting from Xarelto to parenteral anticoagulants
Give the first dose of parenteral anticoagulant at the time the next Xarelto dose would be taken.

Special populations
Renal impairment
Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, Xarelto is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance < 15 ml/min (see sections 4.4 and 5.2).

In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment the following dose recommendations apply:

- For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the recommended dose is 15 mg once daily (see section 5.2).

- For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE: patients should be treated with 15 mg twice daily for the first 3 weeks. Thereafter, when the recommended dose is 20 mg once daily, a reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient’s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2). When the recommended dose is 10 mg once daily, no dose adjustment from the recommended dose is necessary.

No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).

Hepatic impairment
Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).

Elderly population
No dose adjustment (see section 5.2)

Body weight
No dose adjustment (see section 5.2)

Gender
No dose adjustment (see section 5.2)

Paediatric population
The safety and efficacy of Xarelto in children aged 0 to 18 years have not been established. No data are available. Therefore, Xarelto is not recommended for use in children below 18 years of age.

Patients undergoing cardioversion
Xarelto can be initiated or continued in patients who may require cardioversion. For transesophageal echocardiogram (TEE) guided cardioversion in patients not previously treated with anticoagulants, Xarelto treatment should be started at least 4 hours before cardioversion to ensure
adequate anticoagulation (see sections 5.1 and 5.2). For all patients, confirmation should be sought prior to cardioversion that the patient has taken Xarelto as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.

\textit{Patients with non-valvular atrial fibrillation who undergo PCI (percutaneous coronary intervention) with stent placement}

There is limited experience of a reduced dose of 15 mg Xarelto once daily (or 10 mg Xarelto once daily for patients with moderate renal impairment [creatinine clearance 30 - 49 ml/min]) in addition to a P2Y12 inhibitor for a maximum of 12 months in patients with non-valvular atrial fibrillation who require oral anticoagulation and undergo PCI with stent placement (see sections 4.4 and 5.1).

\textbf{Method of administration}

Xarelto is for oral use.

The tablets are to be taken with food (see section 5.2).

For patients who are unable to swallow whole tablets, Xarelto tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally. After the administration of crushed Xarelto 15 mg or 20 mg film-coated tablets, the dose should be immediately followed by food.

The crushed Xarelto tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water. After the administration of crushed Xarelto 15 mg or 20 mg film-coated tablets, the dose should then be immediately followed by enteral feeding (see section 5.2).

\section{4.3 Contraindications}

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active clinically significant bleeding.

Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2).

Pregnancy and breast-feeding (see section 4.6).

\section{4.4 Special warnings and precautions for use}

Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.
Haemorrhagic risk
As with other anticoagulants, patients taking Xarelto are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Xarelto administration should be discontinued if severe haemorrhage occurs.

In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.

Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8).

Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.

Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see sections 5.1 and 5.2).

Renal impairment
In patients with severe renal impairment (creatinine clearance < 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6 fold on average) which may lead to an increased bleeding risk. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance < 15 ml/min (see sections 4.2 and 5.2).

Xarelto should be used with caution in patients with renal impairment concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations (see section 4.5).

Interaction with other medicinal products
The use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk (see section 4.5).

Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5).

Other haemorrhagic risk factors
As with other antithrombotics, rivaroxaban is not recommended in patients with an increased bleeding risk such as:

- congenital or acquired bleeding disorders
- uncontrolled severe arterial hypertension
- other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastrooesophageal reflux disease)
- vascular retinopathy
- bronchiectasis or history of pulmonary bleeding
Patients with prosthetic valves
Safety and efficacy of Xarelto have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Xarelto provides adequate anticoagulation in this patient population. Treatment with Xarelto is not recommended for these patients.

Patients with non-valvular atrial fibrillation who undergo PCI with stent placement
Clinical data are available from an interventional study with the primary objective to assess safety in patients with non-valvular atrial fibrillation who undergo PCI with stent placement. Data on efficacy in this population are limited (see sections 4.2 and 5.1). No data are available for such patients with a history of stroke/TIA.

Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy
Xarelto is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of Xarelto have not been established in these clinical situations.

Spinal/epidural anaesthesia or puncture
When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. There is no clinical experience with the use of 20 mg rivaroxaban in these situations.

To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low. However, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.
For the removal of an epidural catheter and based on the general PK characteristics at least 2x half-life, i.e. at least 18 hours in young patients and 26 hours in elderly patients should elapse after the last administration of rivaroxaban (see section 5.2). Following removal of the catheter, at least 6 hours should elapse before the next rivaroxaban dose is administered.
If traumatic puncture occurs the administration of rivaroxaban is to be delayed for 24 hours.

Dosing recommendations before and after invasive procedures and surgical intervention
If an invasive procedure or surgical intervention is required, Xarelto 20 mg should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician. If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention. Xarelto should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section 5.2).

Elderly population
Increasing age may increase haemorrhagic risk (see section 5.2).

Dermatological reactions
Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of
rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.

Information about excipients
Xarelto contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

CYP3A4 and P-gp inhibitors
Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban Cmax, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp (see section 4.4).

Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5 fold increase in mean rivaroxaban AUC and a 1.4 fold increase in Cmax. The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).

Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3 fold increase in mean rivaroxaban AUC and Cmax. The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8 fold increase in mean rivaroxaban AUC and 1.6 fold increase in Cmax when compared to subjects with normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0 fold increase in mean rivaroxaban AUC and 1.6 fold increase in Cmax when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section 4.4).

Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold increase in mean rivaroxaban AUC and a 1.3 fold increase in mean Cmax. The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).

Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.

Anticoagulants
After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban. Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections 4.3 and 4.4).
**NSAIDs/platelet aggregation inhibitors**
No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15 mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response.

No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with 500 mg acetylsalicylic acid. Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.

Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).

**SSRIs/SNRIs**
As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical programme, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.

**Warfarin**
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.

If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban.

If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the Ctrough of rivaroxaban (24 hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.

No pharmacokinetic interaction was observed between warfarin and rivaroxaban.

**CYP3A4 inducers**
Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John’s Wort (*Hypericum perforatum*)) may also lead to reduced rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.

**Other concomitant therapies**
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4.

**Laboratory parameters**
Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of rivaroxaban (see section 5.1).
4.6 Fertility, pregnancy and lactation

**Pregnancy**
Safety and efficacy of Xarelto have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Xarelto is contraindicated during pregnancy (see section 4.3). Women of child-bearing potential should avoid becoming pregnant during treatment with rivaroxaban.

**Breast-feeding**
Safety and efficacy of Xarelto have not been established in breast-feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore Xarelto is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.

**Fertility**
No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).

4.7 Effects on ability to drive and use machines

Xarelto has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8). Patients experiencing these adverse reactions should not drive or use machines.

4.8 Undesirable effects

**Summary of the safety profile**
The safety of rivaroxaban has been evaluated in thirteen phase III studies including 53,103 patients exposed to rivaroxaban (see Table 1).
Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of patients*</th>
<th>Total daily dose</th>
<th>Maximum treatment duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of venous thromboembolism (VTE) in adult patients undergoing</td>
<td>6,097</td>
<td>10 mg</td>
<td>39 days</td>
</tr>
<tr>
<td>elective hip or knee replacement surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevention of VTE in medically ill patients</td>
<td>3,997</td>
<td>10 mg</td>
<td>39 days</td>
</tr>
<tr>
<td>Treatment of DVT, PE and prevention of recurrence</td>
<td>6,790</td>
<td>Day 1 - 21: 30 mg Day 22 and</td>
<td>21 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>onwards: 20 mg After at least 6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>months: 10 mg or 20 mg</td>
<td></td>
</tr>
<tr>
<td>Prevention of stroke and systemic embolism in patients with non-valvular</td>
<td>7,750</td>
<td>20 mg</td>
<td>41 months</td>
</tr>
<tr>
<td>atrial fibrillation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients after an acute coronary</td>
<td>10,225</td>
<td>5 mg or 10 mg respectively, co-</td>
<td>31 months</td>
</tr>
<tr>
<td>syndrome (ACS)</td>
<td></td>
<td>administered with either ASA or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ASA plus clopidogrel or ticlopidine</td>
<td></td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with CAD/PAD</td>
<td>18,244</td>
<td>5 mg co-administered with ASA or</td>
<td>47 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 mg alone</td>
<td></td>
</tr>
</tbody>
</table>

* Patients exposed to at least one dose of rivaroxaban

The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and ‘Description of selected adverse reactions’ below) (Table 2). The most commonly reported bleedings were epistaxis (4.5 %) and gastrointestinal tract haemorrhage (3.8 %).
Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed phase III studies

<table>
<thead>
<tr>
<th>Indication</th>
<th>Any bleeding</th>
<th>Anaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of VTE in adult patients undergoing elective hip or knee</td>
<td>6.8% of patients</td>
<td>5.9% of patients</td>
</tr>
<tr>
<td>replacement surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevention of VTE in medically ill patients</td>
<td>12.6% of patients</td>
<td>2.1% of patients</td>
</tr>
<tr>
<td>Treatment of DVT, PE and prevention of recurrence</td>
<td>23% of patients</td>
<td>1.6% of patients</td>
</tr>
<tr>
<td>Prevention of stroke and systemic embolism in patients with non-valvular</td>
<td>28 per 100 patient</td>
<td>2.5 per 100 patient years</td>
</tr>
<tr>
<td>atrial fibrillation</td>
<td>years</td>
<td></td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients after an ACS</td>
<td>22 per 100 patient</td>
<td>1.4 per 100 patient years</td>
</tr>
<tr>
<td>years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with CAD/PAD</td>
<td>6.7 per 100 patient</td>
<td>0.15 per 100 patient years**</td>
</tr>
<tr>
<td>years</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.

** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied.

Tabulated list of adverse reactions

The frequencies of adverse reactions reported with Xarelto are summarised in Table 3 below by system organ class (in MedDRA) and by frequency.

Frequencies are defined as:
very common (≥ 1/10)
common (≥ 1/100 to < 1/10)
uncommon (≥ 1/1,000 to < 1/100)
rare (≥ 1/10,000 to < 1/1,000)
very rare (< 1/10,000)
not known (cannot be estimated from the available data)

Table 3: All adverse reactions reported in patients in phase III clinical trials or through post-marketing use*

<table>
<thead>
<tr>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Very rare</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaemia (incl. respective laboratory parameters)</td>
<td>Thrombocytosis (incl. platelet count increased)A, Thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Allergic reaction, dermatitis allergic, Angioedema and allergic oedema</td>
<td></td>
<td>Anaphylactic reactions including anaphylactic shock</td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness, headache</td>
<td>Cerebral and intracranial haemorrhage, syncope</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
<td>Very rare</td>
<td>Not known</td>
</tr>
<tr>
<td>--------------</td>
<td>----------</td>
<td>------------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye haemorrhage (incl. conjunctival haemorrhage)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Tachycardia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Hypotension, haematoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Epistaxis, haemoptysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation^A, diarrhoea, vomiting^A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase in transaminases</td>
<td>Hepatic impairment, Increased bilirubin, increased blood alkaline phosphatase^A, increased GGT^A</td>
<td>Jaundice, Bilirubin conjugated increased (with or without concomitant increase of ALT), Cholestasis, Hepatitis (incl. hepatocellular injury)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus (incl. uncommon cases of generalised pruritus), rash, ecchymosis, cutaneous and subcutaneous haemorrhage</td>
<td>Urticaria</td>
<td></td>
<td>Stevens-Johnson syndrome/ Toxic Epidermal Necrolysis, DRESS syndrome</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain in extremity^A</td>
<td>Haemarthrosis</td>
<td>Muscle haemorrhage</td>
<td></td>
<td>Compartent syndrome secondary to a bleeding</td>
</tr>
<tr>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
<td>Very rare</td>
<td>Not known</td>
</tr>
<tr>
<td>--------</td>
<td>----------</td>
<td>------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urogenital tract haemorrhage (incl. haematuria and menorrhagia&lt;sup&gt;B&lt;/sup&gt;), renal impairment (incl. blood creatinine and urea increased)&lt;sup&gt;A&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever&lt;sup&gt;A&lt;/sup&gt;, peripheral oedema, decreased general strength and energy (incl. fatigue and asthenia)</td>
<td>Feeling unwell (incl. malaise)</td>
<td>Localised oedema&lt;sup&gt;A&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased LDH&lt;sup&gt;A&lt;/sup&gt;, increased lipase&lt;sup&gt;A&lt;/sup&gt;, increased amylase&lt;sup&gt;A&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Injury, poisoning and procedural complications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postprocedural haemorrhage (incl. postoperative anaemia, and wound haemorrhage), contusion, wound secretion&lt;sup&gt;A&lt;/sup&gt;</td>
<td>Vascular pseudoaneurysm&lt;sup&gt;C&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery
B: observed in treatment of DVT, PE and prevention of recurrence as very common in women <.55 years
C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)

* A pre-specified selective approach to adverse event collection was applied. As incidence of adverse reactions did not increase and no new adverse reaction was identified, COMPASS study data were not included for frequency calculation in this table.

**Description of selected adverse reactions**
Due to the pharmacological mode of action, the use of Xarelto may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 “Management of bleeding”). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section 4.4 “Haemorrhagic risk”). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained...
swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed. Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Xarelto. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**

Rare cases of overdose up to 600 mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50 mg rivaroxaban or above. A specific antidote antagonising the pharmacodynamic effect of rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.

**Management of bleeding**
Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a half-life of approximately 5 to 13 hours (see section 5.2). Management should be individualised according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets. If bleeding cannot be controlled by the above measures, administration of a specific procoagulant reversal agent should be considered, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa). However, there is currently very limited clinical experience with the use of these medicinal products in individuals receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings (see section 5.1).

Protamine sulphate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic haemostatic desmopressin in individuals receiving rivaroxaban. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**
Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF01

**Mechanism of action**
Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.
Pharmacodynamic effects
Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant.

In patients receiving rivaroxaban for treatment of DVT and PE and prevention of recurrence, the 5/95 percentiles for PT (Neoplastin) 2 - 4 hours after tablet intake (i.e. at the time of maximum effect) for 15 mg rivaroxaban twice daily ranged from 17 to 32 s and for 20 mg rivaroxaban once daily from 15 to 30 s. At trough (8 - 16 h after tablet intake) the 5/95 percentiles for 15 mg twice daily ranged from 14 to 24 s and for 20 mg once daily (18 - 30 h after tablet intake) from 13 to 20 s.

In patients with non-valvular atrial fibrillation receiving rivaroxaban for the prevention of stroke and systemic embolism, the 5/95 percentiles for PT (Neoplastin) 1 - 4 hours after tablet intake (i.e. at the time of maximum effect) in patients treated with 20 mg once daily ranged from 14 to 40 s and in patients with moderate renal impairment treated with 15 mg once daily from 10 to 50 s. At trough (16 - 36 h after tablet intake) the 5/95 percentiles in patients treated with 20 mg once daily ranged from 12 to 26 s and in patients with moderate renal impairment treated with 15 mg once daily from 12 to 26 s.

In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3-factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9).

The activated partial thromboplastin time (aPTT) and HepTest are also prolonged dose-dependently; however, they are not recommended to assess the pharmacodynamic effect of rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated rivaroxaban levels can be measured by calibrated quantitative anti-factor Xa tests (see section 5.2).

Clinical efficacy and safety
Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
The Xarelto clinical programme was designed to demonstrate the efficacy of Xarelto for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. In the pivotal double-blind ROCKET AF study, 14,264 patients were assigned either to Xarelto 20 mg once daily (15 mg once daily in patients with creatinine clearance 30 - 49 ml/min) or to warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0). The median time on treatment was 19 months and overall treatment duration was up to 41 months.

34.9% of patients were treated with acetylsalicylic acid and 11.4% were treated with class III antiarrhythmic including amiodarone.

Xarelto was non-inferior to warfarin for the primary composite endpoint of stroke and non-CNS systemic embolism. In the per-protocol population on treatment, stroke or systemic embolism occurred in 188 patients on rivaroxaban (1.71% per year) and 241 on warfarin (2.16% per year) (HR 0.79; 95% CI, 0.66 - 0.96; P<0.001 for non-inferiority). Among all randomised patients analysed according to ITT, primary events occurred in 269 on rivaroxaban (2.12% per year) and 306 on warfarin (2.42% per year) (HR 0.88; 95% CI, 0.74 - 1.03; P<0.001 for non-inferiority; P=0.117 for superiority). Results for secondary endpoints as tested in hierarchical order in the ITT analysis are displayed in Table 4. Among patients in the warfarin group, INR values were within the therapeutic range (2.0 to 3.0) a mean of 55% of the time (median, 58%; interquartile range, 43 to 71). The effect of rivaroxaban did not differ across the level of centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized quartiles (P=0.74 for interaction). Within the highest quartile according to centre, the Hazard Ratio (HR) with rivaroxaban versus warfarin was 0.74 (95% CI, 0.49 - 1.12).
The incidence rates for the principal safety outcome (major and non-major clinically relevant bleeding events) were similar for both treatment groups (see Table 5).

### Table 4: Efficacy results from phase III ROCKET AF

<table>
<thead>
<tr>
<th>Study population</th>
<th>ITT analyses of efficacy in patients with non-valvular atrial fibrillation</th>
<th>Warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0)</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Treatment dose</td>
<td>Event rate (100 pt-yr)</td>
<td>p-value, test for superiority</td>
</tr>
<tr>
<td>Stroke and non-CNS systemic embolism</td>
<td>Xarelto 20 mg od (15 mg od in patients with moderate renal impairment)</td>
<td>269 (2.12)</td>
<td>0.88 (0.74 - 1.03) 0.117</td>
</tr>
<tr>
<td></td>
<td>Warfarin</td>
<td>306 (2.42)</td>
<td></td>
</tr>
<tr>
<td>Stroke, non-CNS systemic embolism and vascular death</td>
<td>Xarelto 20 mg od (15 mg od in patients with moderate renal impairment)</td>
<td>572 (4.51)</td>
<td>0.94 (0.84 - 1.05) 0.265</td>
</tr>
<tr>
<td></td>
<td>Warfarin</td>
<td>609 (4.81)</td>
<td></td>
</tr>
<tr>
<td>Stroke, non-CNS systemic embolism, vascular death and myocardial infarction</td>
<td>Xarelto 20 mg od (15 mg od in patients with moderate renal impairment)</td>
<td>659 (5.24)</td>
<td>0.93 (0.83 - 1.03) 0.158</td>
</tr>
<tr>
<td></td>
<td>Warfarin</td>
<td>709 (5.65)</td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td>Xarelto 20 mg od (15 mg od in patients with moderate renal impairment)</td>
<td>253 (1.99)</td>
<td>0.90 (0.76 - 1.07) 0.221</td>
</tr>
<tr>
<td></td>
<td>Warfarin</td>
<td>281 (2.22)</td>
<td></td>
</tr>
<tr>
<td>Non-CNS systemic embolism</td>
<td>Xarelto 20 mg od (15 mg od in patients with moderate renal impairment)</td>
<td>20 (0.16)</td>
<td>0.74 (0.42 - 1.32) 0.308</td>
</tr>
<tr>
<td></td>
<td>Warfarin</td>
<td>27 (0.21)</td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>Xarelto 20 mg od (15 mg od in patients with moderate renal impairment)</td>
<td>130 (1.02)</td>
<td>0.91 (0.72 - 1.16) 0.464</td>
</tr>
<tr>
<td></td>
<td>Warfarin</td>
<td>142 (1.11)</td>
<td></td>
</tr>
</tbody>
</table>
Table 5: Safety results from phase III ROCKET AF

<table>
<thead>
<tr>
<th>Study population</th>
<th>Patients with non-valvular atrial fibrillation&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Treatment dose</th>
<th>Warfarin titrated to a target INR of 2.5 (therapeutic range 2.0 to 3.0)</th>
<th>HR (95% CI) p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Xarelto 20 mg once a day (15 mg once a day in patients with moderate renal impairment) Event rate (100 pt-yr)</td>
<td></td>
<td>Event rate (100 pt-yr)</td>
<td></td>
</tr>
<tr>
<td>Major and non-major clinically relevant bleeding events</td>
<td>1,475 (14.91)</td>
<td>1,449 (14.52)</td>
<td>1.03 (0.96 - 1.11)</td>
<td>0.442</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>395 (3.60)</td>
<td>386 (3.45)</td>
<td>1.04 (0.90 - 1.20)</td>
<td>0.576</td>
</tr>
<tr>
<td>Death due to bleeding*</td>
<td>27 (0.24)</td>
<td>55 (0.48)</td>
<td>0.50 (0.31 - 0.79)</td>
<td>0.003</td>
</tr>
<tr>
<td>Critical organ bleeding*</td>
<td>91 (0.82)</td>
<td>133 (1.18)</td>
<td>0.69 (0.53 - 0.91)</td>
<td>0.007</td>
</tr>
<tr>
<td>Intracranial haemorrhage*</td>
<td>55 (0.49)</td>
<td>84 (0.74)</td>
<td>0.67 (0.47 - 0.93)</td>
<td>0.019</td>
</tr>
<tr>
<td>Haemoglobin drop*</td>
<td>305 (2.77)</td>
<td>254 (2.26)</td>
<td>1.22 (1.03 - 1.44)</td>
<td>0.019</td>
</tr>
<tr>
<td>Transfusion of 2 or more units of packed red blood cells or whole blood*</td>
<td>183 (1.65)</td>
<td>149 (1.32)</td>
<td>1.25 (1.01 - 1.55)</td>
<td>0.044</td>
</tr>
<tr>
<td>Non-major clinically relevant bleeding events</td>
<td>1,185 (11.80)</td>
<td>1,151 (11.37)</td>
<td>1.04 (0.96 - 1.13)</td>
<td>0.345</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>208 (1.87)</td>
<td>250 (2.21)</td>
<td>0.85 (0.70 - 1.02)</td>
<td>0.073</td>
</tr>
</tbody>
</table>

**a)** Safety population, on treatment

* Nominally significant

In addition to the phase III ROCKET AF study, a prospective, single-arm, post-authorization, non-interventional, open-label cohort study (XANTUS) with central outcome adjudication including thromboembolic events and major bleeding has been conducted. 6,785 patients with non-valvular atrial fibrillation were enrolled for prevention of stroke and non-central nervous system (CNS) systemic embolism in clinical practice. The mean CHADS<sub>2</sub> and HAS-BLED scores were both 2.0 in XANTUS, compared to a mean CHADS<sub>2</sub> and HAS-BLED score of 3.5 and 2.8 in ROCKET AF, respectively. Major bleeding occurred in 2.1 per 100 patient years. Fatal haemorrhage was reported in 0.2 per 100 patient years and intracranial haemorrhage in 0.4 per 100 patient years. Stroke or non-CNS systemic embolism was recorded in 0.8 per 100 patient years.

These observations in clinical practice are consistent with the established safety profile in this indication.

**Patients undergoing cardioversion**

A prospective, randomised, open-label, multicentre, exploratory study with blinded endpoint evaluation (X-VERT) was conducted in 1504 patients (oral anticoagulant naive and pre-treated) with non-valvular atrial fibrillation scheduled for cardioversion to compare rivaroxaban with dose-adjusted VKA (randomised 2:1), for the prevention of cardiovascular events. TEE-guided (1 - 5 days of pre-treatment) or conventional cardioversion (at least three weeks of pre-treatment) strategies were employed. The primary efficacy outcome (all stroke, transient ischaemic attack, non-CNS systemic embolism, myocardial infarction (MI) and cardiovascular death) occurred in 5 (0.5%) patients in the rivaroxaban group (n = 978) and 5 (1.0%) patients in the VKA group (n = 492; RR 0.50; 95% CI 0.15-
The principal safety outcome (major bleeding) occurred in 6 (0.6%) and 4 (0.8%) patients in the rivaroxaban (n = 988) and VKA (n = 499) groups, respectively (RR 0.76; 95% CI 0.21-2.67; safety population). This exploratory study showed comparable efficacy and safety between rivaroxaban and VKA treatment groups in the setting of cardioversion.

Patients with non-valvular atrial fibrillation who undergo PCI with stent placement
A randomised, open-label, multicentre study (PIONEER AF-PCI) was conducted in 2,124 patients with non-valvular atrial fibrillation who underwent PCI with stent placement for primary atherosclerotic disease to compare safety of two rivaroxaban regimens and one VKA regimen. Patients were randomly assigned in a 1:1:1 fashion for an overall 12-month-therapy. Patients with a history of stroke or TIA were excluded.

Group 1 received rivaroxaban 15 mg once daily (10 mg once daily in patients with creatinine clearance 30 - 49 ml/min) plus P2Y12 inhibitor. Group 2 received rivaroxaban 2.5 mg twice daily plus DAPT (dual antiplatelet therapy i.e. clopidogrel 75 mg [or alternate P2Y12 inhibitor] plus low-dose acetylsalicylic acid [ASA]) for 1, 6 or 12 months followed by rivaroxaban 15 mg (or 10 mg for subjects with creatinine clearance 30 - 49 ml/min) once daily plus low-dose ASA. Group 3 received dose-adjusted VKA plus DAPT for 1, 6 or 12 months followed by dose-adjusted VKA plus low-dose ASA.

The primary safety endpoint, clinically significant bleeding events, occurred in 109 (15.7%), 117 (16.6%), and 167 (24.0%) subjects in group 1, group 2 and group 3, respectively (HR 0.59; 95% CI 0.47-0.76; p<0.001, and HR 0.63; 95% CI 0.50-0.80; p<0.001, respectively). The secondary endpoint (composite of cardiovascular events CV death, MI, or stroke) occurred in 41 (5.9%), 36 (5.1%), and 36 (5.2%) subjects in the group 1, group 2 and group 3, respectively. Each of the rivaroxaban regimens showed a significant reduction in clinically significant bleeding events compared to the VKA regimen in patients with non-valvular atrial fibrillation who underwent a PCI with stent placement.

The primary objective of PIONEER AF-PCI was to assess safety. Data on efficacy (including thromboembolic events) in this population are limited.

Treatment of DVT, PE and prevention of recurrent DVT and PE
The Xarelto clinical programme was designed to demonstrate the efficacy of Xarelto in the initial and continued treatment of acute DVT and PE and prevention of recurrence.

Over 12,800 patients were studied in four randomised controlled phase III clinical studies (Einstein DVT, Einstein PE, Einstein Extension and Einstein Choice) and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted. The overall combined treatment duration in all studies was up to 21 months.

In Einstein DVT 3,449 patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study). The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.

For the initial 3 week treatment of acute DVT 15 mg rivaroxaban was administered twice daily. This was followed by 20 mg rivaroxaban once daily.

In Einstein PE, 4,832 patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE. The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.

For the initial treatment of acute PE 15 mg rivaroxaban was administered twice daily for three weeks. This was followed by 20 mg rivaroxaban once daily.

In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until the PT/INR was in therapeutic range (≥ 2.0). Treatment was continued with a vitamin K antagonist dose-adjusted to maintain the PT/INR values within the therapeutic range of 2.0 to 3.0.

In Einstein Extension 1,197 patients with DVT or PE were studied for the prevention of recurrent
DVT and PE. The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator. Xarelto 20 mg once daily was compared with placebo.

Einstein DVT, PE and Extension used the same pre-defined primary and secondary efficacy outcomes. The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE. The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all-cause mortality.

In Einstein Choice, 3,396 patients with confirmed symptomatic DVT and/or PE who completed 6-12 months of anticoagulant treatment were studied for the prevention of fatal PE or non-fatal symptomatic recurrent DVT or PE. Patients with an indication for continued therapeutic-dosed anticoagulation were excluded from the study. The treatment duration was up to 12 months depending on the individual randomisation date (median: 351 days). Xarelto 20 mg once daily and Xarelto 10 mg once daily were compared with 100 mg acetylsalicylic acid once daily.

The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE.

In the Einstein DVT study (see Table 6) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p < 0.0001 (test for non-inferiority); HR: 0.680 (0.443 - 1.042), p=0.076 (test for superiority)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.67 ((95% CI: 0.47 - 0.95), nominal p value p=0.027) in favour of rivaroxaban. INR values were within the therapeutic range a mean of 60.3% of the time for the mean treatment duration of 189 days, and 55.4%, 60.1%, and 62.8% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).

The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.

<table>
<thead>
<tr>
<th>Table 6: Efficacy and safety results from phase III Einstein DVT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study population</td>
</tr>
<tr>
<td><strong>Treatment dose and duration</strong></td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
</tr>
<tr>
<td>Major bleeding events</td>
</tr>
</tbody>
</table>

<sup>a</sup> Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily

<sup>b</sup> Enoxaparin for at least 5 days, overlapped with and followed by VKA

* p < 0.0001 (non-inferiority to a prespecified HR of 2.0); HR: 0.680 (0.443 - 1.042), p=0.076 (superiority)
In the Einstein PE study (see Table 7) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); HR: 1.123 (0.749 - 1.684)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.849 ((95% CI: 0.633 - 1.139), nominal p value p= 0.275). INR values were within the therapeutic range a mean of 63% of the time for the mean treatment duration of 215 days, and 57%, 62%, and 65% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.642 (95% CI: 0.277 - 1.484).

The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4% (274/2405)). The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a HR 0.493 (95% CI: 0.308 - 0.789).

Table 7: Efficacy and safety results from phase III Einstein PE

<table>
<thead>
<tr>
<th>Study population</th>
<th>4,832 patients with an acute symptomatic PE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose and duration</strong></td>
<td><strong>Xarelto</strong>a) 3, 6 or 12 months N=2,419</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>50 (2.1%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>23 (1.0%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>18 (0.7%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>0</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>11 (0.5%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>249 (10.3%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>26 (1.1%)</td>
</tr>
</tbody>
</table>

a) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily
b) Enoxaparin for at least 5 days, overlapped with and followed by VKA
* p < 0.0026 (non-inferiority to a prespecified HR of 2.0); HR: 1.123 (0.749 - 1.684)

A prespecified pooled analysis of the outcome of the Einstein DVT and PE studies was conducted (see Table 8).
Table 8: Efficacy and safety results from pooled analysis of phase III Einstein DVT and Einstein PE

<table>
<thead>
<tr>
<th>Study population</th>
<th>8,281 patients with an acute symptomatic DVT or PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment dose and duration</td>
<td>Xarelto&lt;sup&gt;a&lt;/sup&gt;) 3, 6 or 12 months N=4,150</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>86 (2.1%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>43 (1.0%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>32 (0.8%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>1 (&lt;0.1%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>15 (0.4%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>388 (9.4%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>40 (1.0%)</td>
</tr>
</tbody>
</table>

<sup>a</sup>) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily
<sup>b</sup>) Enoxaparin for at least 5 days, overlapped with and followed by VKA

* p < 0.0001 (non-inferiority to a prespecified HR of 1.75); HR: 0.886 (0.661 - 1.186)

The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a HR of 0.771 ([95% CI: 0.614 - 0.967], nominal p value p = 0.0244).

In the Einstein Extension study (see Table 9) rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes. For the primary safety outcome (major bleeding events) there was a non-significant numerically higher incidence rate for patients treated with rivaroxaban 20 mg once daily compared to placebo. The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with rivaroxaban 20 mg once daily compared to placebo.

Table 9: Efficacy and safety results from phase III Einstein Extension

<table>
<thead>
<tr>
<th>Study population</th>
<th>1,197 patients continued treatment and prevention of recurrent venous thromboembolism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment dose and duration</td>
<td>Xarelto&lt;sup&gt;a&lt;/sup&gt;) 6 or 12 months N=602</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>8 (1.3%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>2 (0.3%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>5 (0.8%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>4 (0.7%)</td>
</tr>
<tr>
<td>Clinically relevant non-major bleeding</td>
<td>32 (5.4%)</td>
</tr>
</tbody>
</table>

<sup>a</sup>) Rivaroxaban 20 mg once daily

* p < 0.0001 (superiority), HR: 0.185 (0.087 - 0.393)
In the Einstein Choice study (see Table 10) Xarelto 20 mg and 10 mg were both superior to 100 mg acetylsalicylic acid for the primary efficacy outcome. The principal safety outcome (major bleeding events) was similar for patients treated with Xarelto 20 mg and 10 mg once daily compared to 100 mg acetylsalicylic acid.

Table 10: Efficacy and safety results from phase III Einstein Choice

<table>
<thead>
<tr>
<th>Study population</th>
<th>3,396 patients continued prevention of recurrent venous thromboembolism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment dose</td>
<td>Xarelto 20 mg od N=1,107</td>
</tr>
<tr>
<td>Sympomatic recurrent VTE</td>
<td>17 (1.5%)*</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>6 (0.5%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>9 (0.8%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>2 (0.2%)</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE, MI, stroke, or non-CNS systemic embolism</td>
<td>19 (1.7%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>6 (0.5%)</td>
</tr>
<tr>
<td>Clinically relevant non-major bleeding</td>
<td>30 (2.7)</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE or major bleeding (net clinical benefit)</td>
<td>23 (2.1%)*</td>
</tr>
</tbody>
</table>

* p<0.001 (superiority) Xarelto 20 mg od vs ASA 100 mg od; HR=0.34 (0.20-0.59)
** p<0.001 (superiority) Xarelto 10 mg od vs ASA 100 mg od; HR=0.26 (0.14-0.47)
† Xarelto 20 mg od vs. ASA 100 mg od; HR=0.44 (0.27-0.71), p=0.0009 (nominal)
++ Xarelto 10 mg od vs. ASA 100 mg od; HR=0.32 (0.18-0.55), p<0.0001 (nominal)

In addition to the phase III EINSTEIN programme, a prospective, non-interventional, open-label cohort study (XALIA) with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted. 5,142 patients with acute DVT were enrolled to investigate the long-term safety of rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice. Rates of major bleeding, recurrent VTE and all-cause mortality for rivaroxaban were 0.7%, 1.4% and 0.5%, respectively. There were differences in patient baseline characteristics including age, cancer and renal impairment. A pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results. Adjusted HRs comparing rivaroxaban and standard-of-care for major bleeding, recurrent VTE and all-cause mortality were 0.77 (95% CI 0.40 - 1.50), 0.91 (95% CI 0.54 - 1.54) and 0.51 (95% CI 0.24 - 1.07), respectively. These results in clinical practice are consistent with the established safety profile in this indication.

Paediatric population
The European Medicines Agency has deferred the obligation to submit the results of studies with Xarelto in one or more subsets of the paediatric population in the treatment of thromboembolic events. The European Medicines Agency has waived the obligation to submit the results of studies with Xarelto in all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).
5.2 Pharmacokinetic properties

Absorption
Rivaroxaban is rapidly absorbed with maximum concentrations (C\text{max}) appearing 2 - 4 hours after tablet intake.
Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5 mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or C\text{max} at the 2.5 mg and 10 mg dose.
Due to a reduced extent of absorption an oral bioavailability of 66% was determined for the 20 mg tablet under fasting conditions. When Xarelto 20 mg tablets are taken together with food increases in mean AUC by 39% were observed when compared to tablet intake under fasting conditions, indicating almost complete absorption and high oral bioavailability. Xarelto 15 mg and 20 mg are to be taken with food (see section 4.2).
Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily in fasting state. Under fed conditions Xarelto 10 mg, 15 mg and 20 mg tablets demonstrated dose-proportionality. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose.
Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%.
Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and C\text{max} compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure.
Bioavailability (AUC and C\text{max}) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.

Distribution
Plasma protein binding in humans is high at approximately 92% to 95%, with serum albumin being the main binding component. The volume of distribution is moderate with V\text{ss} being approximately 50 litres.

Biotransformation and elimination
Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.
Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on in vitro investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).
Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.
Special populations

Gender
There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients.

Elderly population
Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.

Different weight categories
Extremes in body weight (< 50 kg or > 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.

Inter-ethnic differences
No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.

Hepatic impairment
Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.

The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT.

Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).

Renal impairment
There was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively. There are no data in patients with creatinine clearance < 15 ml/min.

Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.

Use is not recommended in patients with creatinine clearance < 15 ml/min. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).

Pharmacokinetic data in patients
In patients receiving rivaroxaban for treatment of acute DVT 20 mg once daily the geometric mean concentration (90% prediction interval) 2 - 4 h and about 24 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 215 (22 - 535) and 32 (6 - 239) mcg/l, respectively.
Pharmacokinetic/pharmacodynamic relationship
The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor Xa activity was best described by an Emax model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 mcg/l). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects.

Paediatric population
Safety and efficacy have not been established for children and adolescents up to 18 years.

5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity. Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels. In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. haemorrhagic complications). Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Tablet core
Microcrystalline cellulose
Crocarmellose sodium
Lactose monohydrate
Hypromellose 2910
Sodium laurilsulphate
Magnesium stearate

Film-coat
Macrogol 3350
Hypromellose 2910
Titanium dioxide (E 171)
Iron oxide red (E 172)

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
3 years
6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

PP/Aluminium foil blisters in cartons of 10, 14, 28 or 98 film-coated tablets or perforated unit dose blisters in cartons of 10 x 1, or 100 x 1 or in multipacks containing 100 (10 packs of 10 x 1) film-coated tablets.
PVC/PVDC/Aluminium foil blisters in cartons of 14 film-coated tablets.
HDPE bottles with a PP screw cap containing 100 film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/472/017-021, EU/1/08/472/024, EU/1/08/472/037, EU/1/08/472/039, EU/1/08/472/049.

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 30 September 2008
Date of latest renewal: 22 May 2018

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Treatment Initiation Pack

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Xarelto 15 mg film-coated tablets
Xarelto 20 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 15 mg film-coated tablet contains 15 mg rivaroxaban.
Each 20 mg film-coated tablet contains 20 mg rivaroxaban.

Excipient with known effect
Each 15 mg film-coated tablet contains 24.13 mg lactose (as monohydrate), see section 4.4.
Each 20 mg film-coated tablet contains 21.76 mg lactose (as monohydrate), see section 4.4.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet)

15 mg film-coated tablet: red, round biconvex tablets (6 mm diameter, 9 mm radius of curvature) marked with the BAYER-cross on one side and “15” and a triangle on the other side.
20 mg film-coated tablet: brown-red, round biconvex tablets (6 mm diameter, 9 mm radius of curvature) marked with the BAYER-cross on one side and “20” and a triangle on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)

4.2 Posology and method of administration

Posology

Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE

The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE.

Short duration of therapy (at least 3 months) should be considered in patients with DVT or PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT or PE not related to major transient risk factors, unprovoked DVT or PE, or a history of recurrent DVT or PE.
When extended prevention of recurrent DVT and PE is indicated (following completion of at least 6 months therapy for DVT or PE), the recommended dose is 10 mg once daily. In patients in whom the risk of recurrent DVT or PE is considered high, such as those with complicated comorbidities, or who have developed recurrent DVT or PE on extended prevention with Xarelto 10 mg once daily, a dose of Xarelto 20 mg once daily should be considered.

The duration of therapy and dose selection should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).

<table>
<thead>
<tr>
<th>Time period</th>
<th>Dosing schedule</th>
<th>Total daily dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment and prevention of recurrent DVT and PE</td>
<td>Day 1 - 21 15 mg twice daily</td>
<td>30 mg</td>
</tr>
<tr>
<td></td>
<td>Day 22 onwards 20 mg once daily</td>
<td>20 mg</td>
</tr>
<tr>
<td>Prevention of recurrent DVT and PE</td>
<td>Following completion of at least 6 months therapy for DVT or PE</td>
<td>10 mg once daily or 20 mg once daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 mg or 20 mg</td>
</tr>
</tbody>
</table>

The 4-week treatment initiation pack of Xarelto is dedicated to patients who will transition from 15 mg twice daily to 20 mg once daily from Day 22 onwards (see section 6.5). For patients with moderate or severe renal impairment where the decision has been taken for 15 mg once daily from Day 22 onwards, other pack sizes only containing 15 mg film-coated tablets are available (see dosing instructions in section “Special populations” below).

If a dose is missed during the 15 mg twice daily treatment phase (day 1 - 21), the patient should take Xarelto immediately to ensure intake of 30 mg Xarelto per day. In this case two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.

If a dose is missed during the once daily treatment phase, the patient should take Xarelto immediately, and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.

**Converting from Vitamin K Antagonists (VKA) to Xarelto**

For patients treated for DVT, PE and prevention of recurrence, VKA treatment should be stopped and Xarelto therapy should be initiated once the International Normalised Ratio (INR) is ≤ 2.5. When converting patients from VKAs to Xarelto, INR values will be falsely elevated after the intake of Xarelto. The INR is not valid to measure the anticoagulant activity of Xarelto, and therefore should not be used (see section 4.5).

**Converting from Xarelto to Vitamin K antagonists (VKA)**

There is a potential for inadequate anticoagulation during the transition from Xarelto to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Xarelto can contribute to an elevated INR. In patients converting from Xarelto to VKA, VKA should be given concurrently until the INR is ≥ 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Xarelto and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Xarelto. Once Xarelto is discontinued INR testing may be done reliably at least 24 hours after the last dose (see sections 4.5 and 5.2).

**Converting from parenteral anticoagulants to Xarelto**

For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Xarelto 0 to 2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).
Converting from Xarelto to parenteral anticoagulants
Give the first dose of parenteral anticoagulant at the time the next Xarelto dose would be taken.

Special populations
Renal impairment
Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, Xarelto is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance < 15 ml/min (see sections 4.4 and 5.2).

In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment the following dose recommendations apply:

- For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE, patients should be treated with 15 mg twice daily for the first 3 weeks. Thereafter, when the recommended dose is 20 mg once daily, a reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient’s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2).
  When the recommended dose is 10 mg once daily, no dose adjustment from the recommended dose is necessary.

No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).

Hepatic impairment
Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).

Elderly population
No dose adjustment (see section 5.2)

Body weight
No dose adjustment (see section 5.2)

Gender
No dose adjustment (see section 5.2)

Paediatric population
The safety and efficacy of Xarelto in children aged 0 to 18 years have not been established. No data are available. Therefore, Xarelto is not recommended for use in children below 18 years of age.

Method of administration
Xarelto is for oral use. The tablets are to be taken with food (see section 5.2).

For patients who are unable to swallow whole tablets, Xarelto tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally. After the administration of crushed Xarelto 15 mg or 20 mg film-coated tablets, the dose should be immediately followed by food.

The crushed Xarelto tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water. After the administration of crushed
Xarelto 15 mg or 20 mg film-coated tablets, the dose should then be immediately followed by enteral feeding (see section 5.2).

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active clinically significant bleeding.

Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2).

Pregnancy and breast-feeding (see section 4.6).

4.4 Special warnings and precautions for use

Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.

Haemorrhagic risk

As with other anticoagulants, patients taking Xarelto are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Xarelto administration should be discontinued if severe haemorrhage occurs.

In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.

Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8).

Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.

Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see sections 5.1 and 5.2).

Renal impairment

In patients with severe renal impairment (creatinine clearance < 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6 fold on average) which may lead to an increased bleeding risk.
Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance < 15 ml/min (see sections 4.2 and 5.2). Xarelto should be used with caution in patients with renal impairment concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations (see section 4.5).

Interaction with other medicinal products
The use of Xarelto is not recommended in patients receiving concomitant systemic treatment withazole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk (see section 4.5).

Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5).

Other haemorrhagic risk factors
As with other antithrombotics, rivaroxaban is not recommended in patients with an increased bleeding risk such as:
- congenital or acquired bleeding disorders
- uncontrolled severe arterial hypertension
- other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)
- vascular retinopathy
- bronchiectasis or history of pulmonary bleeding

Patients with prosthetic valves
Safety and efficacy of Xarelto have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Xarelto provides adequate anticoagulation in this patient population. Treatment with Xarelto is not recommended for these patients.

Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy
Xarelto is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of Xarelto have not been established in these clinical situations.

Spinal/epidural anaesthesia or puncture
When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. There is no clinical experience with the use of 15 mg or 20 mg rivaroxaban in these situations.

To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when
the anticoagulant effect of rivaroxaban is estimated to be low. However, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known. For the removal of an epidural catheter and based on the general PK characteristics at least 2x half-life, i.e. at least 18 hours in young patients and 26 hours in elderly patients should elapse after the last administration of rivaroxaban (see section 5.2). Following removal of the catheter, at least 6 hours should elapse before the next rivaroxaban dose is administered. If traumatic puncture occurs the administration of rivaroxaban is to be delayed for 24 hours.

Dosing recommendations before and after invasive procedures and surgical intervention
If an invasive procedure or surgical intervention is required, Xarelto 15 mg/ Xarelto 20 mg should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician. If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention. Xarelto should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section 5.2).

Elderly population
Increasing age may increase haemorrhagic risk (see section 5.2).

Dermatological reactions
Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.

Information about excipients
Xarelto contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

CYP3A4 and P-gp inhibitors
Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban C\text{max}, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole,itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp (see section 4.4).

Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5 fold increase in mean rivaroxaban AUC and a 1.4 fold increase in C\text{max}. The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).

Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3 fold increase in mean rivaroxaban AUC and C\text{max}. The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients.
In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8 fold increase in mean rivaroxaban AUC and 1.6 fold increase in $C_{\text{max}}$ when compared to subjects with normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0 fold increase in mean rivaroxaban AUC and 1.6 fold increase in $C_{\text{max}}$ when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section 4.4).

Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold increase in mean rivaroxaban AUC and a 1.3 fold increase in mean $C_{\text{max}}$. The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).

Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.

**Anticoagulants**

After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban. Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections 4.3 and 4.4).

**NSAIDs/platelet aggregation inhibitors**

No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15 mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response. No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with 500 mg acetylsalicylic acid.

Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.

Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).

**SSRIs/SNRIs**

As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical programme, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.

**Warfarin**

Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.

If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban.

If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the $C_{\text{trough}}$ of rivaroxaban (24 hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.

No pharmacokinetic interaction was observed between warfarin and rivaroxaban.
CYP3A4 inducers
Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John’s Wort (*Hypericum perforatum*)) may also lead to reduced rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.

Other concomitant therapies
No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4.

Laboratory parameters
Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of rivaroxaban (see section 5.1).

4.6 Fertility, pregnancy and lactation

Pregnancy
Safety and efficacy of Xarelto have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Xarelto is contraindicated during pregnancy (see section 4.3). Women of child-bearing potential should avoid becoming pregnant during treatment with rivaroxaban.

Breast-feeding
Safety and efficacy of Xarelto have not been established in breast-feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore Xarelto is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.

Fertility
No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).

4.7 Effects on ability to drive and use machines

Xarelto has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8). Patients experiencing these adverse reactions should not drive or use machines.

4.8 Undesirable effects

Summary of the safety profile
The safety of rivaroxaban has been evaluated in thirteen phase III studies including 53,103 patients exposed to rivaroxaban (see Table 1).
Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of patients*</th>
<th>Total daily dose</th>
<th>Maximum treatment duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</td>
<td>6,097</td>
<td>10 mg</td>
<td>39 days</td>
</tr>
<tr>
<td>Prevention of VTE in medically ill patients</td>
<td>3,997</td>
<td>10 mg</td>
<td>39 days</td>
</tr>
<tr>
<td>Treatment of DVT, PE and prevention of recurrence</td>
<td>6,790</td>
<td>Day 1 - 21: 30 mg Day 22 and onwards: 20 mg After at least 6 months: 10 mg or 20 mg</td>
<td>21 months</td>
</tr>
<tr>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</td>
<td>7,750</td>
<td>20 mg</td>
<td>41 months</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS)</td>
<td>10,225</td>
<td>5 mg or 10 mg respectively, co-administered with either ASA or ASA plus clopidogrel or ticlopidine</td>
<td>31 months</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with CAD/PAD</td>
<td>18,244</td>
<td>5 mg co-administered with ASA or 10 mg alone</td>
<td>47 months</td>
</tr>
</tbody>
</table>

* Patients exposed to at least one dose of rivaroxaban

The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and ‘Description of selected adverse reactions’ below) (Table 2). The most commonly reported bleedings were epistaxis (4.5 %) and gastrointestinal tract haemorrhage (3.8 %).

Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed phase III studies

<table>
<thead>
<tr>
<th>Indication</th>
<th>Any bleeding</th>
<th>Anaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</td>
<td>6.8% of patients</td>
<td>5.9% of patients</td>
</tr>
<tr>
<td>Prevention of VTE in medically ill patients</td>
<td>12.6% of patients</td>
<td>2.1% of patients</td>
</tr>
<tr>
<td>Treatment of DVT, PE and prevention of recurrence</td>
<td>23% of patients</td>
<td>1.6% of patients</td>
</tr>
<tr>
<td>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</td>
<td>28 per 100 patient years</td>
<td>2.5 per 100 patient years</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients after an ACS</td>
<td>22 per 100 patient years</td>
<td>1.4 per 100 patient years</td>
</tr>
<tr>
<td>Prevention of atherothrombotic events in patients with CAD/PAD</td>
<td>6.7 per 100 patient years</td>
<td>0.15 per 100 patient years**</td>
</tr>
</tbody>
</table>

* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.
** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied.
Tabulated list of adverse reactions
The frequencies of adverse reactions reported with Xarelto are summarised in Table 3 below by system organ class (in MedDRA) and by frequency.

Frequencies are defined as:
very common (≥ 1/10)
common (≥ 1/100 to < 1/10)
uncommon (≥ 1/1,000 to < 1/100)
rare (≥ 1/10,000 to < 1/1,000)
very rare ( < 1/10,000)
not known (cannot be estimated from the available data)

Table 3: All adverse reactions reported in patients in phase III clinical trials or through post-marketing use*

<table>
<thead>
<tr>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Very rare</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaemia (incl. respective laboratory parameters)</td>
<td>Thrombocytosis (incl. platelet count increased)A, Thrombocytopenia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Allergic reaction, dermatitis allergic, Angioedema and allergic oedema</td>
<td>Anaphylactic reactions including anaphylactic shock</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness, headache</td>
<td>Cerebral and intracranial haemorrhage, syncope</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye haemorrhage (incl. conjunctival haemorrhage)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tachycardia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypotension, haematoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epistaxis, haemoptyisis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipationA, diarrhoea, vomitingA</td>
<td></td>
<td></td>
<td>Dry mouth</td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>Uncommon</td>
<td>Rare</td>
<td>Very rare</td>
<td>Not known</td>
</tr>
<tr>
<td>--------</td>
<td>----------</td>
<td>------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td><strong>Hepatobilary disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase in transaminases</td>
<td>Hepatic impairment, increased bilirubin, increased blood alkaline phosphatase&lt;sup&gt;A&lt;/sup&gt;, increased GGT&lt;sup&gt;A&lt;/sup&gt;</td>
<td>Jaundice, Bilirubin conjugated increased (with or without concomitant increase of ALT), Cholestasis, Hepatitis (incl. hepatocellular injury)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus (incl. uncommon cases of generalised pruritus), rash, ecchymosis, cutaneous and subcutaneous haemorrhage</td>
<td>Urticaria</td>
<td>Stevens-Johnson syndrome/ Toxic Epidermal Necrolysis, DRESS syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain in extremity&lt;sup&gt;A&lt;/sup&gt;</td>
<td>Haemarthrosis</td>
<td>Muscle haemorrhage</td>
<td>Compartment syndrome secondary to a bleeding</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urogenital tract haemorrhage (incl. haematuria and menorrhagia&lt;sup&gt;B&lt;/sup&gt;), renal impairment (incl. blood creatinine increased, blood urea increased)&lt;sup&gt;A&lt;/sup&gt;</td>
<td></td>
<td>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever&lt;sup&gt;A&lt;/sup&gt;, peripheral oedema, decreased general strength and energy (incl. fatigue and asthenia)</td>
<td>Feeling unwell (incl. malaise)</td>
<td>Localised oedema&lt;sup&gt;A&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased LDH&lt;sup&gt;A&lt;/sup&gt;, increased lipase&lt;sup&gt;A&lt;/sup&gt;, increased amylase&lt;sup&gt;A&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Injuries, poisoning and procedural complications

<table>
<thead>
<tr>
<th>Common</th>
<th>Uncommon</th>
<th>Rare</th>
<th>Very rare</th>
<th>Not known</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postprocedural haemorrhage (incl. postoperative anaemia, and wound haemorrhage), contusion, wound secretion</td>
<td>Vascular pseudoaneurysm</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery
B: observed in treatment of DVT, PE and prevention of recurrence as very common in women < 55 years
C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)
* A pre-specified selective approach to adverse event collection was applied. As incidence of adverse reactions did not increase and no new adverse reaction was identified, COMPASS study data were not included for frequency calculation in this table.

**Description of selected adverse reactions**

Due to the pharmacological mode of action, the use of Xarelto may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 “Management of bleeding”). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section 4.4 “Haemorrhagic risk”). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed. Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Xarelto. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**

Rare cases of overdose up to 600 mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50 mg rivaroxaban or above. A specific antidote antagonising the pharmacodynamic effect of rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.
Management of bleeding
Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a half-life of approximately 5 to 13 hours (see section 5.2). Management should be individualised according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.

If bleeding cannot be controlled by the above measures, administration of a specific procoagulant reversal agent should be considered, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa). However, there is currently very limited clinical experience with the use of these medicinal products in individuals receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings (see section 5.1).

Protamine sulphate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic haemostatic desmopressin in individuals receiving rivaroxaban. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF01

Mechanism of action
Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.

Pharmacodynamic effects
Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant.

In patients receiving rivaroxaban for treatment of DVT and PE and prevention of recurrence, the 5/95 percentiles for PT (Neoplastin) 2 - 4 hours after tablet intake (i.e. at the time of maximum effect) for 15 mg rivaroxaban twice daily ranged from 17 to 32 s and for 20 mg rivaroxaban once daily from 15 to 30 s. At trough (8 - 16 h after tablet intake) the 5/95 percentiles for 15 mg twice daily ranged from 14 to 24 s and for 20 mg once daily (18 - 30 h after tablet intake) from 13 to 20 s.

In patients with non-valvular atrial fibrillation receiving rivaroxaban for the prevention of stroke and systemic embolism, the 5/95 percentiles for PT (Neoplastin) 1 - 4 hours after tablet intake (i.e. at the time of maximum effect) in patients treated with 20 mg once daily ranged from 14 to 40 s and in patients with moderate renal impairment treated with 15 mg once daily from 10 to 50 s. At trough (16 - 36 h after tablet intake) the 5/95 percentiles in patients treated with 20 mg once daily ranged from 12 to 26 s and in patients with moderate renal impairment treated with 15 mg once daily from 12 to 26 s.
In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3-factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9).

The activated partial thromboplastin time (aPTT) and HepTest are also prolonged dose-dependently; however, they are not recommended to assess the pharmacodynamic effect of rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated rivaroxaban levels can be measured by calibrated quantitative anti-factor Xa tests (see section 5.2).

Clinical efficacy and safety

Treatment of DVT, PE and prevention of recurrent DVT and PE

The Xarelto clinical programme was designed to demonstrate the efficacy of Xarelto in the initial and continued treatment of acute DVT and PE and prevention of recurrence.

Over 12,800 patients were studied in four randomised controlled phase III clinical studies (Einstein DVT, Einstein PE, Einstein Extension and Einstein Choice) and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted. The overall combined treatment duration in all studies was up to 21 months.

In Einstein DVT 3,449 patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study). The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.

For the initial 3 week treatment of acute DVT 15 mg rivaroxaban was administered twice daily. This was followed by 20 mg rivaroxaban once daily.

In Einstein PE, 4,832 patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE. The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.

For the initial treatment of acute PE 15 mg rivaroxaban was administered twice daily for three weeks. This was followed by 20 mg rivaroxaban once daily.

In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until the PT/INR was in therapeutic range (≥ 2.0). Treatment was continued with a vitamin K antagonist dose-adjusted to maintain the PT/INR values within the therapeutic range of 2.0 to 3.0.

In Einstein Extension 1,197 patients with DVT or PE were studied for the prevention of recurrent DVT and PE. The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator. Xarelto 20 mg once daily was compared with placebo.

Einstein DVT, PE and Extension used the same pre-defined primary and secondary efficacy outcomes. The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE. The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all-cause mortality.

In Einstein Choice, 3,396 patients with confirmed symptomatic DVT and/or PE who completed 6-12 months of anticoagulant treatment were studied for the prevention of fatal PE or non-fatal symptomatic recurrent DVT or PE. Patients with an indication for continued therapeutic-dosed anticoagulation were excluded from the study. The treatment duration was up to 12 months depending on the individual randomisation date (median: 351 days). Xarelto 20 mg once daily and Xarelto 10 mg once daily were compared with 100 mg acetylsalicylic acid once daily.
The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE.

In the Einstein DVT study (see Table 4) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p < 0.0001 (test for non-inferiority); Hazard Ratio (HR): 0.680 (0.443 - 1.042), p=0.076 (test for superiority)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.67 ((95% CI: 0.47 - 0.95), nominal p value p=0.027) in favour of rivaroxaban. INR values were within the therapeutic range a mean of 60.3% of the time for the mean treatment duration of 189 days, and 55.4%, 60.1%, and 62.8% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 - 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).

The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.

Table 4: Efficacy and safety results from phase III Einstein DVT

<table>
<thead>
<tr>
<th>Study population</th>
<th>3,449 patients with symptomatic acute deep vein thrombosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose and duration</strong></td>
<td><strong>Xarelto(^a)</strong> 3, 6 or 12 months N=1,731</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>36 (2.1%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>20 (1.2%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>14 (0.8%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>1 (0.1%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>4 (0.2%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>139 (8.1%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>14 (0.8%)</td>
</tr>
</tbody>
</table>

\(^{a}\) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily  
\(^{b}\) Enoxaparin for at least 5 days, overlapped with and followed by VKA  
* p < 0.0001 (non-inferiority to a prespecified HR of 2.0); HR: 0.680 (0.443 - 1.042), p=0.076 (superiority)

In the Einstein PE study (see Table 5) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); HR: 1.123 (0.749 - 1.684)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.849 ((95% CI: 0.633 - 1.139), nominal p value p=0.275). INR values were within the therapeutic range a mean of 63% of the time for the mean treatment duration of 215 days, and 57%, 62%, and 65% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 – 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction). Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.642 (95% CI: 0.277 - 1.484).

The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the
The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1% (26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a HR 0.493 (95% CI: 0.308 - 0.789).

### Table 5: Efficacy and safety results from phase III Einstein PE

<table>
<thead>
<tr>
<th>Study population</th>
<th>4,832 patients with an acute symptomatic PE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose and duration</strong></td>
<td>Xarelto(^a) 3, 6 or 12 months N=2,419</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>50 (2.1%)</td>
</tr>
<tr>
<td></td>
<td>23 (1.0%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>18 (0.7%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>0</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>11 (0.5%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>249 (10.3%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>26 (1.1%)</td>
</tr>
</tbody>
</table>

\(^a\) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily  
\(^b\) Enoxaparin for at least 5 days, overlapped with and followed by VKA  
* \(p < 0.0026\) (non-inferiority to a prespecified HR of 2.0); HR: 1.123 (0.749 - 1.684)

A prespecified pooled analysis of the outcome of the Einstein DVT and PE studies was conducted (see Table 6).

### Table 6: Efficacy and safety results from pooled analysis of phase III Einstein DVT and Einstein PE

<table>
<thead>
<tr>
<th>Study population</th>
<th>8,281 patients with an acute symptomatic DVT or PE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose and duration</strong></td>
<td>Xarelto(^a) 3, 6 or 12 months N=4,150</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>86 (2.1%)</td>
</tr>
<tr>
<td></td>
<td>43 (1.0%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>32 (0.8%)</td>
</tr>
<tr>
<td>Symptomatic PE and DVT</td>
<td>1 (&lt;0.1%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>15 (0.4%)</td>
</tr>
<tr>
<td>Major or clinically relevant non-major bleeding</td>
<td>388 (9.4%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>40 (1.0%)</td>
</tr>
</tbody>
</table>

\(^a\) Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily  
\(^b\) Enoxaparin for at least 5 days, overlapped with and followed by VKA  
* \(p < 0.0001\) (non-inferiority to a prespecified HR of 1.75); HR: 0.886 (0.661 - 1.186)

The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) of the
pooled analysis was reported with a HR of 0.771 ((95% CI: 0.614 - 0.967), nominal p value p = 0.0244).

In the Einstein Extension study (see Table 7) rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes. For the primary safety outcome (major bleeding events) there was a non-significant numerically higher incidence rate for patients treated with rivaroxaban 20 mg once daily compared to placebo. The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with rivaroxaban 20 mg once daily compared to placebo.

Table 7: Efficacy and safety results from phase III Einstein Extension

<table>
<thead>
<tr>
<th>Study population</th>
<th>1,197 patients continued treatment and prevention of recurrent venous thromboembolism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment dose and duration</td>
<td>Xarelto(^{a)}) 6 or 12 months N=602</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE*</td>
<td>8 (1.3%)</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>2 (0.3%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>5 (0.8%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>4 (0.7%)</td>
</tr>
<tr>
<td>Clinically relevant non-major bleeding</td>
<td>32 (5.4%)</td>
</tr>
</tbody>
</table>

\(^{a)}\) Rivaroxaban 20 mg once daily
* \( p < 0.0001 \) (superiority), HR: 0.185 (0.087 - 0.393)

In the Einstein Choice study (see Table 8) Xarelto 20 mg and 10 mg were both superior to 100 mg acetylsalicylic acid for the primary efficacy outcome. The principal safety outcome (major bleeding events) was similar for patients treated with Xarelto 20 mg and 10 mg once daily compared to 100 mg acetylsalicylic acid.
### Table 8: Efficacy and safety results from phase III Einstein Choice Study population

<table>
<thead>
<tr>
<th>Study population</th>
<th>3,396 patients continued prevention of recurrent venous thromboembolism</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dose</strong></td>
<td>Xarelto 20 mg od N=1,107</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE</td>
<td>17 (1.5%)*</td>
</tr>
<tr>
<td>Symptomatic recurrent PE</td>
<td>6 (0.5%)</td>
</tr>
<tr>
<td>Symptomatic recurrent DVT</td>
<td>9 (0.8%)</td>
</tr>
<tr>
<td>Fatal PE/death where PE cannot be ruled out</td>
<td>2 (0.2%)</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE, MI, stroke, or non-CNS systemic embolism</td>
<td>19 (1.7%)</td>
</tr>
<tr>
<td>Major bleeding events</td>
<td>6 (0.5%)</td>
</tr>
<tr>
<td>Clinically relevant non-major bleeding</td>
<td>30 (2.7)</td>
</tr>
<tr>
<td>Symptomatic recurrent VTE or major bleeding (net clinical benefit)</td>
<td>23 (2.1%)*</td>
</tr>
</tbody>
</table>

* p<0.001 (superiority) Xarelto 20 mg od vs ASA 100 mg od; HR=0.34 (0.20-0.59)
** p<0.001 (superiority) Xarelto 10 mg od vs ASA 100 mg od; HR=0.26 (0.14-0.47)
+ Xarelto 20 mg od vs. ASA 100 mg od; HR=0.44 (0.27-0.71), p=0.0009 (nominal)
++ Xarelto 10 mg od vs. ASA 100 mg od; HR=0.32 (0.18-0.55), p<0.0001 (nominal)

In addition to the phase III EINSTEIN programme, a prospective, non-interventional, open-label cohort study (XALIA) with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted. 5,142 patients with acute DVT were enrolled to investigate the long-term safety of rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice. Rates of major bleeding, recurrent VTE and all-cause mortality for rivaroxaban were 0.7%, 1.4% and 0.5%, respectively. There were differences in patient baseline characteristics including age, cancer and renal impairment. A pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results. Adjusted HRs comparing rivaroxaban and standard-of-care for major bleeding, recurrent VTE and all-cause mortality were 0.77 (95% CI 0.40 - 1.50), 0.91 (95% CI 0.54 - 1.54) and 0.51 (95% CI 0.24 - 1.07), respectively. These results in clinical practice are consistent with the established safety profile in this indication.

**Paediatric population**

The European Medicines Agency has deferred the obligation to submit the results of studies with Xarelto in one or more subsets of the paediatric population in the treatment of thromboembolic events. The European Medicines Agency has waived the obligation to submit the results of studies with Xarelto in all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).

### 5.2 Pharmacokinetic properties

**Absorption**

Rivaroxaban is rapidly absorbed with maximum concentrations ($C_{max}$) appearing 2 - 4 hours after tablet intake.
Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5 mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or Cmax at the 2.5 mg and 10 mg dose. Due to a reduced extent of absorption an oral bioavailability of 66% was determined for the 20 mg tablet under fasting conditions. When Xarelto 20 mg tablets are taken together with food increases in mean AUC by 39% were observed when compared to tablet intake under fasting conditions, indicating almost complete absorption and high oral bioavailability. Xarelto 15 mg and 20 mg are to be taken with food (see section 4.2).

Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily in fasting state. Under fed conditions Xarelto 10 mg, 15 mg and 20 mg tablets demonstrated dose-proportionality. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose. Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%.

Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and Cmax compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure. Bioavailability (AUC and Cmax) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.

**Distribution**

Plasma protein binding in humans is high at approximately 92% to 95%, with serum albumin being the main binding component. The volume of distribution is moderate with Vss being approximately 50 litres.

**Biotransformation and elimination**

Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion. Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on *in vitro* investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein). Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.

**Special populations**

**Gender**

There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients.

**Elderly population**

Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.
**Different weight categories**  
Extremes in body weight (< 50 kg or > 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.

**Inter-ethnic differences**  
No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.

**Hepatic impairment**  
Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.

The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT.

Xarelto is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).

**Renal impairment**  
There was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.9, 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.4 respectively. There are no data in patients with creatinine clearance < 15 ml/min.

Due to the high plasma protein binding rivaroxaban is not expected to be dialysable. Use is not recommended in patients with creatinine clearance < 15 ml/min. Xarelto is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).

**Pharmacokinetic data in patients**  
In patients receiving rivaroxaban for treatment of acute DVT 20 mg once daily the geometric mean concentration (90% prediction interval) 2 - 4 h and about 24 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 215 (22 - 535) and 32 (6 - 239) mcg/l, respectively.

**Pharmacokinetic/pharmacodynamic relationship**  
The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor Xa activity was best described by an $E_{\text{max}}$ model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 mcg/l). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects.
Paediatric population
Safety and efficacy have not been established for children and adolescents up to 18 years.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.

Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.

In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. haemorrhagic complications). Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
- Microcrystalline cellulose
- Croscarmellose sodium
- Lactose monohydrate
- Hypromellose 2910
- Sodium laurilsulphate
- Magnesium stearate

Film-coat
- Macrogol 3350
- Hypromellose 2910
- Titanium dioxide (E 171)
- Iron oxide red (E 172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Treatment initiation pack for the first 4 weeks of treatment:
PP/Aluminium foil blisters in a wallet containing 49 film-coated tablets:
42 film-coated tablets Xarelto 15 mg and 7 film-coated tablets Xarelto 20 mg.
6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/472/040

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 30 September 2008
Date of latest renewal: 22 May 2018

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Bayer AG
Kaiser-Wilhelm-Allee
51368 Leverkusen
Germany

Bayer HealthCare Manufacturing Srl.
Via delle Groane, 126
20024 Garbagnate Milanese
Italy

Bayer Bitterfeld GmbH
Ortsteil Greppin, Salegaster Chaussee 1
06803 Bitterfeld-Wolfen
Germany

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
• **Additional risk minimisation measures**

The MAH shall provide an educational pack prior to launch, targeting all physicians who are expected to prescribe/use Xarelto. The educational pack is aimed at increasing awareness about the potential risk of bleeding during treatment with Xarelto and providing guidance on how to manage that risk.

The physician educational pack should contain:

- The Summary of Product Characteristics
- Prescriber Guide
- Patient Alert Cards [Text included in Annex III]

The MAH must agree the content and format of the Prescriber Guide together with a communication plan, with the national competent authority in each Member State prior to distribution of the educational pack in their territory. The Prescriber Guide should contain the following key safety messages:

- Details of populations potentially at higher risk of bleeding
- Recommendations for dose reduction in at risk populations
- Guidance regarding switching from or to rivaroxaban treatment
- The need for intake of the 15 mg and 20 mg tablets with food
- Management of overdose situations
- The use of coagulation tests and their interpretation
- That all patients should be counselled about:
  - Signs or symptoms of bleeding and when to seek attention from a health care provider.
  - Importance of treatment compliance
  - The need for intake of the 15 mg and 20 mg tablets with food
  - Necessity to carry the Patient Alert Card that is included in each pack, with them at all times
  - The need to inform Health Care Professionals that they are taking Xarelto if they need to have any surgery or invasive procedure.

The MAH shall also provide a Patient Alert Card in each medicine pack, the text of which is included in Annex III.
Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

<table>
<thead>
<tr>
<th>Description</th>
<th>Due dates</th>
</tr>
</thead>
</table>
| A post-authorisation study programme that addresses the safety of rivaroxaban in the secondary prevention of Acute Coronary Syndrome (ACS) outside the clinical trial setting, especially with regard to incidence, severity, management and outcome of bleeding events in all population and particularly in patients at increased risk of bleeding consisting of the following remaining studies: | • Interim analyses reports provided annually beginning Q4 2015 until completion of the study programme.  
• Final Study Reports submitted by Q4 2020 |
| • Drug Utilisation and Outcome Studies in the UK, Germany, The Netherlands and Sweden    |                                                                          |
| • Specialist Cohort Event Monitoring (SCEM) ACS Study                                     |                                                                          |
| With the submission of the last final study report from the programme, the MAH should provide an overview and discussion of the results from all studies of the programme in view of ACS patients. |                                                                          |
ANNEX III
LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON FOR 2.5 MG

1. NAME OF THE MEDICINAL PRODUCT

Xarelto 2.5 mg film-coated tablets
rivaroxaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 2.5 mg rivaroxaban.

3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>20</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>28</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>56</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>60</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>98</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>168</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>196</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>10 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>100 x 1</td>
<td>film-coated tablets</td>
</tr>
<tr>
<td>30</td>
<td>film-coated tablets</td>
</tr>
</tbody>
</table>

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY
8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Marketing Authorisation Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/08/472/025</td>
<td>14 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/026</td>
<td>28 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/027</td>
<td>56 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/028</td>
<td>60 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/029</td>
<td>98 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/030</td>
<td>168 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/031</td>
<td>196 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/032</td>
<td>10 x 1 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/033</td>
<td>100 x 1 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/035</td>
<td>30 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/041</td>
<td>20 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/047</td>
<td>14 film-coated tablets (PVC/PVDC/Aluminium foil blisters)</td>
</tr>
</tbody>
</table>

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Xarelto 2.5 mg
<table>
<thead>
<tr>
<th>17. UNIQUE IDENTIFIER – 2D BARCODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2D barcode carrying the unique identifier included.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC:</td>
</tr>
<tr>
<td>SN:</td>
</tr>
<tr>
<td>NN:</td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX) FOR 2.5 MG

1. NAME OF THE MEDICINAL PRODUCT

Xarelto 2.5 mg film-coated tablets
rivaroxaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 2.5 mg rivaroxaban.

3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Multipack: 100 (10 packs of 10 x 1) film-coated tablets.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
<table>
<thead>
<tr>
<th><strong>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</strong></th>
</tr>
</thead>
</table>
| Bayer AG  
51368 Leverkusen  
Germany |

<table>
<thead>
<tr>
<th><strong>12. MARKETING AUTHORISATION NUMBER(S)</strong></th>
</tr>
</thead>
</table>
| EU/1/08/472/034  
100 film-coated tablets (10 x 10 x 1) (multipack) (PP/Aluminium foil blisters) |

<table>
<thead>
<tr>
<th><strong>13. BATCH NUMBER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Batch</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>14. GENERAL CLASSIFICATION FOR SUPPLY</strong></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>15. INSTRUCTIONS ON USE</strong></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>16. INFORMATION IN BRAILLE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto 2.5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>17. UNIQUE IDENTIFIER – 2D BARCODE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>2D barcode carrying the unique identifier included.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</strong></th>
</tr>
</thead>
</table>
| PC:  
SN:  
NN: |
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) FOR 2.5 MG

1. NAME OF THE MEDICINAL PRODUCT

Xarelto 2.5 mg film-coated tablets
rivaroxaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 2.5 mg rivaroxaban.

3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

10 x 1 film-coated tablets.
Component of a multipack, can’t be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/472/034 100 film-coated tablets (10 x 10 x 1) (multipack) (PP/Aluminium foil blisters)

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Xarelto 2.5 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNIT DOSE BLISTER (10 x 1 TABLETS) FOR 2.5 MG</td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

   Xarelto 2.5 mg tablets
   rivaroxaban

2. **NAME OF THE MARKETING AUTHORITY HOLDING**

   Bayer (logo)

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER**
**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**BLISTER OF 10 TABLETS FOR 2.5 MG**

1. **NAME OF THE MEDICINAL PRODUCT**
   
   Xarelto 2.5 mg tablets
   rivaroxaban

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**
   
   Bayer (logo)

3. **EXPIRY DATE**
   
   EXP

4. **BATCH NUMBER**
   
   Lot

5. **OTHER**


MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
BLISTER OF 14 TABLETS FOR 2.5 MG

1. NAME OF THE MEDICINAL PRODUCT
Xarelto 2.5 mg tablets
rivaroxaban

2. NAME OF THE MARKETING AUTHORISATION HOLDER
Bayer (logo)

3. EXPIRY DATE
EXP

4. BATCH NUMBER
Lot

5. OTHER
Mon.
Tue.
Wed.
Thu.
Fri.
Sat.
Sun.

sun as symbol
moon as symbol
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING

**OUTER CARTON AND LABEL FOR HDPE BOTTLE FOR 2.5 MG**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto 2.5 mg film-coated tablets</td>
</tr>
<tr>
<td>rivaroxaban</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each film-coated tablet contains 2.5 mg rivaroxaban.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contains lactose. See package leaflet for further information.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 film-coated tablets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Oral use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. SPECIAL STORAGE CONDITIONS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</th>
</tr>
</thead>
</table>
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/472/046  100 film-coated tablets (HDPE Bottle)

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription. (only applicable for bottle label, not applicable for outer carton)

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Xarelto 2.5 mg (only applicable for outer carton, not applicable for bottle label)

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included. (only applicable for outer carton, not applicable for bottle label)

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC: (only applicable for outer carton, not applicable for bottle label)
SN: (only applicable for outer carton, not applicable for bottle label)
NN: (only applicable for outer carton, not applicable for bottle label)
## PARTICULARS TO APPEAR ON THE OUTER PACKAGING

### OUTER CARTON FOR 10 MG

### 1. NAME OF THE MEDICINAL PRODUCT

Xarelto 10 mg film-coated tablets
rivaroxaban

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 10 mg rivaroxaban.

### 3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

### 4. PHARMACEUTICAL FORM AND CONTENTS

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 film-coated tablets</td>
<td></td>
</tr>
<tr>
<td>10 film-coated tablets</td>
<td></td>
</tr>
<tr>
<td>14 film-coated tablets</td>
<td></td>
</tr>
<tr>
<td>28 film-coated tablets</td>
<td></td>
</tr>
<tr>
<td>30 film-coated tablets</td>
<td></td>
</tr>
<tr>
<td>98 film-coated tablets</td>
<td></td>
</tr>
<tr>
<td>10 x 1 film-coated tablets</td>
<td></td>
</tr>
<tr>
<td>100 x 1 film-coated tablets</td>
<td></td>
</tr>
</tbody>
</table>

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

### 8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/08/472/001</td>
<td>5 film-coated tablets (PVC/PVDC/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/002</td>
<td>10 film-coated tablets (PVC/PVDC/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/003</td>
<td>30 film-coated tablets (PVC/PVDC/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/004</td>
<td>100 x 1 film-coated tablets (PVC/PVDC/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/005</td>
<td>5 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/006</td>
<td>10 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/007</td>
<td>30 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/008</td>
<td>100 x 1 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/009</td>
<td>10 x 1 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/010</td>
<td>10 x 1 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/042</td>
<td>14 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/043</td>
<td>28 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/044</td>
<td>98 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
</tbody>
</table>

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

Xarelto 10 mg

16. INFORMATION IN BRAILLE

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX) FOR 10 MG

1. NAME OF THE MEDICINAL PRODUCT

Xarelto 10 mg film-coated tablets
rivaroxaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 10 mg rivaroxaban.

3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Multipack: 100 (10 packs of 10 x 1) film-coated tablets.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY


8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS


10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE


11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/472/022 100 film-coated tablets (10 x 10 x 1) (multipack) (PP/Aluminium foil blisters)

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Xarelto 10 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) FOR 10 MG

1. NAME OF THE MEDICINAL PRODUCT
Xarelto 10 mg film-coated tablets
rivaroxaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)
Each film-coated tablet contains 10 mg rivaroxaban.

3. LIST OF EXCIPIENTS
Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS
10 x 1 film-coated tablets.
Component of a multipack, can’t be sold separately.

5. METHOD AND ROUTE(S) OF ADMINISTRATION
Read the package leaflet before use.
Oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE
EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/08/472/022 100 film-coated tablets (10 x 10 x 1) (multipack) (PP/Aluminium foil blisters)

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Xarelto 10 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**BLISTER OF 10 TABLETS FOR 10 MG**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
| **1. NAME OF THE MEDICINAL PRODUCT** | Xarelto 10 mg tablets  
  rivaroxaban |
<p>| <strong>2. NAME OF THE MARKETING AUTHORISATION HOLDER</strong> | Bayer (logo) |
| <strong>3. EXPIRY DATE</strong> | EXP |
| <strong>4. BATCH NUMBER</strong> | Lot |
| <strong>5. OTHER</strong> |   |</p>
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLISTER OF 14 TABLETS FOR 10 MG</td>
</tr>
</tbody>
</table>

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
| 1. NAME OF THE MEDICINAL PRODUCT | Xarelto 10 mg tablets  
rivaroxaban |
| 2. NAME OF THE MARKETING AUTHORISATION HOLDER | Bayer (logo) |
| 3. EXPIRY DATE | EXP |
| 4. BATCH NUMBER | Lot |
| 5. OTHER | Mon.  
Tue.  
Wed.  
Thu.  
Fri.  
Sat.  
Sun. |
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING

**OUTER CARTON AND LABEL FOR HDPE BOTTLE FOR 10 MG**

1. **NAME OF THE MEDICINAL PRODUCT**

   Xarelto 10 mg film-coated tablets
   rivaroxaban

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each film-coated tablet contains 10 mg rivaroxaban.

3. **LIST OF EXCIPIENTS**

   Contains lactose. See package leaflet for further information.

4. **PHARMACEUTICAL FORM AND CONTENTS**

   100 film-coated tablets

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Read the package leaflet before use.
   Oral use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**
11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Bayer AG  
51368 Leverkusen  
Germany

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/08/472/045  
100 film-coated tablets (HDPE Bottle)

13. **BATCH NUMBER**

Batch

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription. (only applicable for bottle label, not applicable for outer carton)

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Xarelto 10 mg (only applicable for outer carton, not applicable for bottle label)

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included. (only applicable for outer carton, not applicable for bottle label)

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC: (only applicable for outer carton, not applicable for bottle label)  
SN: (only applicable for outer carton, not applicable for bottle label)  
NN: (only applicable for outer carton, not applicable for bottle label)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON FOR UNIT PACK FOR 15 MG

1. NAME OF THE MEDICINAL PRODUCT

Xarelto 15 mg film-coated tablets
rivaroxaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 15 mg rivaroxaban.

3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

10 film-coated tablets
14 film-coated tablets
28 film-coated tablets
42 film-coated tablets
98 film-coated tablets
10 x 1 film-coated tablets
100 x 1 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer AG
51368 Leverkusen
Germany

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/08/472/011</td>
<td>14 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/012</td>
<td>28 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/013</td>
<td>42 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/014</td>
<td>98 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/015</td>
<td>10 x 1 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/016</td>
<td>100 x 1 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/038</td>
<td>10 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/048</td>
<td>14 film-coated tablets (PVC/PVDC/Aluminium foil blisters)</td>
</tr>
</tbody>
</table>

13. BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Xarelto 15 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX) FOR 15 MG

1. NAME OF THE MEDICINAL PRODUCT

Xarelto 15 mg film-coated tablets
rivaroxaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 15 mg rivaroxaban.

3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Multipack: 100 (10 packs of 10 x 1) film-coated tablets.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
<table>
<thead>
<tr>
<th>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer AG</td>
</tr>
<tr>
<td>51368 Leverkusen</td>
</tr>
<tr>
<td>Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12. MARKETING AUTHORISATION NUMBER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/08/472/023</td>
</tr>
<tr>
<td>100 film-coated tablets (10 x 10 x 1) (multipack) (PP/Aluminium foil blisters)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batch</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14. GENERAL CLASSIFICATION FOR SUPPLY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>15. INSTRUCTIONS ON USE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>16. INFORMATION IN BRAILLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto 15 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17. UNIQUE IDENTIFIER – 2D BARCODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2D barcode carrying the unique identifier included.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC:</td>
</tr>
<tr>
<td>SN:</td>
</tr>
<tr>
<td>NN:</td>
</tr>
<tr>
<td>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</td>
</tr>
<tr>
<td>INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) FOR 15 MG</td>
</tr>
<tr>
<td>1. NAME OF THE MEDICINAL PRODUCT</td>
</tr>
<tr>
<td>Xarelto 15 mg film-coated tablets</td>
</tr>
<tr>
<td>rivaroxaban</td>
</tr>
<tr>
<td>2. STATEMENT OF ACTIVE SUBSTANCE(S)</td>
</tr>
<tr>
<td>Each film-coated tablet contains 15 mg rivaroxaban.</td>
</tr>
<tr>
<td>3. LIST OF EXCIPIENTS</td>
</tr>
<tr>
<td>Contains lactose. See package leaflet for further information.</td>
</tr>
<tr>
<td>4. PHARMACEUTICAL FORM AND CONTENTS</td>
</tr>
<tr>
<td>10 x 1 film-coated tablets.</td>
</tr>
<tr>
<td>Component of a multipack, can’t be sold separately.</td>
</tr>
<tr>
<td>5. METHOD AND ROUTE(S) OF ADMINISTRATION</td>
</tr>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Oral use.</td>
</tr>
<tr>
<td>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</td>
</tr>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
<tr>
<td>7. OTHER SPECIAL WARNING(S), IF NECESSARY</td>
</tr>
<tr>
<td>8. EXPIRY DATE</td>
</tr>
<tr>
<td>EXP</td>
</tr>
<tr>
<td>9. SPECIAL STORAGE CONDITIONS</td>
</tr>
<tr>
<td>10.</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>11.</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>12.</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>13.</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>14.</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>15.</td>
</tr>
<tr>
<td>16.</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>17.</td>
</tr>
<tr>
<td>18.</td>
</tr>
<tr>
<td><strong>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</strong></td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td><strong>UNIT DOSE BLISTER (10 X 1 TABLETS) FOR 15 MG</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto 15 mg tablets</td>
</tr>
<tr>
<td>rivaroxaban</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>2. NAME OF THE MARKETING AUTHORISATION HOLDER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer (logo)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>3. EXPIRY DATE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>4. BATCH NUMBER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>5. OTHER</strong></th>
</tr>
</thead>
</table>

### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**BLISTER OF 14 TABLETS FOR 15 MG**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto 15 mg tablets</td>
</tr>
<tr>
<td>rivaroxaban</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer (logo)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mon.</td>
</tr>
<tr>
<td>Tue.</td>
</tr>
<tr>
<td>Wed.</td>
</tr>
<tr>
<td>Thu.</td>
</tr>
<tr>
<td>Fri.</td>
</tr>
<tr>
<td>Sat.</td>
</tr>
<tr>
<td>Sun.</td>
</tr>
<tr>
<td>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</td>
</tr>
<tr>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>BLISTER OF 10 TABLETS FOR 15 MG</td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

   Xarelto 15 mg tablets  
   rivaroxaban

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

   Bayer (logo)

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER**
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING**

**OUTER CARTON AND LABEL FOR HDPE BOTTLE FOR 15 MG**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto 15 mg film-coated tablets</td>
</tr>
<tr>
<td>rivaroxaban</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each film-coated tablet contains 15 mg rivaroxaban.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contains lactose. See package leaflet for further information.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 film-coated tablets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Oral use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. SPECIAL STORAGE CONDITIONS</th>
</tr>
</thead>
</table>

| 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE |

162
**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Bayer AG  
51368 Leverkusen  
Germany

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/08/472/036  
100 film-coated tablets (HDPE Bottle)

**13. BATCH NUMBER**

Batch

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription. *(only applicable for bottle label, not applicable for outer carton)*

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Xarelto 15 mg *(only applicable for outer carton, not applicable for bottle label)*

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included. *(only applicable for outer carton, not applicable for bottle label)*

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC: *(only applicable for outer carton, not applicable for bottle label)*  
SN: *(only applicable for outer carton, not applicable for bottle label)*  
NN: *(only applicable for outer carton, not applicable for bottle label)*
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</th>
</tr>
</thead>
<tbody>
<tr>
<td>OUTER CARTON FOR UNIT PACK FOR 20 MG</td>
</tr>
</tbody>
</table>

### 1. NAME OF THE MEDICINAL PRODUCT

Xarelto 20 mg film-coated tablets
rivaroxaban

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 20 mg rivaroxaban.

### 3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

### 4. PHARMACEUTICAL FORM AND CONTENTS

<table>
<thead>
<tr>
<th>10 film-coated tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 film-coated tablets</td>
</tr>
<tr>
<td>28 film-coated tablets</td>
</tr>
<tr>
<td>98 film-coated tablets</td>
</tr>
<tr>
<td>10 x 1 film-coated tablets</td>
</tr>
<tr>
<td>100 x 1 film-coated tablets</td>
</tr>
</tbody>
</table>

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

### 8. EXPIRY DATE

EXP

### 9. SPECIAL STORAGE CONDITIONS
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Bayer AG  
51368 Leverkusen  
Germany

12. **MARKETING AUTHORISATION NUMBER(S)**

<table>
<thead>
<tr>
<th>Batch Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/08/472/017</td>
<td>14 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/018</td>
<td>28 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/019</td>
<td>98 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/020</td>
<td>10 x 1 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/021</td>
<td>100 x 1 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/039</td>
<td>10 film-coated tablets (PP/Aluminium foil blisters)</td>
</tr>
<tr>
<td>EU/1/08/472/049</td>
<td>14 film-coated tablets (PVC/PVDC/Aluminium foil blisters)</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Batch

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Xarelto 20 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC:  
SN:  
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX) FOR 20 MG

1. NAME OF THE MEDICINAL PRODUCT
Xarelto 20 mg film-coated tablets
rivaroxaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)
Each film-coated tablet contains 20 mg rivaroxaban.

3. LIST OF EXCIPIENTS
Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS
Multipack: 100 (10 packs of 10 x 1) film-coated tablets.

5. METHOD AND ROUTE(S) OF ADMINISTRATION
Read the package leaflet before use.
Oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE
EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
<table>
<thead>
<tr>
<th>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer AG</td>
</tr>
<tr>
<td>51368 Leverkusen</td>
</tr>
<tr>
<td>Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12. MARKETING AUTHORISATION NUMBER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/08/472/024 100 film-coated tablets (10 x 10 x 1) (multipack) (PP/Aluminium foil blisters)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batch</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14. GENERAL CLASSIFICATION FOR SUPPLY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>15. INSTRUCTIONS ON USE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>16. INFORMATION IN BRAILLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto 20 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17. UNIQUE IDENTIFIER – 2D BARCODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2D barcode carrying the unique identifier included.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC:</td>
</tr>
<tr>
<td>SN:</td>
</tr>
<tr>
<td>NN:</td>
</tr>
</tbody>
</table>
# PARTICULARS TO APPEAR ON THE OUTER PACKAGING

## INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) FOR 20 MG

### 1. NAME OF THE MEDICINAL PRODUCT

Xarelto 20 mg film-coated tablets
rivaroxaban

### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 20 mg rivaroxaban.

### 3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

### 4. PHARMACEUTICAL FORM AND CONTENTS

10 x 1 film-coated tablets.
Component of a multipack, can’t be sold separately.

### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

### 8. EXPIRY DATE

EXP

### 9. SPECIAL STORAGE CONDITIONS
<table>
<thead>
<tr>
<th>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
</table>

Bayer AG  
51368 Leverkusen  
Germany

<table>
<thead>
<tr>
<th>12. MARKETING AUTHORISATION NUMBER(S)</th>
</tr>
</thead>
</table>

EU/1/08/472/024  
100 film-coated tablets (10 x 10 x 1) (multipack) (PP/Aluminium foil blisters)

<table>
<thead>
<tr>
<th>13. BATCH NUMBER</th>
</tr>
</thead>
</table>

Batch

<table>
<thead>
<tr>
<th>14. GENERAL CLASSIFICATION FOR SUPPLY</th>
</tr>
</thead>
</table>

Medicinal product subject to medical prescription.

<table>
<thead>
<tr>
<th>15. INSTRUCTIONS ON USE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>16. INFORMATION IN BRAILLE</th>
</tr>
</thead>
</table>

Xarelto 20 mg

<table>
<thead>
<tr>
<th>17. UNIQUE IDENTIFIER – 2D BARCODE</th>
</tr>
</thead>
</table>

<p>| 18. UNIQUE IDENTIFIER - HUMAN READABLE DATA |</p>
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNIT DOSE BLISTER (10 X 1 TABLETS) FOR 20 MG</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xarelto 20 mg tablets</td>
</tr>
<tr>
<td>rivaroxaban</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer (logo)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</strong></td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td><strong>BLISTER OF 14 TABLETS FOR 20 MG</strong></td>
</tr>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
</tr>
<tr>
<td>Xarelto 20 mg tablets</td>
</tr>
<tr>
<td>rivaroxaban</td>
</tr>
<tr>
<td><strong>2. NAME OF THE MARKETING AUTHORISATION HOLDER</strong></td>
</tr>
<tr>
<td>Bayer (logo)</td>
</tr>
<tr>
<td><strong>3. EXPIRY DATE</strong></td>
</tr>
<tr>
<td>EXP</td>
</tr>
<tr>
<td><strong>4. BATCH NUMBER</strong></td>
</tr>
<tr>
<td>Lot</td>
</tr>
<tr>
<td><strong>5. OTHER</strong></td>
</tr>
<tr>
<td>Mon.</td>
</tr>
<tr>
<td>Tue.</td>
</tr>
<tr>
<td>Wed.</td>
</tr>
<tr>
<td>Thu.</td>
</tr>
<tr>
<td>Fri.</td>
</tr>
<tr>
<td>Sat.</td>
</tr>
<tr>
<td>Sun.</td>
</tr>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
</tr>
<tr>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Xarelto 20 mg tablets</td>
</tr>
<tr>
<td>rivaroxaban</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>2. NAME OF THE MARKETING AUTHORISATION HOLDER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bayer (logo)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>3. EXPIRY DATE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>4. BATCH NUMBER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>5. OTHER</strong></th>
</tr>
</thead>
</table>
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING**

**OUTER CARTON AND LABEL FOR HDPE BOTTLE FOR 20 MG**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
<td></td>
</tr>
<tr>
<td>Xarelto 20 mg film-coated tablets rivaroxaban</td>
<td></td>
</tr>
<tr>
<td><strong>2. STATEMENT OF ACTIVE SUBSTANCE(S)</strong></td>
<td></td>
</tr>
<tr>
<td>Each film-coated tablet contains 20 mg rivaroxaban.</td>
<td></td>
</tr>
<tr>
<td><strong>3. LIST OF EXCIPIENTS</strong></td>
<td></td>
</tr>
<tr>
<td>Contains lactose. See package leaflet for further information.</td>
<td></td>
</tr>
<tr>
<td><strong>4. PHARMACEUTICAL FORM AND CONTENTS</strong></td>
<td></td>
</tr>
<tr>
<td>100 film-coated tablets</td>
<td></td>
</tr>
<tr>
<td><strong>5. METHOD AND ROUTE(S) OF ADMINISTRATION</strong></td>
<td></td>
</tr>
<tr>
<td>Read the package leaflet before use. Oral use.</td>
<td></td>
</tr>
<tr>
<td><strong>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</strong></td>
<td></td>
</tr>
<tr>
<td>Keep out of the sight and reach of children.</td>
<td></td>
</tr>
<tr>
<td><strong>7. OTHER SPECIAL WARNING(S), IF NECESSARY</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>8. EXPIRY DATE</strong></td>
<td></td>
</tr>
<tr>
<td>EXP</td>
<td></td>
</tr>
<tr>
<td><strong>9. SPECIAL STORAGE CONDITIONS</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</td>
</tr>
<tr>
<td>---</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Bayer AG</td>
</tr>
<tr>
<td></td>
<td>51368 Leverkusen</td>
</tr>
<tr>
<td></td>
<td>Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>MARKETING AUTHORISATION NUMBER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EU/1/08/472/037 100 film-coated tablets (HDPE Bottle)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Batch</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>GENERAL CLASSIFICATION FOR SUPPLY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Medicinal product subject to medical prescription. (only applicable for bottle label, not applicable for outer carton)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>INSTRUCTIONS ON USE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th>INFORMATION IN BRAILLE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Xarelto 20 mg (only applicable for outer carton, not applicable for bottle label)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>UNIQUE IDENTIFIER – 2D BARCODE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2D barcode carrying the unique identifier included. (only applicable for outer carton, not applicable for bottle label)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>UNIQUE IDENTIFIER - HUMAN READABLE DATA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PC: (only applicable for outer carton, not applicable for bottle label)</td>
</tr>
<tr>
<td></td>
<td>SN: (only applicable for outer carton, not applicable for bottle label)</td>
</tr>
<tr>
<td></td>
<td>NN: (only applicable for outer carton, not applicable for bottle label)</td>
</tr>
</tbody>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF TREATMENT INITIATION PACK (42 FILM-COATED TABLETS OF 15 MG AND 7 FILM-COATED TABLETS OF 20 MG) (INCLUDING BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Xarelto 15 mg
Xarelto 20 mg
film-coated tablets
rivaroxaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each red film-coated tablet for week 1, 2 and 3 contains 15 mg rivaroxaban.
Each brown-red film-coated tablet for week 4 contains 20 mg rivaroxaban.

3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Each pack of 49 film-coated tablets contains:
42 film-coated tablets of 15 mg rivaroxaban
7 film-coated tablets of 20 mg rivaroxaban

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

Treatment Initiation Pack

This treatment initiation pack is only for the first 4 weeks of treatment.

DOSE
Day 1 to 21: One 15 mg tablet twice a day (one 15 mg tablet in the morning and one in the evening) together with food.
From Day 22: One 20 mg tablet once a day (taken at same time each day) together with food.

Day 1 to 21: 15 mg 1 tablet twice a day (one 15 mg tablet in the morning and one in the evening) together with food.
From Day 22: 20 mg 1 tablet once a day (taken at same time each day) together with food.
6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Bayer AG  
51368 Leverkusen  
Germany

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/08/472/040  
42 film-coated tablets of 15 mg rivaroxaban and 7 film-coated tablets of 20 mg rivaroxaban (treatment initiation pack)

13. **BATCH NUMBER**

Batch

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Xarelto 15 mg  
Xarelto 20 mg
17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

WALLET OF TREATMENT INITIATION PACK (42 FILM-COATED TABLETS OF 15 MG AND 7 FILM-COATED TABLETS OF 20 MG) (WITHOUT BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Xarelto 15 mg
Xarelto 20 mg
film-coated tablets
rivaroxaban

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each red film-coated tablet for week 1, 2 and 3 contains 15 mg rivaroxaban.
Each brown-red film-coated tablet for week 4 contains 20 mg rivaroxaban.

3. LIST OF EXCIPIENTS

Contains lactose. See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Each pack of 49 film-coated tablets contains:
42 film-coated tablets of 15 mg rivaroxaban
7 film-coated tablets of 20 mg rivaroxaban

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use.

Treatment Initiation Pack

This treatment initiation pack is only for the first 4 weeks of treatment.

Day 1 to 21: 15 mg 1 tablet twice a day (one 15 mg tablet in the morning and one in the evening) together with food.
From Day 22: 20 mg 1 tablet once a day (taken at same time each day) together with food.

DOSE and DOSING SCHEME

Day 1 to 21: One 15 mg tablet twice a day (one 15 mg tablet in the morning and one in the evening).
From Day 22: One 20 mg tablet once a day (taken at same time each day).

Initial treatment Xarelto 15 mg twice a day First 3 weeks
Continuous treatment Xarelto 20 mg once a day Week 4 onwards Visit your doctor to ensure continued treatment.
To be taken with food.
Xarelto 15 mg  
Start of therapy  
15 mg  
twice a day  
Start date  
WEEK 1, WEEK 2, WEEK 3  
DAY 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

\[sun\ as\ symbol\]
\[moon\ as\ symbol\]

Dose change  
Xarelto 20 mg  
20 mg  
once a day  
taken at same time each day  
Date of dose change  
WEEK 4  
DAY 22 DAY 23 DAY 24 DAY 25 DAY 26 DAY 27 DAY 28

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Bayer AG  
51368 Leverkusen  
Germany
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12. MARKETING AUTHORISATION NUMBER(S)</strong></td>
<td>EU/1/08/472/040 42 film-coated tablets of 15 mg rivaroxaban and 7 film-coated tablets of 20 mg rivaroxaban (treatment initiation pack)</td>
</tr>
<tr>
<td><strong>13. BATCH NUMBER</strong></td>
<td>Batch</td>
</tr>
<tr>
<td><strong>14. GENERAL CLASSIFICATION FOR SUPPLY</strong></td>
<td>Medicinal product subject to medical prescription.</td>
</tr>
<tr>
<td><strong>15. INSTRUCTIONS ON USE</strong></td>
<td></td>
</tr>
<tr>
<td><strong>16. INFORMATION IN BRAILLE</strong></td>
<td>Justification for not including Braille accepted.</td>
</tr>
<tr>
<td><strong>17. UNIQUE IDENTIFIER – 2D BARCODE</strong></td>
<td></td>
</tr>
<tr>
<td><strong>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</strong></td>
<td></td>
</tr>
<tr>
<td>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>BLISTER OF TREATMENT INITIATION PACK IN WALLET (42 FILM-COATED TABLETS OF 15 MG AND 7 FILM-COATED TABLETS OF 20 MG)</td>
<td></td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

   Xarelto 15 mg tablets
   Xarelto 20 mg tablets
   rivaroxaban

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

   Bayer (logo)

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER**
Patient Alert Card
Bayer (logo)

Xarelto 2.5 mg (tick box to tick the prescribed dose)
Xarelto 10 mg (tick box to tick the prescribed dose)
Xarelto 15 mg (tick box to tick the prescribed dose)
Xarelto 20 mg (tick box to tick the prescribed dose)

♦ Keep this card with you at all times
♦ Present this card to every physician or dentist prior to treatment

I am under anticoagulation treatment with Xarelto (rivaroxaban)
Name:
Address:
Birth date:
Weight:
Other medicines / conditions:

In case of emergency, please notify:
Doctor’s name:
Doctor’s phone:
Doctor’s stamp:

Please also notify:
Name:
Phone:
Relationship:

Information for health care providers:
♦ INR values should not be used as they are not a dependable measure of the anticoagulant activity of Xarelto.

What should I know about Xarelto?
♦ Xarelto thins the blood, which prevents you from getting dangerous blood clots.
♦ Xarelto must be taken exactly as prescribed by your doctor. To ensure optimal protection from blood clots, never skip a dose.
♦ You must not stop taking Xarelto without first talking to your doctor as your risk of blood clots may increase.
♦ Tell your health care provider about any other medicines you are currently taking, took recently or intend to start taking, before you start Xarelto.
♦ Tell your health care provider that you are taking Xarelto before any surgery or invasive procedure.
When should I seek advice from my health care provider?
When taking a blood thinner such as Xarelto it is important to be aware of its possible side effects. Bleeding is the most common side effect. Do not start taking Xarelto if you know you are at risk of bleeding, without first discussing this with your doctor. Tell your health care provider straight away if you have any signs or symptoms of bleeding such as the following:
♦ pain
♦ swelling or discomfort
♦ headache, dizziness or weakness
♦ unusual bruising, nosebleeds, bleeding of gums, cuts that take a long time to stop bleeding
♦ menstrual flow or vaginal bleeding that is heavier than normal
♦ blood in your urine which may be pink or brown, red or black stools
♦ coughing up blood, or vomiting blood or material that looks like coffee grounds

How do I take Xarelto?
♦ To ensure optimal protection, Xarelto
  - 2.5 mg can be taken with or without food
  - 10 mg can be taken with or without food
  - 15 mg must be taken with food
  - 20 mg must be taken with food
B. PACKAGE LEAFLET
Package leaflet: Information for the user

Xarelto 2.5 mg film-coated tablets
rivaroxaban

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Xarelto is and what it is used for
2. What you need to know before you take Xarelto
3. How to take Xarelto
4. Possible side effects
5. How to store Xarelto
6. Contents of the pack and other information

1. What Xarelto is and what it is used for

You have been given Xarelto because
- you have been diagnosed with an acute coronary syndrome (a group of conditions that includes heart attack and unstable angina, a severe type of chest pain) and have been shown to have had an increase in certain cardiac blood tests. Xarelto reduces the risk in adults of having another heart attack or reduces the risk of dying from a disease related to your heart or your blood vessels. Xarelto will not be given to you on its own. Your doctor will also tell you to take either: acetylsalicylic acid or acetylsalicylic acid plus clopidogrel or ticlopidine.

or

- you have been diagnosed with a high risk of getting a blood clot due to a coronary artery disease or peripheral artery disease which causes symptoms. Xarelto reduces the risk in adults of getting blot clots (atherothrombotic events). Xarelto will not be given to you on its own. Your doctor will also tell you to take acetylsalicylic acid.

Xarelto contains the active substance rivaroxaban and belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.

2. What you need to know before you take Xarelto
Do not take Xarelto
- if you are allergic to rivaroxaban or any of the other ingredients of this medicine (listed in section 6)
- if you are bleeding excessively
- if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)
- if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open
- if you have an acute coronary syndrome and previously had a bleeding or a blood clot in your brain (stroke)
- if you have coronary artery disease or peripheral artery disease and previously had a bleeding in your brain (stroke) or where there was a blockage of the small arteries providing blood to the brain’s deep tissues (lacunar stroke) or if you had a blood clot in your brain (ischaemic, non-lacunar stroke) in the previous month
- if you have a liver disease which leads to an increased risk of bleeding
- if you are pregnant or breast-feeding
Do not take Xarelto and tell your doctor if any of these apply to you.

Warnings and precautions
Talk to your doctor or pharmacist before taking Xarelto.
Xarelto should not be used in combination with certain other medicines which reduce blood clotting such as prasugrel or ticagrelor other than acetylsalicylic acid and clopidogrel/ticlopidine.

Take special care with Xarelto
- if you have an increased risk of bleeding, as could be the case in situations such as:
  - severe kidney disease, since your kidney function may affect the amount of medicine that works in your body
  - if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section “Other medicines and Xarelto”)
  - bleeding disorders
  - very high blood pressure, not controlled by medical treatment
  - diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet), e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus)
  - a problem with the blood vessels in the back of your eyes (retinopathy)
  - a lung disease where your bronchi are widened and filled with pus (bronchiecstasis), or previous bleeding from your lung
  - you are older than 75 years
  - you weigh 60 kg or less
- if you have a prosthetic heart valve

If any of the above apply to you, tell your doctor before you take Xarelto. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.

If you need to have an operation
- it is very important to take Xarelto before and after the operation exactly at the times you have been told by your doctor.
- If your operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):
  - it is very important to take Xarelto before and after the injection or removal of the catheter exactly at the times you have been told by your doctor
• tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.

**Children and adolescents**

Xarelto is **not recommended for people under 18 years of age.** There is not enough information on its use in children and adolescents.

**Other medicines and Xarelto**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

- **If you are taking**
  - some medicines for fungal infections (e.g. fluconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin
  - ketoconazole tablets (used to treat Cushing’s syndrome - when the body produces an excess of cortisol)
  - some medicines for bacterial infections (e.g. clarithromycin, erythromycin)
  - some anti-viral medicines for HIV / AIDS (e.g. ritonavir)
  - other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin K antagonists such as warfarin and acenocoumarol, prasugrel and ticagrelor (see section “Warnings and Precautions”))
  - anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)
  - dronedarone, a medicine to treat abnormal heart beat
  - some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))

  **If any of the above apply to you, tell your doctor** before taking Xarelto, because the effect of Xarelto may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.

If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.

- **If you are taking**
  - some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)
  - St John’s Wort (*Hypericum perforatum*), a herbal product used for depression
  - rifampicin, an antibiotic

  **If any of the above apply to you, tell your doctor** before taking Xarelto, because the effect of Xarelto may be reduced. Your doctor will decide, if you should be treated with Xarelto and if you should be kept under closer observation.

**Pregnancy and breast-feeding**

Do not take Xarelto if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Xarelto. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.

**Driving and using machines**

Xarelto may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4, “Possible side effects”). You should not drive or use machines if you are affected by these symptoms.

**Xarelto contains lactose and sodium**

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially "sodium-free".
3. How to take Xarelto

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

How much to take
The recommended dose is one 2.5 mg tablet twice a day. Take Xarelto around the same time every day (for example, one tablet in the morning and one in the evening). This medicine can be taken with or without food.

If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Xarelto. The tablet may be crushed and mixed with water or apple puree immediately before you take it.

If necessary, your doctor may also give you the crushed Xarelto tablet through a stomach tube.

Xarelto will not be given to you on its own. Your doctor will also tell you to take acetylsalicylic acid. If you get Xarelto after an acute coronary syndrome, your doctor may tell you to also take clopidogrel or ticlopidine.

Your doctor will tell you how much of these to take (usually between 75 to 100 mg acetylsalicylic acid daily or a daily dose of 75 to 100 mg acetylsalicylic acid plus a daily dose of either 75 mg clopidogrel or a standard daily dose of ticlopidine).

When to start Xarelto
Treatment with Xarelto after an acute coronary syndrome should be started as soon as possible after stabilisation of the acute coronary syndrome, at the earliest 24 hours after admission to hospital and at the time when parenteral (via injection) anticoagulation therapy would normally be stopped.

Your doctor will tell you when to start treatment with Xarelto if you have been diagnosed with coronary artery disease or peripheral artery disease.

Your doctor will decide how long you must continue treatment.

If you take more Xarelto than you should
Contact your doctor immediately if you have taken too many Xarelto tablets. Taking too much Xarelto increases the risk of bleeding.

If you forget to take Xarelto
Do not take a double dose to make up for a missed dose. If you miss a dose, take your next dose at the usual time.

If you stop taking Xarelto
Take Xarelto on a regular basis and for as long as your doctor keeps prescribing it.

Do not stop taking Xarelto without talking to your doctor first. If you stop taking this medicine, it may increase your risk of having another heart attack or stroke or dying from a disease related to your heart or your blood vessels.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, Xarelto can cause side effects, although not everybody gets them.

Like other similar medicines (antithrombotic agents), Xarelto may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.
**Possible side effects which may be a sign of bleeding**

Tell your doctor immediately if you experience any of the following side effects:
- long or excessive bleeding
- exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris, which may be signs of bleeding.

Your doctor may decide to keep you under closer observation or change how you should be treated.

**Possible side effects which may be a sign of severe skin reaction**

Tell your doctor immediately if you experience skin reactions such as:
- spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (Stevens-Johnson syndrome/toxic epidermal necrolysis). The frequency of this side effect is very rare (up to 1 in 10,000).
- a drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS syndrome). The frequency of this side effect is very rare (up to 1 in 10,000).

**Possible side effects which may be a sign of severe allergic reactions**

Tell your doctor immediately if you experience any of the following side effects:
- swelling of the face, lips, mouth, tongue or throat; difficulty swallowing; hives and breathing difficulties; sudden drop in blood pressure. The frequencies of these side effects are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic oedema; may affect up to 1 in 100 people).

**Overall list of possible side effects**

**Common** (may affect up to 1 in 10 people)
- reduction in red blood cells which can make the skin pale and cause weakness or breathlessness
- bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum
- bleeding into the eye (including bleeding from the whites of the eyes)
- bleeding into tissue or a cavity of the body (haematoma, bruising)
- coughing up blood
- bleeding from the skin or under the skin
- bleeding following an operation
- oozing of blood or fluid from surgical wound- swelling in the limbs
- pain in the limbs
- impaired function of the kidneys (may be seen in tests performed by your doctor)
- fever
- stomach ache, indigestion, feeling or being sick, constipation, diarrhoea
- low blood pressure (symptoms may be feeling dizzy or fainting when standing up)
- decreased general strength and energy (weakness, tiredness), headache, dizziness
- rash, itchy skin
- blood tests may show an increase in some liver enzymes

**Uncommon** (may affect up to 1 in 100 people)
- bleeding into the brain or inside the skull
- bleeding into a joint causing pain and swelling
- thrombocytopenia (low number of platelets, which are cells that help blood to clot)
- allergic reactions, including allergic skin reactions
- impaired function of the liver (may be seen in tests performed by your doctor)
- blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets
- fainting
- feeling unwell
- faster heartbeat
- dry mouth
- hives

**Rare** (may affect up to 1 in 1,000 people)
- bleeding into a muscle
- cholestasis (decreased bile flow), hepatitis incl. hepatocellular injury (inflamed liver incl. liver injury)
- yellowing of the skin and eye (jaundice)
- localised swelling
- collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)

**Not known** (frequency cannot be estimated from the available data)
- kidney failure after a severe bleeding
- increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. **How to store Xarelto**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on each blister or bottle after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Xarelto contains**
- The active substance is rivaroxaban. Each tablet contains 2.5 mg of rivaroxaban.
- The other ingredients are:
  - Tablet core: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose 2910, sodium laurilsulphate, magnesium stearate. See section 2 “Xarelto contains lactose and sodium”.
  - Tablet film coat: macrogol 3350, hypromellose 2910, titanium dioxide (E 171), iron oxide yellow (E 172).

**What Xarelto looks like and contents of the pack**
Xarelto 2.5 mg film-coated tablets are light yellow, round, biconvex and marked with the BAYER-cross on one side and “2.5” and a triangle on the other side. They come
- in blisters in cartons of 14, 20, 28, 30, 56, 60, 98, 168 or 196 film-coated tablets or
- in unit dose blisters in cartons of 10 x 1 or 100 x 1 or
- in multipacks comprising 10 cartons, each containing 10 x 1 film-coated tablets or
- in bottles of 100 film-coated tablets.
Not all pack sizes may be marketed.

**Marketing Authorisation Holder**

Bayer AG  
51368 Leverkusen  
Germany

**Manufacturer**

The manufacturer can be identified by the batch number printed on the side flap of the carton and on each blister or bottle:

- If the first and second characters are BX, the manufacturer is  
  Bayer AG  
  Kaiser-Wilhelm-Allee  
  51368 Leverkusen  
  Germany

- If the first and second characters are IT, the manufacturer is  
  Bayer HealthCare Manufacturing Srl.  
  Via delle Groane, 126  
  20024 Garbagnate Milanese  
  Italy

- If the first and second characters are BT, the manufacturer is  
  Bayer Bitterfeld GmbH  
  Ortsteil Greppin, Salegaster Chaussee 1  
  06803 Bitterfeld-Wolfen  
  Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België / Belgique / Belgien**  
Bayer SA-NV  
Tél/Tel: +32-(0)2-535 63 11

**Lietuva**  
UAB Bayer  
Tel: +370-5-233 68 68

**България**  
Байер България ЕООД  
Тел: +359-(0)2-424 72 80

**Luxembourg / Luxemburg**  
Bayer SA-NV  
Tél/Tel: +32-(0)2-535 63 11

**Česká republika**  
Bayer s.r.o.  
Tel: +420-266 101 111

**Magyarország**  
Bayer Hungária KFT  
Tel: +36-1-487 4100

**Danmark**  
Bayer A/S  
Tlf: +45-45 235 000

**Malta**  
Alfred Gera and Sons Ltd.  
Tel: +356-21 44 62 05

**Deutschland**  
Bayer Vital GmbH  
Tel: +49-(0)214-30 513 48

**Nederland**  
Bayer B.V.  
Tel: +31-(0)297-28 06 66

**Eesti**  
Bayer OÜ  
Tel: +372-655 85 65

**Norge**  
Bayer AS  
Tlf: +47-23 13 05 00

**Ελλάδα**  
Bayer Ελλάς ΑΒΕΕ  
Τηλ: +30-210-618 75 00

**Österreich**  
Bayer Austria Ges. m. b. H.  
Tel: +43-(0)1-711 460

**España**  
Bayer Hispania S.L.  
Tel: +34-93-495 65 00

**Polska**  
Bayer Sp. z o.o.  
Tel: +48-22-572 35 00

**France**  
Bayer HealthCare  
Tél (N° vert): +33-(0)800 87 54 54

**Portugal**  
Bayer Portugal, Lda.  
Tel: +351-21-416 42 00

**Hrvatska**  
Bayer d.o.o.  
Tel: +385-(0)1-6599 900

**România**  
SC Bayer SRL  
Tel: +40-(0)21-528 59 00

**Ireland**  
Bayer Limited  
Tel: +353-(0)1-2999 313

**Slovenija**  
Bayer d. o. o.  
Tel: +386-(0)1-58 14 400

**Ísland**  
Icepharma hf.  
Sími: +354-540 80 00

**Slovenská republika**  
Bayer, spol. s r.o.  
Tel: +421-(0)2-59 21 31 11

**Italia**  
Bayer S.p.A.  
Tel: +39-02-3978 1

**Suomi/Finland**  
Bayer Oy  
Puh/Tel: +358-(0)20-78521
This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Xarelto is and what it is used for
2. What you need to know before you take Xarelto
3. How to take Xarelto
4. Possible side effects
5. How to store Xarelto
6. Contents of the pack and other information

1. What Xarelto is and what it is used for
Xarelto contains the active substance rivaroxaban and is used in adults to
- prevent blood clots in the veins after a hip or knee replacement operation. Your doctor has prescribed this medicine for you because after an operation you are at an increased risk of getting blood clots.
- treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.

Xarelto belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.

2. What you need to know before you take Xarelto
Do not take Xarelto
- if you are allergic to rivaroxaban or any of the other ingredients of this medicine (listed in section 6)
- if you are bleeding excessively
- if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)
- if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open
- if you have a liver disease which leads to an increased risk of bleeding
- if you are pregnant or breast-feeding
Do not take Xarelto and tell your doctor if any of these apply to you.
Warnings and precautions
Talk to your doctor or pharmacist before taking Xarelto.

Take special care with Xarelto
- if you have an increased risk of bleeding, as could be the case in situations such as:
  ▪ moderate or severe kidney disease, since your kidney function may affect the amount of medicine that works in your body
  ▪ if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section “Other medicines and Xarelto”)
  ▪ bleeding disorders
  ▪ very high blood pressure, not controlled by medical treatment
  ▪ diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet), e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus)
  ▪ a problem with the blood vessels in the back of your eyes (retinopathy)
  ▪ a lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung
- if you have a prosthetic heart valve
- if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned.

If any of the above apply to you, tell your doctor before you take Xarelto. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.

If you need to have an operation
- it is very important to take Xarelto before and after the operation exactly at the times you have been told by your doctor.
- If your operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):
  ▪ it is very important to take Xarelto exactly at the times you have been told by your doctor
  ▪ tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.

Children and adolescents
Xarelto is not recommended for people under 18 years of age. There is not enough information on its use in children and adolescents.

Other medicines and Xarelto
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

- If you are taking
  ▪ some medicines for fungal infections (e.g. fluconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin
  ▪ ketoconazole tablets (used to treat Cushing’s syndrome - when the body produces an excess of cortisol)
  ▪ some medicines for bacterial infections (e.g. clarithromycin, erythromycin)
  ▪ some anti-viral medicines for HIV / AIDS (e.g. ritonavir)
  ▪ other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin K antagonists such as warfarin and acenocoumarol)
  ▪ anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)
  ▪ dronedarone, a medicine to treat abnormal heart beat
• some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))

If any of the above apply to you, tell your doctor before taking Xarelto, because the effect of Xarelto may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation. If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.

- If you are taking
  ▪ some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)
  ▪ St John’s Wort (Hypericum perforatum), a herbal product used for depression
  ▪ rifampicin, an antibiotic

If any of the above apply to you, tell your doctor before taking Xarelto, because the effect of Xarelto may be reduced. Your doctor will decide, if you should be treated with Xarelto and if you should be kept under closer observation.

Pregnancy and breast-feeding
Do not take Xarelto if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Xarelto. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.

Driving and using machines
Xarelto may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4 “Possible side effects”). You should not drive or use machines if you are affected by these symptoms.

Xarelto contains lactose and sodium
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially “sodium-free”.

3. How to take Xarelto

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

How much to take
- To prevent blood clots in the veins after a hip or knee replacement operation
  The recommended dose is one tablet Xarelto 10 mg once a day.

- To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs, and for preventing blood clots from re-occurring
  After at least 6 months blood clot treatment, the recommended dose is either one 10 mg tablet once a day or one 20 mg tablet once a day. Your doctor has prescribed you Xarelto 10 mg once a day.

Swallow the tablet preferably with water.
Xarelto can be taken with or without food.

If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Xarelto. The tablet may be crushed and mixed with water or apple puree immediately before you take it.
If necessary, your doctor may also give you the crushed Xarelto tablet through a stomach tube.
When to take Xarelto
Take the tablet every day until your doctor tells you to stop.
Try to take the tablet at the same time every day to help you to remember it.
Your doctor will decide how long you must continue treatment.

To prevent blood clots in the veins after a hip or knee replacement operation:
Take the first tablet 6 - 10 hours after your operation.
If you have had a major hip operation you will usually take the tablets for 5 weeks.
If you have had a major knee operation you will usually take the tablets for 2 weeks.

If you take more Xarelto than you should
Contact your doctor immediately if you have taken too many Xarelto tablets. Taking too much Xarelto increases the risk of bleeding.

If you forget to take Xarelto
If you have missed a dose, take it as soon as you remember. Take the next tablet on the following day and then carry on taking a tablet once a day as normal.
Do not take a double dose to make up for a forgotten tablet.

If you stop taking Xarelto
Do not stop taking Xarelto without talking to your doctor first, because Xarelto prevents the development of a serious condition.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects
Like all medicines, Xarelto can cause side effects, although not everybody gets them.

Like other similar medicines (antithrombotic agents), Xarelto may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.

Possible side effects which may be a sign of bleeding
Tell your doctor immediately, if you experience any of the following side effects:
- long or excessive bleeding
- exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris, which may be signs of bleeding.
Your doctor may decide to keep you under closer observation or change how you should be treated.

Possible side effects which may be a sign of severe skin reaction
Tell your doctor immediately if you experience skin reactions such as:
- spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (Stevens-Johnson syndrome/toxic epidermal necrolysis). The frequency of this side effect is very rare (up to 1 in 10,000).
- a drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS syndrome). The frequency of this side effect is very rare (up to 1 in 10,000).

Possible side effects which may be a sign of severe allergic reactions
Tell your doctor immediately if you experience any of the following side effects:
- swelling of the face, lips, mouth, tongue or throat; difficulty swallowing; hives and breathing difficulties; sudden drop in blood pressure. The frequencies of these side effects are very rare
(anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic oedema; may affect up to 1 in 100 people).

**Overall list of possible side effects**

**Common** (may affect up to 1 in 10 people)
- reduction in red blood cells which can make the skin pale and cause weakness or breathlessness
- bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum
- bleeding into the eye (including bleeding from the whites of the eyes)
- bleeding into tissue or a cavity of the body (haematoma, bruising)
- coughing up blood
- bleeding from the skin or under the skin
- bleeding following an operation
- oozing of blood or fluid from surgical wound
- swelling in the limbs
- pain in the limbs
- impaired function of the kidneys (may be seen in tests performed by your doctor)
- fever
- stomach ache, indigestion, feeling or being sick, constipation, diarrhoea
- low blood pressure (symptoms may be feeling dizzy or fainting when standing up)
- decreased general strength and energy (weakness, tiredness), headache, dizziness
- rash, itchy skin
- blood tests may show an increase in some liver enzymes

**Uncommon** (may affect up to 1 in 100 people)
- bleeding into the brain or inside the skull
- bleeding into a joint causing pain and swelling
- thrombocytopenia (low number of platelets, which are cells that help blood to clot)
- allergic reactions, including allergic skin reactions
- impaired function of the liver (may be seen in tests performed by your doctor)
- blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets
- fainting
- feeling unwell
- faster heartbeat
- dry mouth
- hives

**Rare** (may affect up to 1 in 1,000 people)
- bleeding into a muscle
- cholestasis (decreased bile flow), hepatitis incl. hepatocellular injury (inflamed liver incl. liver injury)
- yellowing of the skin and eye (jaundice)
- collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)

**Not known** (frequency cannot be estimated from the available data)
- kidney failure after a severe bleeding
- increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system](#).
By reporting side effects, you can help provide more information on the safety of this medicine.

5. **How to store Xarelto**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on each blister or bottle after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Xarelto contains**
- The active substance is rivaroxaban. Each tablet contains 10 mg of rivaroxaban.
- The other ingredients are:
  - Tablet core: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose 2910, sodium laurilsulphate, magnesium stearate. See section 2 “Xarelto contains lactose and sodium”.
  - Tablet film coat: macrogol 3350, hypromellose 2910, titanium dioxide (E 171), iron oxide red (E 172).

**What Xarelto looks like and contents of the pack**
Xarelto 10 mg film-coated tablets are light red, round, biconvex and marked with the BAYER-cross on one side and “10” and a triangle on the other side.

They come
- in blisters in cartons of 5, 10, 14, 28, 30 or 98 film-coated tablets or
- in unit dose blisters in cartons of 10 x 1 or 100 x 1 or
- in multipacks comprising 10 cartons, each containing 10 x 1 film-coated tablets or in bottles of 100 film-coated tablets.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder**

Bayer AG
51368 Leverkusen
Germany
**Manufacturer**

The manufacturer can be identified by the batch number printed on the side flap of the carton and on each blister or bottle:

- If the first and second characters are BX, the manufacturer is Bayer AG
  Kaiser-Wilhelm-Allee
  51368 Leverkusen
  Germany

- If the first and second characters are IT, the manufacturer is Bayer HealthCare Manufacturing Srl.
  Via delle Groane, 126
  20024 Garbagnate Milanese
  Italy

- If the first and second characters are BT, the manufacturer is Bayer Bitterfeld GmbH
  Ortsteil Greppin, Salegaster Chaussee 1
  06803 Bitterfeld-Wolfen
  Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

<table>
<thead>
<tr>
<th>Country</th>
<th>Company Name</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>België / Belgique / Belgien</td>
<td>Bayer SA-NV</td>
<td>+32-(0)2-535 63 11</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Бългaria</td>
<td>Байер България ЕООД</td>
<td>+359-(0)2-424 72 80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Česká republika</td>
<td>Bayer s.r.o.</td>
<td>+420-266 101 111</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Danmark</td>
<td>Bayer A/S</td>
<td>+45-45 235 000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deutschland</td>
<td>Bayer Vital GmbH</td>
<td>+49-(0)214-30 513 48</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eesti</td>
<td>Bayer OÜ</td>
<td>+372-655 85 65</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elláda</td>
<td>Bayer Ελλάς ΑΒΕΕ</td>
<td>+30-210-618 75 00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>España</td>
<td>Bayer Hispania S.L.</td>
<td>+34-93-495 65 00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>Bayer HealthCare</td>
<td>+33-(0)800 87 54 54</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Bayer d.o.o.</td>
<td>+385-(0)1-6599 900</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ireland</td>
<td>Bayer Limited</td>
<td>+353-(0)1-2999 313</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ísland</td>
<td>Icepharma hf.</td>
<td>+354-540 80 00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italia</td>
<td>Bayer S.p.A.</td>
<td>+39-02-3978 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lietuva</td>
<td>UAB Bayer</td>
<td>+370-5-233 68 68</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luxembourg / Luxemburg</td>
<td>Bayer SA-NV</td>
<td>+32-(0)2-535 63 11</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magyarország</td>
<td>Bayer Hungária KFT</td>
<td>+36-1-487 4100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malta</td>
<td>Alfred Gera and Sons Ltd.</td>
<td>+356-21 44 62 05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nederland</td>
<td>Bayer B.V.</td>
<td>+31–(0)297-28 06 66</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norge</td>
<td>Bayer AS</td>
<td>+47-23 13 05 00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Österreich</td>
<td>Bayer Austria Ges. m. b. H.</td>
<td>+43-(0)1-711 460</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polska</td>
<td>Bayer Sp. z o.o.</td>
<td>+48-22-572 35 00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portugal</td>
<td>Bayer Portugal, Lda.</td>
<td>+351-21-416 42 00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>România</td>
<td>SC Bayer SRL</td>
<td>+40-(0)21-528 59 00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovenija</td>
<td>Bayer d. o. o.</td>
<td>+386-(0)1-58 14 400</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovenská republika</td>
<td>Bayer, spol. s r.o.</td>
<td>+421-(0)2-59 21 31 11</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suomi/Finland</td>
<td>Bayer Oy</td>
<td>+358-(0)20-78521</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Xarelto is and what it is used for
2. What you need to know before you take Xarelto
3. How to take Xarelto
4. Possible side effects
5. How to store Xarelto
6. Contents of the pack and other information

1. What Xarelto is and what it is used for

Xarelto contains the active substance rivaroxaban and is used in adults to:
- prevent blood clots in brain (stroke) and other blood vessels in your body if you have a form of irregular heart rhythm called non-valvular atrial fibrillation.
- treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.

Xarelto belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.

2. What you need to know before you take Xarelto

Do not take Xarelto
- if you are allergic to rivaroxaban or any of the other ingredients of this medicine (listed in section 6)
- if you are bleeding excessively
- if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)
- if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open.
- if you have a liver disease which leads to an increased risk of bleeding
- if you are pregnant or breast-feeding

Do not take Xarelto and tell your doctor if any of these apply to you.
Warnings and precautions
Talk to your doctor or pharmacist before taking Xarelto.

Take special care with Xarelto
- if you have an increased risk of bleeding, as could be the case in situations such as:
  - severe kidney disease, since your kidney function may affect the amount of medicine that works in your body
  - if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section “Other medicines and Xarelto”)
  - bleeding disorders
  - very high blood pressure, not controlled by medical treatment
  - diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet), e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus)
  - a problem with the blood vessels in the back of your eyes (retinopathy)
  - a lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung
- if you have a prosthetic heart valve
- if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned

If any of the above apply to you, tell your doctor before you take Xarelto. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.

If you need to have an operation
- it is very important to take Xarelto before and after the operation exactly at the times you have been told by your doctor.
- If your operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):
  - it is very important to take Xarelto before and after the injection or removal of the catheter exactly at the times you have been told by your doctor
  - tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.

Children and adolescents
Xarelto is not recommended for people under 18 years of age. There is not enough information on its use in children and adolescents.

Other medicines and Xarelto
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
- If you are taking
  - some medicines for fungal infections (e.g. fluconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin
ketoconazole tablets (used to treat Cushing’s syndrome - when the body produces an excess of cortisol)

- some medicines for bacterial infections (e.g. clarithromycin, erythromycin)
- some anti-viral medicines for HIV / AIDS (e.g. ritonavir)
- other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin K antagonists such as warfarin and acenocoumarol)
- anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)
- dronedarone, a medicine to treat abnormal heart beat
- some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))

If any of the above apply to you, tell your doctor before taking Xarelto, because the effect of Xarelto may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.

If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.

- If you are taking
  - some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)
  - St John’s Wort (Hypericum perforatum), a herbal product used for depression
  - rifampicin, an antibiotic

If any of the above apply to you, tell your doctor before taking Xarelto, because the effect of Xarelto may be reduced. Your doctor will decide, if you should be treated with Xarelto and if you should be kept under closer observation.

Pregnancy and breast-feeding
Do not take Xarelto if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Xarelto. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.

Driving and using machines
Xarelto may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4, "Possible side effects"). You should not drive or use machines if you are affected by these symptoms.

Xarelto contains lactose and sodium
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially “sodium-free”.

3. How to take Xarelto
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

How much to take
- To prevent blood clots in brain (stroke) and other blood vessels in your body
  The recommended dose is one tablet Xarelto 20 mg once a day.
  If you have kidney problems, the dose may be reduced to one tablet Xarelto 15 mg once a day.

  If you need a procedure to treat blocked blood vessels in your heart (called a percutaneous coronary intervention - PCI with an insertion of a stent), there is limited evidence to reduce the dose to one tablet Xarelto 15 mg once a day (or to one tablet Xarelto 10 mg once a day in case
your kidneys are not working properly) in addition to an antiplatelet medicinal product such as clopidogrel.

- To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs, and for preventing blood clots from re-occurring

The recommended dose is one tablet Xarelto 15 mg twice a day for the first 3 weeks. For treatment after 3 weeks, the recommended dose is one tablet Xarelto 20 mg once a day. After at least 6 months blood clot treatment your doctor may decide to continue treatment with either one 10 mg tablet once a day or one 20 mg tablet once a day.

If you have kidney problems and take one tablet Xarelto 20 mg once a day, your doctor may decide to reduce the dose for the treatment after 3 weeks to one tablet Xarelto 15 mg once a day if the risk for bleeding is greater than the risk for having another blood clot.

Swallow the tablet(s) preferably with water.
Take Xarelto together with a meal.

If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Xarelto. The tablet may be crushed and mixed with water or apple puree immediately before you take it. This mixture should be immediately followed by food. If necessary, your doctor may also give you the crushed Xarelto tablet through a stomach tube.

**When to take Xarelto**
Take the tablet(s) every day until your doctor tells you to stop.
Try to take the tablet(s) at the same time every day to help you to remember it.
Your doctor will decide how long you must continue treatment.

To prevent blood clots in the brain (stroke) and other blood vessels in your body:
If your heart beat needs to be restored to normal by a procedure called cardioversion, take Xarelto at the times your doctor tells you.

**If you take more Xarelto than you should**
Contact your doctor immediately if you have taken too many Xarelto tablets. Taking too much Xarelto increases the risk of bleeding.

**If you forget to take Xarelto**
- If you are taking one 20 mg tablet or one 15 mg tablet once a day and have missed a dose, take it as soon as you remember. Do not take more than one tablet in a single day to make up for a forgotten dose. Take the next tablet on the following day and then carry on taking one tablet once a day.

- If you are taking one 15 mg tablet twice a day and have missed a dose, take it as soon as you remember. Do not take more than two 15 mg tablets in a single day. If you forget to take a dose you can take two 15 mg tablets at the same time to get a total of two tablets (30 mg) on one day. On the following day you should carry on taking one 15 mg tablet twice a day.

**If you stop taking Xarelto**
Do not stop taking Xarelto without talking to your doctor first, because Xarelto treats and prevents serious conditions.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

**4. Possible side effects**

Like all medicines, Xarelto can cause side effects, although not everybody gets them.
Like other similar medicines (antithrombotic agents), Xarelto may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.

**Possible side effects which may be a sign of bleeding**

**Tell your doctor immediately** if you experience any of the following side effects:
- long or excessive bleeding
- exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris, which may be signs of bleeding.

Your doctor may decide to keep you under closer observation or change how you should be treated.

**Possible side effects which may be a sign of severe skin reaction**

**Tell your doctor immediately** if you experience skin reactions such as:
- spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (Stevens-Johnson syndrome/toxic epidermal necrolysis). The frequency of this side effect is very rare (up to 1 in 10,000).
- a drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS syndrome). The frequency of this side effect is very rare (up to 1 in 10,000).

**Possible side effects which may be a sign of severe allergic reactions**

**Tell your doctor immediately** if you experience any of the following side effects:
- swelling of the face, lips, mouth, tongue or throat; difficulty swallowing; hives and breathing difficulties; sudden drop in blood pressure. The frequencies of these side effects are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic oedema; may affect up to 1 in 100 people).

**Overall list of possible side effects**

**Common** (may affect up to 1 in 10 people)
- reduction in red blood cells which can make the skin pale and cause weakness or breathlessness
- bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum
- bleeding into the eye (including bleeding from the whites of the eyes)
- bleeding into tissue or a cavity of the body (haematoma, bruising)
- coughing up blood
- bleeding from the skin or under the skin
- bleeding following an operation
- oozing of blood or fluid from surgical wound
- swelling in the limbs
- pain in the limbs
- impaired function of the kidneys (may be seen in tests performed by your doctor)
- fever
- stomach ache, indigestion, feeling or being sick, constipation, diarrhoea
- low blood pressure (symptoms may be feeling dizzy or fainting when standing up)
- decreased general strength and energy (weakness, tiredness), headache, dizziness
- rash, itchy skin
- blood tests may show an increase in some liver enzymes

**Uncommon** (may affect up to 1 in 100 people)
- bleeding into the brain or inside the skull
- bleeding into a joint causing pain and swelling
- thrombocytopenia (low number of platelets, which are cells that help blood to clot)
- allergic reactions, including allergic skin reactions
- impaired function of the liver (may be seen in tests performed by your doctor)
- blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets
- fainting
- feeling unwell
- faster heartbeat
- dry mouth
- hives

**Rare** (may affect up to 1 in 1,000 people)
- bleeding into a muscle
- cholestasis (decreased bile flow), hepatitis incl. hepatocellular injury (inflamed liver incl. liver injury)
- yellowing of the skin and eye (jaundice)
- localised swelling
- collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)

**Not known** (frequency cannot be estimated from the available data)
- kidney failure after a severe bleeding
- increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in **Appendix V**. By reporting side effects, you can help provide more information on the safety of this medicine.

5. **How to store Xarelto**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on each blister or bottle after EXP.

The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Xarelto contains**
- The active substance is rivaroxaban. Each tablet contains 15 mg or 20 mg of rivaroxaban.
- The other ingredients are:
  - Tablet core: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose 2910, sodium laurilsulphate, magnesium stearate. See section 2 “Xarelto contains lactose and sodium”
  - Tablet film coat: macrogol 3350, hypromellose 2910, titanium dioxide (E 171), iron oxide red (E 172).
What Xarelto looks like and contents of the pack
Xarelto 15 mg film-coated tablets are red, round, biconvex and marked with the BAYER-cross on one side and “15” and a triangle on the other side.
They come
- in blisters in cartons of 10, 14, 28, 42 or 98 film-coated tablets or
- in unit dose blisters in cartons of 10 x 1 or 100 x 1 or
- in multipacks comprising 10 cartons, each containing 10 x 1 film-coated tablets or
- in bottles of 100 film-coated tablets.

Xarelto 20 mg film-coated tablets are brown-red, round, biconvex and marked with the BAYER-cross on one side and “20” and a triangle on the other.
They come
- in blisters in cartons of 10, 14, 28 or 98 film-coated tablets or
- in unit dose blisters in cartons of 10 x 1 or 100 x 1 or
- in multipacks comprising 10 cartons, each containing 10 x 1 film-coated tablets or
- in bottles of 100 film-coated tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Bayer AG
51368 Leverkusen
Germany

Manufacturer

The manufacturer can be identified by the batch number printed on the side flap of the carton and on each blister or bottle:

- If the first and second characters are BX, the manufacturer is Bayer AG
  Kaiser-Wilhelm-Allee
  51368 Leverkusen
  Germany

- If the first and second characters are IT, the manufacturer is Bayer HealthCare Manufacturing Srl.
  Via delle Groane, 126
  20024 Garbagnate Milanese
  Italy

- If the first and second characters are BT, the manufacturer is Bayer Bitterfeld GmbH
  Ortsteil Greppin, Salegaster Chaussee 1
  06803 Bitterfeld-Wolfen
  Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België / Belgique / Belgien
Bayer SA-NV
Tel/Tél: +32-(0)2-535 63 11

Lietuva
UBABayer
Tel: +370-5-233 68 68

България
Байер България ЕООД
Тел: +359-(0)2-424 72 80

Luxembourg / Luxemburg
Bayer SA-NV
Tel/Tél: +32-(0)2-535 63 11

Česká republika
Bayer s.r.o.
Tel: +420-266 101 111

Magyarország
Bayer Hungária KFT
Tel: +36-1-487 4100

Danmark
Bayer A/S
Tlf: +45-45 235 000

Malta
Alfred Gera and Sons Ltd.
Tel: +356-21 44 62 05

Deutschland
Bayer Vital GmbH
Tel: +49-(0)214-30 513 48

Nederland
Bayer B.V.
Tel: +31–(0)297-28 06 66

Eesti
Bayer OÜ
Tel: +372-655 85 65

Norge
Bayer AS
Tlf: +47-23 13 05 00

Ελλάδα
Bayer Ελλάς ΑΒΕΕ
Τηλ: +30-210-618 75 00

Österreich
Bayer Austria Ges. m. b. H.
Tel: +43-(0)1-711 460

España
Bayer Hispania S.L.
Tel: +34-93-495 65 00

Polska
Bayer Sp. z o.o.
Tel: +48-22-572 35 00

France
Bayer HealthCare
Tél (N° vert): +33-(0)800 87 54 54

Portugal
Bayer Portugal, Lda.
Tel: +351-21-416 42 00

Hrvatska
Bayer d.o.o.
Tel: +385-(0)1-6599 900

România
SC Bayer SRL
Tel: +40-(0)21-528 59 00

Ireland
Bayer Limited
Tel: +353-(0)1-2999 313

Slovenija
Bayer d. o. o.
Tel: +386-(0)1-58 14 400

Ísland
Icepharma hf.
Sími: +354-540 80 00

Slovenská republika
Bayer, spol. s r.o.
Tel: +421-(0)2-59 21 31 11

Italia
Bayer S.p.A.
Tel: +39-02-3978 1

Suomi/Finland
Bayer Oy
Puh/Tel: +358-(0)20-78521
This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
Package leaflet: Information for the user

Xarelto 15 mg film-coated tablets
Xarelto 20 mg film-coated tablets

Treatment Initiation Pack
rivaroxaban

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Xarelto is and what it is used for
2. What you need to know before you take Xarelto
3. How to take Xarelto
4. Possible side effects
5. How to store Xarelto
6. Contents of the pack and other information

1. What Xarelto is and what it is used for

Xarelto contains the active substance rivaroxaban and is used in adults to:
- treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.

Xarelto belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.

2. What you need to know before you take Xarelto

Do not take Xarelto
- if you are allergic to rivaroxaban or any of the other ingredients of this medicine (listed in section 6)
- if you are bleeding excessively
- if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)
- if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open.
- if you have a liver disease which leads to an increased risk of bleeding
- if you are pregnant or breast-feeding

Do not take Xarelto and tell your doctor if any of these apply to you.
Warnings and precautions
Talk to your doctor or pharmacist before taking Xarelto.

Take special care with Xarelto
- if you have an increased risk of bleeding, as could be the case in situations such as:
  ▪ severe kidney disease, since your kidney function may affect the amount of medicine that works in your body
  ▪ if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section “Other medicines and Xarelto”)
  ▪ bleeding disorders
  ▪ very high blood pressure, not controlled by medical treatment
  ▪ diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet), e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus)
  ▪ a problem with the blood vessels in the back of your eyes (retinopathy)
  ▪ a lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung
- if you have a prosthetic heart valve
- if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned

If any of the above apply to you, tell your doctor before you take Xarelto. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.

If you need to have an operation
- it is very important to take Xarelto before and after the operation exactly at the times you have been told by your doctor.
- If your operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):
  ▪ it is very important to take Xarelto before and after the injection or removal of the catheter exactly at the times you have been told by your doctor
  ▪ tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.

Children and adolescents
Xarelto is not recommended for people under 18 years of age. There is not enough information on its use in children and adolescents.

Other medicines and Xarelto
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
- If you are taking
  ▪ some medicines for fungal infections (e.g. fluconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin
- ketoconazole tablets (used to treat Cushing’s syndrome - when the body produces an excess of cortisol)
- some medicines for bacterial infections (e.g. clarithromycin, erythromycin)
- some anti-viral medicines for HIV / AIDS (e.g. ritonavir)
- other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin K antagonists such as warfarin and acenocoumarol)
- anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)
- dronedarone, a medicine to treat abnormal heart beat
- some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))

If any of the above apply to you, tell your doctor before taking Xarelto, because the effect of Xarelto may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.

If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.

- If you are taking
  - some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)
  - St John’s Wort (*Hypericum perforatum*), a herbal product used for depression
  - rifampicin, an antibiotic

If any of the above apply to you, tell your doctor before taking Xarelto, because the effect of Xarelto may be reduced. Your doctor will decide, if you should be treated with Xarelto and if you should be kept under closer observation.

### Pregnancy and breast-feeding
Do not take Xarelto if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Xarelto. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.

### Driving and using machines
Xarelto may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4, “Possible side effects”). You should not drive or use machines if you are affected by these symptoms.

### Xarelto contains lactose and sodium
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially “sodium-free”.

### 3. How to take Xarelto
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

#### How much to take
The recommended dose is one tablet Xarelto 15 mg twice a day for the first 3 weeks. For treatment after 3 weeks, the recommended dose is one tablet Xarelto 20 mg once a day.

This Xarelto 15 mg and 20 mg treatment initiation pack is only for the first 4 weeks of treatment. Upon completion of this pack, treatment will continue on Xarelto 20 mg once daily as your doctor has told you.

If you have kidney problems, your doctor may decide to reduce the dose for the treatment after 3 weeks to one tablet Xarelto 15 mg once a day if the risk for bleeding is greater than the risk for having another blood clot.
Swallow the tablet(s) preferably with water. Take Xarelto together with a meal.

If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Xarelto. The tablet may be crushed and mixed with water or apple puree immediately before you take it. This mixture should be immediately followed by food. If necessary, your doctor may also give you the crushed Xarelto tablet through a stomach tube.

**When to take Xarelto**
Take the tablet(s) every day until your doctor tells you to stop. Try to take the tablet(s) at the same time every day to help you to remember it. Your doctor will decide how long you must continue treatment.

**If you take more Xarelto than you should**
Contact your doctor immediately if you have taken too many Xarelto tablets. Taking too much Xarelto increases the risk of bleeding.

**If you forget to take Xarelto**
- If you are taking one 15 mg tablet twice a day and have missed a dose, take it as soon as you remember. Do not take more than two 15 mg tablets in a single day. If you forget to take a dose you can take two 15 mg tablets at the same time to get a total of two tablets (30 mg) on one day. On the following day you should carry on taking one 15 mg tablet twice a day.
- If you are taking one 20 mg tablet once a day and have missed a dose, take it as soon as you remember. Do not take more than one tablet in a single day to make up for a forgotten dose. Take the next tablet on the following day and then carry on taking one tablet once a day.

**If you stop taking Xarelto**
Do not stop taking Xarelto without talking to your doctor first, because Xarelto treats and prevents serious conditions.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

### 4. Possible side effects

Like all medicines, Xarelto can cause side effects, although not everybody gets them.

Like other similar medicines (antithrombotic agents), Xarelto may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.

**Possible side effects which may be a sign of bleeding**
Tell your doctor immediately if you experience any of the following side effects:

- long or excessive bleeding
- exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris, which may be signs of bleeding.

Your doctor may decide to keep you under closer observation or change how you should be treated.

**Possible side effects which may be a sign of severe skin reaction**
Tell your doctor immediately if you experience skin reactions such as:

- spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (Stevens-Johnson syndrome/toxic epidermal necrolysis). The frequency of this side effect is very rare (up to 1 in 10,000).
- a drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS syndrome). The frequency of this side effect is very rare (up to 1 in 10,000).

**Possible side effects which may be a sign of severe allergic reactions**

**Tell your doctor immediately** if you experience any of the following side effects:
- swelling of the face, lips, mouth, tongue or throat; difficulty swallowing; hives and breathing difficulties; sudden drop in blood pressure. The frequencies of these side effects are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic oedema; may affect up to 1 in 100 people).

**Overall list of possible side effects**

**Common** (may affect up to 1 in 10 people)
- reduction in red blood cells which can make the skin pale and cause weakness or breathlessness
- bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum
- bleeding into the eye (including bleeding from the whites of the eyes)
- bleeding into tissue or a cavity of the body (haematoma, bruising)
- coughing up blood
- bleeding from the skin or under the skin
- bleeding following an operation
- oozing of blood or fluid from surgical wound
- swelling in the limbs
- pain in the limbs
- impaired function of the kidneys (may be seen in tests performed by your doctor)
- fever
- stomach ache, indigestion, feeling or being sick, constipation, diarrhoea
- low blood pressure (symptoms may be feeling dizzy or fainting when standing up)
- decreased general strength and energy (weakness, tiredness), headache, dizziness
- rash, itchy skin
- blood tests may show an increase in some liver enzymes

**Uncommon** (may affect up to 1 in 100 people)
- bleeding into the brain or inside the skull
- bleeding into a joint causing pain and swelling
- thrombocytopenia (low number of platelets, which are cells that help blood to clot)
- allergic reactions, including allergic skin reactions
- impaired function of the liver (may be seen in tests performed by your doctor)
- blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets
- fainting
- feeling unwell
- faster heartbeat
- dry mouth
- hives

**Rare** (may affect up to 1 in 1,000 people)
- bleeding into a muscle
- cholestasis (decreased bile flow), hepatitis incl. hepatocellular injury (inflamed liver incl. liver injury)
- yellowing of the skin and eye (jaundice)
- localised swelling
- collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)
Not known (frequency cannot be estimated from the available data)
- kidney failure after a severe bleeding
- increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. **How to store Xarelto**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on each wallet after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Xarelto contains**
- The active substance is rivaroxaban. Each tablet contains 15 mg or 20 mg of rivaroxaban, respectively.
- The other ingredients are:
  Tablet core: microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose 2910, sodium laurilsulphate, magnesium stearate. See section 2 “Xarelto contains lactose and sodium”. Tablet film coat: macrogol 3350, hypromellose 2910, titanium dioxide (E 171), iron oxide red (E 172).

**What Xarelto looks like and contents of the pack**
Xarelto 15 mg film-coated tablets are red, round, biconvex and marked with the BAYER-cross on one side and “15” and a triangle on the other side.
Xarelto 20 mg film-coated tablets are brown-red, round, biconvex and marked with the BAYER-cross on one side and “20” and a triangle on the other.
First 4 weeks treatment initiation pack: each pack of 49 film-coated tablets for the first 4 weeks of treatment contains:
42 film-coated tablets of 15 mg rivaroxaban and 7 film-coated tablets of 20 mg rivaroxaban in a wallet.

**Marketing Authorisation Holder**

Bayer AG
51368 Leverkusen
Germany
Manufacturer

The manufacturer can be identified by the batch number printed on the side flap of the carton and on each blister or bottle:

- If the first and second characters are BX, the manufacturer is Bayer AG
Kaiser-Wilhelm-Allee
51368 Leverkusen
Germany

- If the first and second characters are IT, the manufacturer is Bayer HealthCare Manufacturing Srl.
Via delle Groane, 126
20024 Garbagnate Milanese
Italy

- If the first and second characters are BT, the manufacturer is Bayer Bitterfeld GmbH
Ortsteil Greppin, Salegaster Chaussee 1
06803 Bitterfeld-Wolfen
Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België / Belgique / Belgien**
Bayer SA-NV
Tél/Tel: +32-(0)2-535 63 11

**Bulgaria**
Байер България ЕООД
Тел: +359-(0)2-424 72 80

**Česká republika**
Bayer s.r.o.
Tel: +420-266 101 111

**Danmark**
Bayer A/S
Tlf: +45-45 235 000

**Deutschland**
Bayer Vital GmbH
Tel: +49-(0)214-30 513 48

**Eesti**
Bayer OÜ
Tel: +372-655 85 65

**Ελλάδα**
Bayer Ελλάς AΒΕΕ
Τηλ: +30-210-618 75 00

**España**
Bayer Hispania S.L.
Tel: +34-93-495 65 00

**France**
Bayer HealthCare
Tél (N° vert): +33-(0)800 87 54 54

**Hrvatska**
Bayer d.o.o.
Tel: +385-(0)1-6599 900

**Ireland**
Bayer Limited
Tel: +353-(0)1-2999 313

**Ísland**
Icepharma hf.
Simi: +354-540 80 00

**Italia**
Bayer S.p.A.
Tel: +39-02-3978 1

**Istria**
Sc Bayer SRL
Tel: +351-21-416 42 00

**İslan**
Icepharma hf.
Simi: +354-540 80 00

**İtalia**
Bayer S.p.A.
Tel: +39-02-3978 1

**Lietuva**
UAB Bayer
Tel: +370-5-233 68 68

**Luxembourg / Luxemburg**
Bayer SA-NV
Tél/Tel: +32-(0)2-535 63 11

**Magyarország**
Bayer Hungária KFT
Tel: +36-1-487 4100

**Malta**
Alfred Gera and Sons Ltd.
Tel: +356-21 44 62 05

**Nederland**
Bayer B.V.
Tel: +31–(0)297-28 06 66

**Norge**
Bayer AS
Tlf: +47-23 13 05 00

**Österreich**
Bayer Austria Ges. m. b. H.
Tel: +43-(0)1-711 460

**Polska**
Bayer Sp. z o.o.
Tel: +48-22-572 35 00

**Portugal**
Bayer Portugal, Lda.
Tel: +351-21-416 42 00

**România**
SC Bayer SRL
Tel: +40-(0)21-528 59 00

**Slovenija**
Bayer d. o. o.
Tel: +386-(0)1-58 14 400

**Slovenská republika**
Bayer, spol. s r.o.
Tel: +421-(0)2-59 21 31 11

**Suomi/Finland**
Bayer Oy
Puh/Tel: +358-(0)20-78521
This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
ANNEX IV

SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORIZATION(S)
Scientific conclusions

Taking into account the PRAC Assessment Report for the non-interventional imposed PASS final study report for the medicinal product(s) mentioned above, the scientific conclusions of CHMP are as follows:

Considering that this study as part of the study programme outlined in Annex II is finalised, the PRAC considered it relevant to state the details of the remaining data from the programme expected in the coming years.

Therefore, in view of available data regarding the PASS final study report, the PRAC considered that changes to the conditions of the marketing authorisation were warranted.

The CHMP agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for the results of the study for the medicinal product(s) mentioned above, the CHMP is of the opinion that the benefit-risk balance of these medicinal product(s) is unchanged, subject to the proposed changes to the product information.

The CHMP is of the opinion that the terms of the marketing authorisation(s) of the medicinal product(s) mentioned above should be varied.